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SUMMARY
Transfection of mammalian cells with recombinant 
plasmid DNAs containing the bacterial chloramphenicol acetyl 
transferase (CAT) gene as a reporter has been used to 
analyse genomic sequences regulating the transcription of 
the human c-myc proto-oncogene. Several regulatory domains 
5' to the c-myc coding region have been identified, and 
their locations defined by deletion analysis. Each of these 
sites encompass previously identified DNase I in vivo 
hypersensitive sites.
Published data suggested that the c-myc gene may be 
regulated in vivo by a repressor. The mapping of 
translocation breakpoints for Burkitt's lymphoma and murine 
plasmacytoma which involve the c-myc gene, suggests that 
the cis-acting recognition sequence for this putative 
repressor is located within the 5' flanking region. I have 
identified a negative regulatory element (NRE-2) in the 5' 
flanking region of the gene and localised it to a region 
between -1052 and -607bp 5' to the PI start site of the 
c-myc mRNA, by deletion analysis. Subsequent competition 
experiments showed a 270bp sub-fragment to contain an 
essential component of the negative regulatory element. This 
element can function in an orientation independent manner, 
and has the ability to repress heterologous promoters (both 
viral and eukaryotic), but to a lesser degree than when 
acting in cis upon its homologous promoter. My data from 
both DNA titration and competition transfection analysis 
indicates that this repression is mediated by at least one 
trans-acting factor. Since the repression was observed in 
every cell line used as the transfection recipients, a 
certain promiscuity in the tissue- and species- specificity 
of the trans-acting repressor(s) is implied. In vivo 
footprint analysis tentatively identified two
sequence-specific DNA-binding proteins which interact with 
this domain. Both the CCAAT-binding Transcription Factor 
(CTF) and Spl bind within the NRE-2 domain. This is the
8
first time either of these DNA-binding factors have been 
implicated in the transcriptional repression of a gene.
In addition, deletion analyses identified an Upstream 
Promoter Element (UPE), located between the NRE-2 and the 
c-myc mRNA major cap sites, which is responsible for 
activation of the high levels of CAT expression observed in 
cells transfected with the recombinant plasmids. This UPE 
appears to be a highly complex domain which was shown, by 
DNase I in vivo footprint analysis, to bind several Spl-like 
factors. In addition, the UPE is somehow involved in the 
control of the repression function, although it is not 
required for the repression of heterologous promoters by the 
NRE-2.
Other data (assayed preliminary) suggested also that 
two other distal regulatory domains are involved in the 
control of c-myc expression. The more distal element (PRE) 
has an activating activity, and was localised to a region 
which showed sequence homology to enhancer elements. A 
second element (NRE-1) was tentatively identified which had 
a negative effect on CAT activity.
I conclude that the removal, and/or the rearrangement, 
of these transcription regulatory domains may play a 
crucial role in the deregulation of the expression of c-myc 
that is observed in some neoplastic cells.
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CHAPTER ONE
INTRODUCTION
1.1. Introduction: Cancer and Oncogenes
Cancer can best be described as a cruel subversion from 
the normal growth parameters of a cell. Such a subversion, 
if not coded for by the cell, must be induced by external 
factors. In either case, since the majority of cells for 
the whole of their life-span pursue a normal existence, 
cancer must be due to the aberrant regulation of normal 
cellular processes. This aberrant control could manifest 
itself in many ways - temporally, qualitatively, 
quantitatively - but must act through disruption of the 
individual genes coding for the effectors of these cellular 
processes. The compelling questions are obvious: which
genes, and how are they altered to give rise to the 
transformed phenotype?
Our first insight into the answers to these questions 
came from the study of a subset of animal viruses. The 
retroviruses are an heterogeneous group of RNA viruses (for 
review see Bishop, 1978), which can be further subdivided 
into two groups. The acutely transforming retroviruses 
contain a transforming gene (the viral oncogene), which we 
now know was derived by transduction of a cellular gene (for 
reviews see Bishop, 1983; Bishop and Varmus, 1985), while 
the slowly transforming retroviruses do not harbour a 
transforming gene but appear to activate cellular genes by 
promoter insertion (Hayward, Neel and Astrin, 1981). The 
cellular genes activated in either of these cases are termed 
proto-oncogenes, and we can now from this line of 
investigation account for about 25 of then. Upon further 
analysis, using several in vivo systems, these genes have 
been shown to be intimatly associated with the genesis of 
the neoplastic cell.
A separate line of research has led to the same 
conclusion. DNA-mediated gene transfer, which allows the 
identification of dominantly active oncogenes from tumour 
cells (for review see Marshall, 1985), has brought the total
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number of proto-oncogenes to nearly 40. By their nature, 
these studies can only identify dominantly acting oncogenes* 
however, recent evidence from somatic cell hybridisation 
experiments has indicated the likelihood that recessive 
oncogenes (suppressor genes) may be involved in generating 
the transformed phenotype (for reviews see Stanbridge, 
1985; Sager, 1986).
Thus, there appears to be a fairly large, very 
heterogeneous group of cellular genes which have the
potential, when their actions are disrupted in some fashion, 
to cause cellular transformation. This concept has been
supported by recent, elegant work using transgenic mice
(Adams et al, 1985).
The members of the proto-oncogene family have been found 
to be highly conserved through evolution, being present in 
every mammalian and avian species examined to date, with myb 
and the ras family also represented in Saccharomyces
cerevisiae (Katzen, Kornberg and Bishop, 1985). Such 
conservation implies essential and fundamental roles for
these genes in normal cellular metabolism. These roles are 
only now beginning to be elucidated (for review see Bishop 
and Varmus, 1985). The gene products of a few
proto-oncogenes have been identified. Not surprisingly
these include a growth factor (sis and Platelet Derived 
Growth Factor; Waterfield et al, 1983) and growth factor 
receptors (erb-B and Epidermal Growth Factor receptor, 
Downward et al, 1984; fms and Colony Stimulating Factor 
receptor, Sacca et al, 1986). The identity of the other 
proto-oncogene products we can, as yet, only speculate 
about. The ras-gene family possess GTPase activity and may 
be related to the G-proteins (for reveiw see Balmain,1985). 
Some are found in the nucleus, (e.g. myc, myb, ski), while 
there are numerous examples of proto-oncogene products 
having protein kinase activity (for review see Bishop and 
Varmus, 1985). The proto-oncogenes appear to code for 
proteins which are essential for the sequential steps
12
required for the correct growth response of a cell. 
Presumably, in such a role, they act synergistically to 
bring about the normal growth of a cell.
The consensus of opinion, gleaned from all aspects of 
oncogenic research, points to cancer being a multistage 
process. However, when proto-oncogenes were first 
identified, it was considered possible that one genetic 
change could bring about the transformed state by the 
disruption of a single proto-oncogene. As we have learned 
more about these genes it is now thought that more than one 
activated proto-oncogene is required for the initiation and 
maintainance of the neoplastic state (Land, Parada and 
Weinberg, 1983; Adams et al, 1985; Oshimura, Gilmer and 
Barrett, 1985). Indeed, studies using the NIH-3T3 cell line 
have shown that fibroblast immortality is a prerequisite for 
transformation by the EJ c-Ha-ras oncogene when regulated by 
its own promoter domain (Newbold and Overell, 1983). 
However, in some cases the activation of one proto-oncogene 
may be enough for at least the initial stages (Spandidos and 
Wilkie, 1984b; Balmain, 1985).
At the basis of this concept is the disruption of the 
normal cellular role of the proto-oncogene. There is now 
evidence for both the alteration of coding sequences (for 
reveiw see Balmain, 1985; Bargmann, Hung and Weinberg, 1986) 
and the aberrant regulation of expression (for reveiw see 
Leder et al, 1983; Stewart, Pattengale and Leder, 1984; 
Adams et al, 1985). Such changes could be brought about by 
several mechanisms: amplification, deletion, translocation, 
point mutation, methylation. How the functions of these 
proto-oncogenes are subverted is of central importance in 
the quest to understand cancer. The work described in this 
thesis will hopefully help to shed light on how the 
expression of one of these proto-oncogenes, c-myc, is 
regulated, thus helping in understanding how regulation of 
this proto-oncogene is corrupted in the neoplastic cell.
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1.2. Avian Myelocytomatosis Virus
On the basis of their oncogenicity avian retroviruses 
have been assigned to either of two classes; those that are 
weakly oncogenic and those that are highly oncogenic. The 
avian myelocytomatosis virus (AMV) in which the myc gene was 
first identified, falls into the latter category. These 
highly oncogenic retroviruses contain a transforming gene in 
their genome and cause disease after a short latency period 
of days to weeks. They are themselves split into the 
replication-competent sarcoma viruses and the
replication-defective leukaemia viruses (DLV), which require 
a helper virus (a non-defective leukosis virus) for their 
replication (for review see Graf and Beug, 1978).
The oncogenicity of these viruses was found to be due to 
the presence of a transforming gene, a viral oncogene 
(v-onc), in their respective genomes. All the acutely 
transforming retroviruses have at least one, sometimes two 
viral oncogenes in their respective genomes (for review see 
Bishop and Vamus, 1985). These viral oncogenes have turned 
out to be the transduced forms, sometimes truncated, of 
normal cellular genes, the proto-oncogenes. Work done by 
Roussel et al (1979) showed that the DLV group represents 
recombinants between a vector related to a chicken 
endogenous virus and one of three cellular genes: erb, myb
and in the case of AMV, myc. Other proto-oncogenes have 
since been identified through their transduction into avian 
retroviruses (Bishop and Varmus, 1983).
The AMV-type viruses (MC29, CMII, OKIO and MH2) belong 
to the DLV class of avian retrovirus. They transform 
macrophage-like cells in vitro and some strains induce 
myelocytomatosis in vivo. In addition, MC29 can transform 
fibroblasts and epithelial cells in vitro and induce 
carcinomas and occasionally sarcomas in vivo (for review 
see Hayward, 1983). The activation of c-myc by retroviral 
transduction is only one of the possible activation
14
mechanisms by which activation can occur (see section
1.5.3. )
1.3. v-myc
The myc gene was first defined as the unique
transforming sequence of the MC29 family of retroviruses by 
Rousell et al, (1979). Since then, the topography of the
v-myc gene has been found to differ from one AMV isolate to 
another. In the prototype, MC29, it is fused to a portion 
of the viral gag gene (Alitalo et al, 1983; Reddy et al,
1983) which encodes the internal structural protein of the 
virus. The hybrid gene gives rise to a polyprotein with a 
molecular weight of 110,000 (pllOgag-myc; Bunte et al,
1984). While the closely related virus, CMII, encodes a 
similar protein (p90gag-myc; Hayman, Kitchner and Graf, 
1979), the OKlO and MH-2 strains contain v-myc as an 
independent genetic unit that is expressed by means of a 
spliced subgenomic mRNA (Chiswell, Ramswey and Hayman, 1981; 
Pachl, Beigalke and Linial, 1982).
Recent hybridisation studies with the MH2 virus have 
detected a second v-onc (v-mil/mht) which again has a 
cellular counterpart (Coll et al, 1983; Kan et al, 1983). 
This gene is transformation specific, but as yet no direct 
function has been designed to it (Zhou et al, 1985). The 
MH2 virus is not the only avian retrovirus which harbours
two viral oncogenes (Symonds et al, 1984; Watson et al,
1985).
The nucleotide sequence of v-myc, from the MC29 virus, 
was determined simultaneously by two independent research
groups (Alitalo et al, 1983; Reddy et al, 1983) and revealed
a single open reading frame that could encode a protein of 
875 amino acids, with the v-myc sequences coding for 425 of 
them. The v-myc gene itself is capable of encoding an 
hydrophilic polypeptide which in its highly conserved 
(between viral isolates) carboxy-terminal region is rich in
15
basic residues, which may account for its DNA binding 
properties (Alitalo et al, 1983). More recent work has shown 
that the v-myc gene products from MC29- and MH2- type
viruses have DNA binding properties, and that the MH2 
product has a further RNA-binding property (Alitalo et al,
1983). In addition, the majority of the MC29-type virus 
gene product is found in the nucleus (Alitalo et al, 1983) 
while the majority of MH2 gene product is cytoplasmic 
(Bunte, Greiser-Wilke and Moelling, 1983; Bunte et al,
1984). The significance of this is not fully understood, as 
each virus causes only a slightly different spectrum of 
diseases (Roussel et al, 1979). The reported molecular 
weight of the v-myc gene product varies between 47000 and
58000 daltons (Alitalo et al, 1983; Bunte et al, 1984)
possibly due to post-translational processing, degradation 
or the inherent lack of resolution in the assay techniques 
used (analogous migration variations in SDS-polyacrylamide 
gels is seen for other proteins, e.g. adenovirus Ela: 
Perrson et al, 1984).
It had been thought that the myc gene had only been
transduced by avian retroviruses, until recent work from
two separate research groups identified v-myc as the 
transforming gene of the acutely transforming variants of 
feline leukaemia virus (Neil et al, 1984; Levy, Gardner and 
Casey, 1984). It is tempting to speculate that as the 
transforming genes of more and more retroviral isolates are 
analysed, the transduction of the myc oncogene may be found 
to be a common occurrence. As a corollary of this, there 
may only be a subset of the cellular oncogenes which 
retroviruses have picked up. As this appears to be the case 
(new isolates are revealing previously identified v-onc), in 
order to identify all the cellular oncogenes we will have to 
utilise different avenues of research (see section 1.1.).
1.4. c-myc
Since being identified as the transforming gene of AMV
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the cellular homologue, c-myc, has been detected in the 
normal DNA of species as diverse as chicken and man, with 
myc hybridising sequences being found in Drosophila (Shilo 
and Weinberg, 1981). Therefore this gene appears to have 
been conserved through evolution, with specific internal 
domains (e-g- the carboxy terminus) showing strong 
conservation, and as a correlation presumably has an 
important if not vital function in the normal cell. It is 
becoming apparent that, similar to the ras oncogene (Hall et 
al, 1983), there is a myc-like family of proto-oncogenes 
(Nau et al, 1985; Kohl et al, 1986). Gene mapping studies 
have assigned the three known human myc-like proto-oncogenes 
to separate chromosomes; c-myc to chromosome 8 (Dalla-Favera 
et al, 1982a; Neel et al, 1982; Taub et al, 1982), N-myc to 
chromosome 2 (Schwab et al, 1984) and L-myc to chromosome 1 
(Nau et al, 1985). Further investigation may reveal the 
presence of additional members of this family.
1.4.1. Gene Structure
Heteroduplex analysis of the c-myc gene has shown that 
the v-myc hybridising regions are separated by an intron 
(Dalla-Favera et al 1982b). Since then, by comparative 
analysis of the RNA transcript and the cellular locus from 
the Raji Burkitt Lymphoma cell line a further 5'exon has 
been identified (Hamlyn and Rabbits, 1983), indicating the 
v-myc gene to be a truncated form of its cellular 
counterpart c-myc. Subsequently, this 5' exon has been 
identified in the murine c-myc (Bernard et al, 1983), 
chicken c-myc (Nottenburg and Varmus, 1986) and feline c-myc 
(Stewart et al, 1986), as well as in the human N-myc (Kohl 
et al, 1986; see figure 1.).
The sequences of the c-myc gene from man, mouse, cat and 
chicken (and N-myc) have been determined (Bernard et al, 
1983; Battey et al, 1983; Stewart et al, 1986; Nottenburg 
and Varmus, 1986; Kohl et al, 1986). Although among the 
members of the family the coding sequences are reasonably
17
conserved, there are specific domains dispersed throughout 
the coding region which show strong homology (Kohl et 
al,1986; Stewart et al,1986). The best conservation at the 
amino acid level (70% for v- and c-myc, 50% for c- and
N-myc) is seen in exon 3, in the form of small stretches of 
amino acids (Kohl et al,1986). It is within this region that 
the DNA-binding property of c-myc is thought to reside 
(Persson and Leder, 1984). Upon comparing this region to 
other known protein sequences, the only one with significant 
homology was c-fos, however the region of homology is 
relatively small (Kohl et al, 1986). A stuctural homology 
with the adenovirus Ela gene product has also been suggested 
(Ralston and Bishop, 1983; see section 1.6.4.).
Transcription initiation for the human c-myc can be from 
either of the two promoter sites, identified by the presence 
of the characteristic TATA-consensus sequence and SI 
nuclease studies of mRNA transcripts (Watt et al, 1983; 
Hamlyn and Rabbits, 1983). In normal lymphoid cells, the 
relative ratios of the two 5' ends of stable mRNA imply that 
the downstream promoter is preferentially utilised (Taub et 
al, 1984 and see section 1.5.3.). A similar situation has 
been reported for the murine c-myc (Bernard et al, 1983). 
Recent evidence indicates the presence of an upstream start 
site (P0), approximatly 600bp 5' of PI in the human c-myc 
(Bentley and Groudine, 1986), but its relevance to c-myc 
expression is unknown. The level of stable transcripts 
initiating from this site is very low, being less than that 
of PI. The transcription start sites for N-myc and chicken 
c-myc differ, in that there is no obvious main site but a 
heterogeneous cluster of starts, possibly reflecting a lack 
of a good TATA consensus in each case (Kohl et al,1986; 
Nottenburg and Varmus, 1986). All normal myc messages 
initiate translation at the 5' end of exon 2 (16bp
downstream from the splice acceptor site of exon 1 for human 
c-myc :Saito et al, 1983). Thereby exon 1 is probably an 
untranslated leader sequence (containing several termination 
codons) in all the sequenced myc genes.
The untranslated region (including the dual promoter
domain) has been proposed to have some functional value as
all the myc genes sequenced possess such a domain (see 
section 1.5.3.)- The human c-myc exon 1 encodes an RNA
sequence with the potential to form four hairpin loops 
(Battey et al, 1983). Even though there is only slight 
homology between the exon 1 sequences from the various myc 
genes and between human c- and N-myc, the calculated 
secondary structure including potential loops shows some 
similarities (Kohl et al,1986; Nottenburg and Varmus, 1986; 
Stewart et al, 1986). This untranslated leader, even though 
its sequence is not conserved,, may therefore perform a 
similar funtion for the various members of the myc gene
family. There is one report of an open reading frame, 
capable of encoding an 20 K protein, within exon 1 (Gazin et 
al, 1984). However, as no other sequence data for other 
cloned c-myc genes identified such a region, its existance 
is unlikely.
Presumably the 5' flanking sequences of the c-myc gene 
contain the important elements which regulate at least some 
aspects of its transcription. By looking at the DNase I 
sensitivity of chromatin, which is thought to indicate the 
presence of transcription regulatory elements (for review 
see Weintraub and Groudine, 1976), five hypersensitive sites 
have been identified in the human (Siebenlist et al, 1984) 
and murine c-myc genes (Fahrlander, Piechaczyk and Marcu,
1985). Two closely associated sites are localised around 
the dual promoter region, where there is very good 
interspecies sequence conservation including a repeated 
consensus (Corcoran, Cory and Adams, 1985; Stewart et al,
1986). Another two sites are associated with two similar 
nuclear protein consensus elements (i.e. NF-1: see section
1.9.4.), one of which is localised near the P0 upstream 
transcription initiation site. The fifth site is within a 
sequence strongly conserved between mouse and human about 
2.0Kb upstream from exon 1, which contains two enhancer core 
consensus elements (see section 1.9.4.). Only sites I and
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II-2 are strongly hypersensitive, with site III-2 being 
intermediate in strenth (see figure 2.). However, these are 
only the possible locations of regulatory elements as no 
functional analysis has been done. The work presented in 
this thesis concentrates on this topic.
1.4.2. Gene Product
The human c-myc gene codes for a 62K protein (Evan and 
Hancock, 1985), with several possible precursor or processed 
molecules (Ramsey, Evan and Bishop, 1984; Persson et al,
1986). Apparently this protein has a very short half life, 
about 30 minutes (Ramsey, Evan and Bishop, 1984; Rabbits et 
al, 1985), although recent data may indicate a product which 
is more stable, being generated post-translationally from 
the short lived precursors (Persson et al, 1986). The 
majority of p62 is found in the nucleus (Persson and Leder,
1984) but its exact location is still in question. Original 
studies indicated p62 to be associated with the nuclear 
matrix (Winqvist, Saksela and Alitalo, 1984), however, more 
recent analysis indicates that this association may be an 
artifact due to the isolation procedure, and therefore does 
not indicate what happens in vivo (Evan and Hancock, 1985).
As to what function the c-myc protein plays in the 
nucleus we have as yet very few clues. It does exhibit a 
high (possibly non-specific) affinity for double-stranded 
DNA (Perrson and Leder, 1984; Watt, Shatzman and Rosenberg,
1985). It is a generally hoped concept that the c-myc 
protein may play some role in the governing of gene 
expression (transcriptionally or post-transcriptionally). 
There are several examples of DNA-binding regulatory 
proteins which apparently bind non-specifically to DNA with 
high affinity, e.g. adenovirus Ela protein (for review see 
Kingston, Baldwin and Sharp, 1985), chick oviduct 
progesterone receptor (Hughes et al, 1981). Perhaps the 
c-myc protein, if it does indeed govern gene expression, may 
play a central role in the nuclear response to growth
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signals (see sections 1.5.3., 1.6.3. and 1.6.4.). The
nucleus Is also the location of other oncogene products, 
e.g. c-myb which also has a DNA-binding affinity (Moelling 
et al, 1985; Klempnauer and Sippel, 1986). Whether these 
oncogene products interact with each other in some way, or 
have a similar function, is not known. Hopefully future 
analysis of the c-myc gene product, and the other nuclear 
oncogene products, will answer these questions. These 
answers would not only help in our understanding of the 
roles oncogenes play in the transformed cell, but also 
greatly expand our knowledge of gene regulation.
1.5. Cellular Role of myc
Since both the N- and c-myc (as yet very little is,known 
about L-myc) have a similar gene layout, and show 
significant homology between specific domains of their 
protein products, especially at the carboxy terminus 
(Michitsch and Melera, 1985; Kohl et al, 1986), they may 
have similar functions in the cell. Why should the cell 
have several copies of a similar gene? Expression of the 
three genes, despite these apparent structural similarities, 
appears to be dramatically different with respect to tissue 
and developmental stage specificity, as well as tumour 
specificity (Zimmerman et al, 1985; Kohl et al, 1986). 
Therefore each gene may play the same (or similar) role in 
the different periods of the cell's life span (both N- and 
L-myc being expressed earlier during differention than 
c-myc: Zimmerman et al, 1985), or within the different cell
types present in eukaryotic organisms (c-myc showing a more 
widespread expression range than either N- or L-myc: 
Zimmerman et al, 1985). It is conceivable that the different 
members of the human myc gene family may cross-regulate each 
other (see section 1.6.3.).
By analysing the expression patterns of the endogenous 
c-myc, and of c-myc exogenously introduced into various 
recipient cells, speculation as to its functional role in
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the normal and neoplastic cell can be made.
1.5.1. Involvement in Proliferation
Among the various intracellular events which occur 
during the transition from the quiescent to the 
proliferative state (Chambard and Pouyssegur, 1986), c-myc 
expression is now known to be altered (see figure 3.). When 
quiescent cells (fibroblasts or lymphocytes) are stimulated 
by their respective mitogens (PDGF or Conconavalin A) to 
enter the cell cycle, c-myc expression is transiently, but 
dramatically elevated (Kelly et al, 1983). These studies 
have been expanded to show that c-fos expression is also 
transiently increased, but preceeds c-myc (Muller et al,
1984), and that both these oncogenes are induced by other 
growth factors (e.g. IL-2 and IL-3 on lymphocytes: Reed et
al 1985; Conscience, Verrier and Martin, 1986). Elevation 
of c-myc expression (both the mRNA and protein levels are 
stimulated: Persson et al, 1984; Persson, Gray and Godeau,
1985; Rabbits et al, 1985) although an essential part of the 
induction of competence, appears to require additional 
synergistically acting growth mediator induced events for 
progression through the growth cycle (Armelin et al, 1984; 
Smeland et al, 1985; Bravo et al, 1985; Kaczmarek, Oren and 
Baserga, 1986) However, a v-myc containing retrovirus can 
(without structurally altering the endogenous c-myc locus), 
by itself abrogate the requirement for exogenously added 
growth factors in stimulating cell growth (Armelin et al, 
1984; Rapp et al, 1985). Taken together, the above results 
indicate that c-myc may be an important component (for at 
least a subset of growth factors) in the cascade of events 
leading to cellular proliferation.
There is growing evidence that this induction of c-myc 
by growth factors (e.g. PDGF, one chain of which is encoded 
for by c-sis: Waterfeild et al, 1983) proceeds through the
activation of protein kinase C (Reed et al, 1985; Bravo et 
al, 1985; Rodriguez-Pena and Rozengurt, 1985; Falletto,
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Arrow and Macara, 1985; Coughlin et al, 1985). Numerous 
proto-oncogenes encode a product with protein kinase 
activity (for review see Bishop and Varmus, 1985), while the 
ras-gene family possess GTPase activity and may be related 
to the G proteins (for review see Balmain, 1985). In the 
light of these, and other findings (for review see Marshall, 
1985; Goustin et al, 1985; Kelly et al, 1983), it is 
reasonable to propose a regulatory linkage between several 
different oncogene products. As our knowledge increases 
more and more of the known oncogenes will probably be found 
to be associated with each other in specific growth pathways 
(which are subverted during neoplastic growth).
Persistance of the competence state within the cell 
appears to be independent of c-myc expression (Bravo, 
Burchardt and Muller, 1985) even though it is apparently 
essential for its induction. Both messenger RNA and protein 
levels are constant, but low, throughout the cell cycle in
exponentially growing cells (Rabbits et al, 1985; Persson,
Gray and Godeau, 1985). Thus c-myc may be involved in the 
induction of a quiescent cell to enter the cell cycle, but 
not for the cell's transverse of the cycle (epidermal growth 
factor has been implicated in progression of the cell-cycle: 
Armelin et al, 1984).
Even though many studies have been done, how the 
expression of c-myc is regulated is still not understood. In 
the quiescent cell c-myc transcripts are undetectable
(Campisi et al, 1984; Rabbits et al, 1985), but the level of 
transcription appears to be the same as that of a cycling 
cell (Blanchard et al, 1985; Thompson et al, 1985). This 
implies that the myc transcript in quiesent cells is 
extremely unstable. However, due to different cell lines
being used (HL-60 and Chinese hampster lung fibroblasts 
respectively), and different methods utilised to arrest cell 
growth (contact inhibition and serum deprivation 
respectively), this direct correlation is not conclusive. In 
addition, the probe used for the in vitro run-on
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transcription studies, since it relies upon cross-species 
hybridisation (Blanchard et al, 1985), does not preclude the 
presence of a transcription elongation block. Such a 
phenomenum does play some role in the decrease in c-myc 
message levels observed when HL-60 cells are induced to 
differentiate (Bentley and Groudine, 1986). Indeed, in a 
recent report (unfortunatly a different cell line again and 
the method of growth arrest is not reported), serum 
stimulation was shown to increase the transcription rate of 
c-myc (Endo and Nadal-Ginard,1986). Unfortunately therefore, 
because different systems have been utilised in these 
studies no clear picture emerges.
All the serum stimulation studies have used protein 
synthesis inhibitors, which when added in conjunction with 
serum, allow superinduction of c-myc message (Kelly et al, 
1983; Endo and Nadal-Ginard, 1986). Once again conflicting 
results were obtained depending on the specific cell line 
and inhibitor employed, although the assay system was the
same (nuclear in vitro run-on transcription assays) in the
respective studies. Anisomysin treatment of quiescent 
NIH-3T3 cells prior to serum stimulation potentiated c-myc 
(c-fos and actin) expression at the transcriptional level 
(Greenberg, Hermanowski and Ziff, 1986). However the
opposite, a decrease in transcription, was seen in the
pheochromo.cytoma cell line PC12 (Greenberg, Hermanowski and 
Ziff, 1986). In similar studies, anisomysin or cycloheximide 
treatment resulted both in a marked increase in c-myc 
message stability and a slight decrease in transcription 
initiation upon serum stimulation of quiescent myoblasts 
(Endo and Nadal-Ginard, 1986). In another study, where an 
actinomysin chase was used, a marked increase in c-myc 
message stability was also observed for HeLa and HL-60 
cells, while no change in stability was seen in Daudi 
Burkitt's lymphoma cells (Dani et al, 1984). Again no clear 
picture emerges from these studies.
Thus the actual mechanisms (transcriptional or post-
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transcriptional) utilised by different cell lines in 
regulating c-myc expression within the various phases of the 
cell cycle (including GO) are still debatable. The main 
arguement (although not the only one) for an increase in the 
stability of the normally very unstable c-myc message (Tl/2= 
10-20 minutes: Dani et al, 1984; S.Graham personal
communication) is based on data gleaned using protein 
synthesis inhibitors, and implies that a protein factor is 
selectively degrading the c-myc message. However this system 
revolves around a non-physiological state, in that the 
protein synthesis inhibitors used do not normally exist in 
the cell. Apart from this, the use of protein synthesis 
inhibitors may indeed give rise to artifacts, e.g. the 
resultant stabilisation seen after cycloheximide treatment, 
as this inhibitor functions to prevent termination, could be 
due to the accumulation of RNA polymerase II molecules on 
the transcript. The superinduction of c-myc expression seen 
upon addition of protein synthesis inhibitors may identify 
the presence of a protein factor (e.g. a double-strand- 
specific RNase or a transciption repressor) which functions 
to selectively degrade the c-myc message. Published data 
would suggest that this protein is present in normal and
transformed cells (Dani et al, 1984; Endo and Nadal-Ginard,
1986). Thus, regulation at the post-transcriptional level 
may occur during serum stimulation, but there is no evidence 
which completely rules out a role for control at the 
transcriptional level.
To further elucidate the involvement of the c-myc gene 
in proliferation, studies on interferon (IFN) -induced 
growth arrest (as opposed to serum inducton of growth) of
Daudi Burkitt's lymphoma cells have been reported. Upon 
IFN-P treatment cells are induced into a quiescent state 
with a corresponding decrease in the level of c-myc mRNA
(Jonak and Knight, 1984). However not all BL cell lines
respond equally to IFN, and indeed cell lines of different 
origins (e.g. HL-60 and Friend cells), although showing a
reduced cell growth, do not arrest in GO after IFN treatment
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(Einat, Resnitzky and Kimchi, 1985). Thus the exact 
relevance of using the Daudi cell line as a model may be 
questioned. Nuclear run-on in vitro transcripton assays were 
undertaken in these studies, and the decrease in mRNA 
abundance attributed to a decrease in c-myc message 
stability (Knight et al, 1985; Dani et al, 1985). IFN-a has 
a similar affect on Daudi cells in that it induces growth 
arrest with a corresponding decrease in c-myc expression, 
however a decrease in c-myc transcription was seen (Einat, 
Resnitzky and Kimchi, 1985). This may mean that the forms of 
interferon have different affects on the control of c-myc 
expression.
The overall picture of the role of c-myc in cellular 
proliferation is still not clear. The fact that serum 
stimulation of quiescent cells induces a transient elevation 
of c-myc expression (with a presumed important function) is 
now generally accepted, but whether this is due to an 
increase in message stability or an increase in 
transcription is still under debate. Perhaps both mechanisms 
are differentially utilised by different cells or even by 
the same cell type at different stages of development or 
differentiation. Of note here, is that c-fos has a 5' 
cis-acting regulatory element which responds to serum 
induction in addition to a 3' element possibly involved in 
message stability (Treisman, 1985 and 1986).
1.5.2. Involvement in Differentiation
The occurrence of c-myc expression appears to be 
dependent on the differentiation state of the cell, being 
turned off in mature cells (Reitsma et al, 1983; Gonda and 
Metcalf, 1984; Lachman and Skoultchi, 1984; Dony, Kessel and 
Gruss, 1985; Brelvi and Studzinski, 1986). Several studies 
have shown that constitutive c-myc expression is 
incompatable (preventing) with the induction of terminal 
differentiation in HL-60 and MEL cells (Falcone, Tato and 
Alema, 1985; Symonds et al, 1986; Coppola and Cole, 1986;
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Dmitrovsky et al, 1986; Prodownik and Kukowsky, 1986).
Once again whether this shut-off is transcriptionally or 
post-transcriptionally regulated is still in question. When 
HL-60 cells are treated with retinoic acid differentiation 
down the granulocytic pathway is induced, with an associated 
decrease in c-myc mRNA abundance. Nuclear in vitro run-on 
transcription assays have shown that a transcription 
elongation block (between exon 1 and 2) can account for most 
of this shut-off (at 6 days post induction: Bentley and
Groudine, 1986). Thus neither regulation of the level of 
transcription induction nor post-transcriptional mechanisms 
need to be evoked in this system. In retinoic acid induced 
differentiation of F9 embryonic carcinoma cells c-myc is 
actively transcribed, even though there is a decrease in 
mRNA levels (Dony, Kessel and Gruss,1985), while the 
decrease in c-myc expression upon Friend cell 
differentiation is due to a decrease in the level of 
transcription (Grosso and Pitot, 1985). Thus the level at 
which regulation of c-myc expression occurs during 
differentiation may depend on the cell type.
Two indirectly relevant results come from different 
experimental approaches. On comparing the methylation 
patterns of the two c-myc alleles in a murine plasmacytoma 
cell line, the silent allele (that responsive to normal 
differentiation-specific regulation) is hypermethylated 
compared to the translocated, active allele (Dunnick et al,
1985). Secondly, upon HL-60 differentiation the DNase 1 
hypersensitive sites 5' to the c-myc gene alter (see
1.4.1.). Both these results indicate that upon 
differentiation the c-myc gene is physically altered, a 
phenomenon which is commonly associated with a change in 
regulation of transcription. Obviously these results do not 
exclude post-transcriptional mechanisms from being involved.
However c-myc expression is controlled during terminal 
differentiation, c-myc shut-off may be a prerequisite for
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normal differentiation to occur. Since c-myc has some role, 
in all likelihood an essential one, in inducing the growth 
factor stimulated competence state, the c-myc gene product 
is probably an essential component of the growth response of 
the cell. The recent studies on transgenic mice harbouring 
c-myc derived constructs, gives further credence to the 
c-myc gene having a role in cellular proliferation.
1.5.3. Involvement in Neoplasia
The c-myc gene has been implicated in the genesis of 
several forms of neoplasm. Classically, v-myc was shown to 
be the transforming gene present in specific avian 
retroviruses, while the cellular homologue (via promoter 
insertion) was implicated in the neoplasia by studies on 
certain slowly transforming retroviruses. More recently the 
activation of c-myc has been implicated in several human 
neoplasias by the analysis of tumour cell lines and primary 
biopsy samples.
(a).Retroviral Transduction
It was through the analysis of the MC-29 virus that the
myc gene was first identified (see section 1.2.). With the
recent identification of c-myc being transduced by a feline 
leukaemia virus (Neil et al, 1984; Levy, Gardner and Casey,
1984), the question of whether c-myc may be transduced by 
other viruses is raised. Perhaps other virus-associated 
leukaemias (which await analysis) may be due to a virally
transduced c-myc.
Transduction presumably activates c-myc by placing it 
under the strong transcriptional control of the proviral
enhancer within the LTR. The v-myc gene is a truncated 
version of c-myc, but still retains all the coding sequence. 
However important regulatory sequences (within exon 1) may 
have been lost during the truncation. Therefore it is 
conceivable that the loss of these sequences confers the
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transforming ability upon the genes (see section 1.6.2.). 
Although the consequence of transduction is an 
over-expression of c-myc, it is also possible that the 
activating step is the removal of normal regulation of 
expression (i.e. deregulation). Although there are cases 
where a common mutation location has been observed (Papas 
and Lautenberger, 1985), not all v-myc isolates harbour this 
mutation (Stewart et al, 1986). Thus, an abnormal mutated 
gene product is not an absolute requirement for transforming 
potential (unless different mutations have the same effect: 
see section 1.5.3.c), but may conceivably have some role in 
directing the spectrum of disease.
(b ).Promoter Insertional Activation
Although first demonstrated for the c-myc gene (Hayward, 
Neel and Astrin, 1981; Fung, Crittenden and Kung, 1982; 
Corcoran et al, 1984) proviral insertion adjacent to, and 
thereby activating, cellular oncogenes has now been 
documented for several viral-oncogene systems (Peters, Lee 
and Dickson, 1982; Fung et al, 1983; Neil et al, 1984; Nusse 
et al, 1984; Swift et al, 1985; Molders et al, 1985). After 
integration of the provirus the original DNase 1 
hypersensitive sites of the endogenous oncogene are no
longer detectable, with a new strong site being present in
the proviral LTR (Schubach and Groudine, 1984). This has
given credence to the promoter insertion theory for the 
activation of cellular oncogenes (for review see Temin, 
1982), where expression of the cellular gene is driven by 
the strong proviral LTR.
Most proviral insertions are either 5' or 3' to the
coding sequences in question. Therefore it is probably 
constitutive, deregulated expression of the cellular 
oncogene, rather than an altered coding potential which 
results in the transformed phenotype. As an aside to this, 
these situations probably give us an insight into how a 
retrovirus integrates into cellular DNA. In ALV-induced
29
lymphoid leukaemia (Hayward, Neel and Astrin, 1981) in the 
majority of cases the provirus integrates in the same 
orientation as the cellular oncogene, while in other systems 
proviral integration is in the opposite orientation 
(Corcoran et al, 1984). Thus the integration specificity of 
each type of provirus differs and through the study of 
these systems we may gain an insight into how.
In addition to provirus insertional activation, a 
movable repetitive DNA element ("retroposon") has been shown 
to activate c-myc (Katzir et al, 1985). Again the insertion 
was upstream of c-myc and caused deregulated expression. It 
is possible that the "retroposon" element directly increases 
c-myc expression but the disruption of the 5' control domain 
of c-myc is also a possibility.
(c ).Chromosomal Aberrations Affecting c-myc
Slamon et al (1984) have shown that c-myc is expressed 
in several tumour types. Since then expression of c-myc has 
been associated with an ever increasing range of tumour 
types (Peschle et al, 1984; Erisman et al, 1985; Sikora et 
al, 1985). However, upon transfection of B-cell lymphoma 
DNA, the transformation-specific gene which was identified 
(B-lym) was not c-myc, although c-myc activation was infeted 
from analysis of the translocation break point (Goubin et 
al, 1983; Diamond et al, 1983; Devine, 1986). At face value 
this would give evidence for cancer being a multistep 
phenomenon, with the co-ordinate activation of more than one 
cellular oncogene. However, there are at present questions 
regarding the cloning strategy used to isolate the B-lym 
gene and its subsequent transforming activity, which are as 
yet unresolved.
Most information on c-myc involvement in neoplasia has 
come from the analysis of c-myc rearrangement in B-cell 
tumours (see below and Neil et al, 1984; Corcoran et al,
1984).
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(i ).Amplification
Amplification of certain oncogenes is common in some 
tumours (for review see Alitalo, 1985), and the increased 
dosage of an oncogene as a result of such a rearrangement 
may contribute to the genesis and/or progression of at least 
some forms of cancer. All three human myc genes have been 
found amplified in specific tumour types, both in tumour 
derived cell lines and clinical biopsy samples (Dalla-Favera 
et al, 1982a; Schwab, 1985; Nepveu et al, 1985; Nau et al 
1985; Alitalo, 1985; Yokota et al, 1986).
How amplification is involved in the transformation 
process (N-myc amplification number correlates with
malignant progression: Schwab et al, 1984), or if it is only
a consequence of transformation (no myc gene has been found
amplified in a normal cell) is not known. Indeed, whether
all copies within the amplified domain are active is not 
known. However, correlating message levels with copy number 
(Graham, Tindle and Birnie, 1985), and the recent DNase 1 
sensitivity studies on HL-60 cells (Dyson et al, 1985) and 
an A-MuLV-transformed fibroblast cell line (Nepveau et al,
1985), imply that at least most copies are active.
(ii).Chromosome translocation
Most of our insight into the ways in which chromosomal
translocations can involve cellular oncogenes has come from 
the study of two types of lymphoid tumour: human Burkitts
lymphoma (BL) and mouse plasmacytoma (MPC). Both of these
tumours are characterised by a chromosomal translocation, in 
each case involving an immunoglobulin locus and the c-myc 
oncogene (see figure 4 and 5). Even though the actual
breakpoint in the c-myc locus varies quite considerably in
both tumour types, the end result of most translocations is
constitutive (i.e. deregulated) c-myc expression, with an
obvious over-expression occuring only infrequently (for 
reviews see Klein, 1983; Leder et al, 1983; Perry, 1983;
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Mushinski et al, 1983; Rabbits et al, 1984; Sun, Showe and 
Croce, 1986).
Whenever the dual promoter region (Battey et al, 1983) 
is preserved during translocation, the relative usage of the 
two promoters changes, i.e. the more 5' promoter (PI) is 
preferentially activated (Leder et al, 1983; Taub et al, 
1984; Fahrlander et al, 1985; Denny et al 1985; Yang et al,
1985). This is similar to the situation where c-myc is 
activated by proviral insertion in certain Feline leukaemias 
(D.Forrest, personal communication). However when the 
breakpoints occur within the exon/intron 1 region then 
truncated mRNA transcripts arising from cryptic promoters 
within intron 1, are generated (Saito et al, 1983; Keath, 
Kelekar and Cole, 1984). These transcripts originate in a 
heterogenous, bipolar fashion (Prehn, Mercola and Calame, 
1984; Calabi and Neuberger, 1985) presumably reflecting a 
lack of a suitable TATA-consensus element. These truncated 
transcripts code for the same gene product as the full 
length transcripts generated from the normal dual promoter 
regions (Piechaczyk et al, 1985).
Since a stable stem-loop structure could form between a 
region in exon 1 which is highly complementary to a region 
in exon 2 (Saito et al, 1983), it has been proposed that 
lack of this structure in the truncated mRNA could result in 
their increased stability. Saito et al (1983) proposed that 
removal of the potential to form this stem-loop structure 
may, in addition, increase the translational efficiency of 
the mRNA. A similar secondary structure is potentially 
possible for all the myc-like genes sequenced to-date (see
1.4.1.).
Upon comparison of the relative stabilities of the 
various c-myc transcripts from the different MPC cell lines 
(where the breakpoints are either 5' or within exon 1) the 
truncated transcripts were found to have a substantially 
greater half life (Piechaczyk et al, 1985). To further
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investigate the role of exon 1, truncated c-myc genes were 
constructed in vitro. Depending on the actual construct used 
either no variation in translation efficiency but an 
increase in message stablility (Butnick et al, 1985), or an 
increase in translation efficiency (Darveau et al, 1985) was 
observed for the truncated transcripts. These differing 
results are probably due to small differences in the 
construction strategies employed by each group. Since the 
constructs of Darveau et al (1985), included a 3' deletion 
this may account for the lack of variation in message 
stability seen in the other .study. Taken together with the 
in vivo data, the untranslated 5' exon would appear to be 
involved to some extent in post-transcriptionally regulating 
the c-myc gene.
The relative stabilities of these different transcripts 
may be partially a red herring in the understanding of c-myc 
expression deregulation. It is probably the fact that c-myc 
is expressed at all that is important, remembering that 
c-myc is not expressed in the mature differentiated cell 
(see section 1.5.2.). The level of c-myc expression in 
these tumours varies quite considerably, from that of a 
normal lymphoblastoid cell to being highly elevated (Taub et 
al, 1984; Keath, Kelekar and Cole, 1984; Sun, Showe and 
Croce, 1986). The level of the protein also varies between 
different BL cell lines (Ramsey, Evan and Bishop, 1984; Hann 
and Eisenman, 1984).
Although there are cases when mutations within the
structural gene have been detected (Rabbits et al, 1984; 
Denny et al, 1985, Murphy et al, 1986) and noted within the
some v-myc isolates (Papas and Lautenberger, 1985), but not
in the FeLV-transduced gene (Stewart et al, 1986) there is 
no unifying mutation found in all activated myc situations 
(unlike the ras oncogene activation: for review see Balmain,
1985). Recently, Martin et al (1986) transformed cells with 
an avian retrovirus containing and expressing a non-mutated 
human c-myc gene. Upon recloning of this gene from a
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transformed cell it was still found not to contain any 
mutations. In addition, augmented transcription of the 
normal c-myc is sufficient for cotransforming activity with 
c-Ha-ras (Lee et al, 1985), makes primary fibroblasts 
tumorigeneic (Pragnell, Spandidos and Wilkie, 1985) and can 
transform cells alone in a rat embryo fibroblast focus 
formation assay (Kelekar and Cole, 1986). However, a mutated 
c-myc gene exhibited a reduced transforming ability (Murphy 
et al, 1986). These results do not exclude coding sequence 
mutations from affecting the disease spectrum of the 
activated, gene but do imply that a coding sequence mutation 
is not a prerequisite for activation.
(d). Cellular transformation
Recent evidence from transfection studies has further
implicated the c-myc gene in the neoplastic process. The
transfection of c-myc, under the control of various 
promoters, induces the recipient cells into a state of
continuous growth with an associated reduced growth factor
requirement (Palmieri, Kahn and Graf, 1983; Mouganeau et al,
1984; Pragnell, Spandidos and Wilkie, 1985; Connan, 
Rassoulzadegan and Cuzin, 1985). Recent experiments
concerning the multistage nature of transformation (Land,
Parada and Weinberg, 1983; Kelekar and Cole, 1986) have 
shown that two active oncogenes can bring about 
transformation of a recipient primary cell. In these 
experiments c-myc was found to confer extended growth 
characteristics (immortalisation) while c-Ha-ras induced 
morphological transformation upon the cells. However since 
these studies, c-myc has been shown to be capable of 
morphologically transforming cells and c-Ha-ras has the
ability to extend the growth capacity of a cell (Pragnell,
Spandidos and Wilkie, 1985). Thus to say that one oncogene
has a specific role in the initiation or progression of the 
transformed phenotype is probably being simplistic. The 
actual role played by individual oncogenes will probably 
depend on the situation in which it finds itself.
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It is conceivable that in some circumstances a single 
activated oncogene will be enough to trigger full 
transformation. Indeed, the c-Ha-ras oncogene alone, driven 
by two enhancer elements is capable of transforming primary 
cells (Spandidos and Wilkie, 1984b; see section 1.6.5.).
1.6. How is c-myc deregulated ?
Therefore, neither an overt over-production of normal 
c-myc nor the mutated form of c-myc appear to be central to 
its activation, although both have been observed. What 
appears to be of prime importance is the deregulated, 
constitutive expression of c-myc. The level of transcription 
may be less important than the potential for transcription 
at an inappropriate time during the cell-cycle or during 
differentiation. Understanding how c-myc is deregulated is 
of crucial importance if we are to comprehend the role c-myc 
plays in the transformation process.
1.6.1. Involvement of a Repressor.
Once again it has been studies on BL and MPC cell lines 
which, have given us an insight into how the c-myc gene is 
deregulated. The translocated c-myc gene is expressed 
constitutively, while the normal allele on the intact 
chromosome 8 is transcriptionally silent (or at least no 
transcripts can be detected). This situation is found both 
in BL and MPC cells (Bernard et al, 1983; Nishikura et al, 
1984; Taub et al, 1984) and interestingly, only the active 
allele is hypomethylated (Dunnick et al, 1985).
Studies on somatic cell hybrids have shown that c-myc 
expression depends on the differentiated state of the cell 
(Nishukura et al, 1985). When a hybrid between a BL cell 
and a human lymphoblastoid cell is made, which retains the 
lymphoblastoid (immature) phenotype, only the normal allele 
is expressed (Croce et al, 1985; Nishikura, et al, 1985). 
However, in a BL/MPC hybrid (where the human chromosomes are
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differentially lost), only the the translocated human allele 
is expressed (Nishikura et al, 1983; Croce et al, 1985). In 
these hybrids, which have a more mature phenotype than the 
lymphoblastoid hybrids previously described, the normal 
non-translocated allele appears to be repressed. This 
apparent repression of a normal c-myc gene is also seen in 
MPC/human fibroblast hybrids (Nishikura et al, 1984), but 
whether this is a differentiation- or tissue- specific event 
is unknown.
Thus, c-myc being expressed in the BL/MPC cell is 
abnormal in that its expression should be shut off in these 
mature cells. Either translocation allows one allele to 
escape the normal regulation (to which the untranslocated 
allele remains subject ) or, the translocation event 
positively activates that allele (by the relocation of 
positive transcription elements). Since, in the somatic 
cell hybrid studies, the translocated allele is not 
expressed in the phenotypically lymphoblastoid hybrids 
(Nishikura et al, 1985) it is unlikely that deregulation is 
under the control of a cis-acting positive element, unlesss 
by a differentiation-speciic element. Differentiation- 
specific elements (e.g. the immunoglobulin enhancer) may in 
some cases be involved in this deregualtion (Croce et al,
1985). However, at least in some cases, translocation allows 
escape from the normal control of expression by the removal 
of (some of) the normal c-myc transcriptional regulatory 
elements.
The silence of the non-translocated allele has led Leder 
et al (1983) to propose that c-myc could be regulated by a 
trans-acting repressor factor that might use as its target 
exon 1 or adjacent 5' flanking sequences. Such a 
trans-acting factor could be a transcriptional repressor but 
complex models (as some breakpoints are outwith the 
transcribed unit), invoking an element that accelerates 
degradation of the c-myc RNA, can also be imagined. The 
translocated c-myc gene would not be affected by this
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repression because of loss or damage to the particular 
control domain through which the repressor interacts.
1.6.2. Possible Sites for a Negative Transcription Element
A destabilisation of the already very unstable c-myc 
message (Dani et al, 1984) could come about in several ways. 
There could be an important seguence element within the 
transcribed sequences which confers instability to the 
message, or as discussed before (see section 1.4.1.) the 
potential secondary structure of the transcripts could be of 
relevance. If a trans-acting transcriptional repressor is 
envisaged a cis-acting responsive element (negative 
regulatory element, NRE) has to be hypothesised. However the 
non-specific binding for adenovirus Ela protein (for review 
see Kingston, Baldwin and Sharp, 1985) gives a precedent for 
transcription factors not requiring specific recognition 
signals (see section 1.6.4.). The circumstantial evidence 
for the presence of transcriptional control elements for the 
human c-myc gene is outlined below.
Somatic alterations in the structure of the exon 1, 
which range from its complete removal to the occurrance of 
scattered mutations within its sequence, have been 
associated with deregulation of c-myc expression (Taub et 
al, 1984; Rabbits et al, 1984). However, this does not 
always occur. Better evidence for the localisation of a 
negative regulatory element comes from the several studies 
which identified the DNase 1 hypersensitive sites around the 
5' region of the human and murine c-myc genes (Siebenlist et 
al, 1984; Fahrlander, Piechaczyk and Marcu, 1985; Dyson et 
al, 1985). Although 5 hypersensitive sites have been 
localised within the 5' flanking sequences and dual promoter 
region (see section 1.4.1.), results from analysis of the 
two allelic forms in BL and MPC cells (Siebenlist et al, 
1984; Fahrlander, Piechaczyk and Marcu, 1985) and the 
changes in the hypersensitivity pattern seen when HL-60 
cells are induced to differentiate (Dyson et al, 1985) has
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put site 1 into the limelight as a candidate for the 
differentiation-specific negative regulatory element. This 
region does show good homology between the human and murine 
c-myc genes (Fahrlander, Piechaczyk and Marcu, 1985).
However, pooling the known data on translocation 
breakpoints shows a clustering around the -450bp to PI
region, infering that a negative regulatory element may be
closer to the dual promoter region than implied by the
DNAase 1 data (Wiman et al, 1984; Yang, et al 1985;
Corcoran, Cory and Adams, 1985; Pelicci et al, 1986). 
Additionally, the upstream transcriptional start (PO) has 
been localised to near DNase 1 hypersensitive site II-2
(Bentley and Groudine, 1986).
Both the studies on differentiation-specific and cell 
cycle regulated c-myc expression indicate the possible 
involvement of a repressor factor. Whether the repressor 
involved in each of these situations is the same factor or 
not is unknown. If different factors were involved then two 
cis-acting recognition elements would require to be 
postulated, although they could overlap. However it is
conceivable that the same factor could function in both a 
cell-cycle and differentiation specific manner, in which
case only one cis-acting recognition element requires to be 
postulated. The work presented in this thesis identifies 
several putative transcriptional control elements within the 
c-myc 5' flanking sequences.
1.6.3. Postulated Repressor Factor
Leder et al, (1983), also postulated that the repression 
of c-myc expression may be mediated directly or indirectly 
by the cellular level of the c-myc protein. Although no 
direct experiments have been done to test this, results from 
transfection of v-myc containing viruses (Rapp et al, 1985) 
or c-myc genes linked to viral promoters (Keath, Caimi and 
Cole, 1984), infer that the c-myc gene product may be
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involved in its own regulation because in each case the
expression of the endogenous c-myc is diminished.
More suggestive data came from analysing the sequence of 
the Raji BL cell line (Rabbits et al, 1984), where both 
c-myc alleles are expressed. Within the coding sequence 
numerous mutations were found, thus perhaps the translocated 
gene product is so altered that it can not function
normally. If its normal function was to repress the normal
allele then these mutations would allow that allele to 
escape repression and thus be expressed, as is indeed the 
case. However, the situation is slightly more complex than 
this. Since both alleles in the Raji cell line are 
expressing a gene product (N.B. there is no protein data to 
confirm this, it is the current thinking),
the translocated gene product (due to the 
mutations present in its coding domains) can not function as 
normal, i.e. to repress its own transcription. However, the 
normal gene product could. Thus, because of mutations within 
the promoter/first exon region of the translocated allele, 
the normal gene product could only interact (repress) with 
the normal allele. As a consequence, expression from the two 
alleles would be biased towards the translocated allele. 
This is indeed what is observed (Rabbits et al, 1984), with 
c-myc mRNA in the Raji cell line comprising of 65% 
translocated and 35% normal transcripts (approximately).
Using protein inhibitors in the serum induction (Kelly 
et atl, 1983) and liver regeneration experiment (Makino, 
Hayashi and Sugimura, 1984), results consistent with a 
labile protein regulating c-myc expression were obtained. 
As the c-myc protein has a short half-life of 20-30 minutes 
(Ramsey, Evan and Bishop, 1984), is located in the nucleus 
(Persson and Leder, 1984), and has a DNA-binding affinity 
(Alitalo et al, 1983), its physical properties are not 
unlike those expected of a transcriptional regulator. 
However, recent studies where a constitutvely expressed 
exogenous c-myc gene prevents induction of MEL cell
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differentiation, both the exogenous and the endogenous c-myc 
genes are expressed (Dmitrovsky et al, 1986; Prochownik and 
Kukoska, 1986; Coppola and Cole, 1986).
One major problem in analysing the results descir bed 
above (apart from the use of different cell lines) is the 
lack of protein (p62) data in every report. Although c-myc 
is being transcribed (mRNA is detected), whether efficient 
or correct translation is occurring has not yet been shown. 
Thus whether c-myc does indeed regulate its own expression 
(directly or indirectly) .is still debatable. Since the 
location of several cis-acting transcriptional elements have 
been identified (see section 4.) direct experiments to test 
whether c-myc regulates itself can be easily devised.
Two other putative proteins have been suggested as the 
c-myc repressor; one of which has since been discarded. 
Gazin et al (1984) reported that exon 1 of c-myc had the 
potential to encode a 20K protein. However, no other 
sequence data showed an open reading frame within the c-myc 
first exon (Bernard et al, 1983; Stewart et al, 1986; Kohl 
et al, 1986; Nottenburg et al, 1986). Working on variant 
t(6;15) translocations in several murine plasmacytomas, a 
breakpoints cluster in a 4.0Kb region has been identified, 
at least 72Kb distant from the c-myc dual promoter domain 
(Cory et al, 1985). Since c-myc is expressed at an elevated 
level in these cells, this variant translocation apparently 
activates the c-myc gene. This could occur directly via a 
long range cis-function (perturbation of chromatin 
suprastructure) or via the putative pvt-1 (break point 
locus) gene product (Cory et al, 1985; Graham, Adams and 
Cory, 1985). As yet no such gene product (or specific mRNA) 
has been identified so this is still speculation, and 
therefore does not remove the possibility that the c-myc 
gene product may regulate itself somehow. It is also 
conceivable that the different members of the myc gene 
family may cross regulate each other.
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1.6.4. Similarity Between c-myc and Adenovirus Ela Gene
Products
The myc and adenovirus Ela gene products show some 
degree of homology (Ralston and Bishop,1983), although the 
exact level of significance has been questioned (McLachlan 
and Boswell, 1985). Perhaps this structural similarity 
reflects a common function. Both these genes can complement 
Ha-ras in the co-transfection assay (Land, Parada and 
Weinberg, 1982). The Ela gene products can 
transcriptionally activate.the human hsp70 gene while this 
gene has been shown to be normally regulated by an 
endogenous cellular Ela-like activity (Kao et al, 1985). 
Although no direct comparison with c-myc can be made, the 
c-myc gene product does stimulate expression of the 
Drosophila hsp70 gene (Kingston, Baldwin and Sharp,1985).
On a similar theme, certain exogenously introduced 
enhancer elements lose their activity when F9-EC cells are 
induced to differentiate, and that enhancer activity is 
associated with an Ela-like activity, since undifferentiated 
cells can support adenovirus mutants deficient in Ela 
activity (Imperiale et al, 1984). As a correlation, the 
induction of the differentiated state in these cells is 
associated with a decrease in c-myc expression 
(Sassone-Corsi and Borrelli, 1986).
Seperate studies have shown Ela to regulate enhancer 
activity in both a positive and a negative manner (for 
review see Jones, 1986). Although these are highly 
circumstantial connections, it is tempting to speculate that 
the c-myc gene, like Ela, may code for a trans-acting 
factor. In addition, through searching for protein sequences 
which show homology to c-myc, the only significant homology 
(albeit, only to a small region of the third exon, where the 
DNA binding domain is thought to reside, but not within a 
region showing homology between c-myc and Ela) was with the 
c-fos gene product (Kohl et al, 1986). Recently, c-fos has
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been shown to encode a trans-acting transcription factor 
(Setoyama et al, 1986).
Since microinjection of Ela containing plasmids releases 
cells from growth arrest (Stabel, Argos and Philipson,
1985), and c-myc expression is induced during the competence 
stage of cell growth (Kelly et al, 1983), this speculation 
can be extended to implicate the c-myc gene having a role in 
governing the expression of the specific genes involved in 
the cells response to growth stimulation.
One apparent difference between the two gene products 
comes from data on the induction of heat-shock genes. Unlike 
Ela which has been shown to exhibit a non-sequence specific 
binding activity (for review see Kingston, Baldwin and 
Sharp, 1985), c-myc requires certain (as yet unidentified 
sequences) to regulate hsp70 expression (Kingston, Baldwin 
and Sharp, 1984). Therefore, even if these gene products do 
have a similar activity they are obviously not identical.
1.6.5. Summary: c-myc
We do not know if expression of c-myc in tumours is a 
consequence of that tumour's maturation arrest, or if c-myc 
expression prevents the neoplastic cells progression into a 
differentiated state, thus causing maturation arrest. What 
we do know, from the recent elegant transgenic experiments 
with c-myc (Adams et al, 1985; Leder et al, 1986), is that a 
deregulated c-myc gene appears to act as a heritable, 
predisposing factor which favours the accelerated 
development of tissue-specific tumours. However, for the 
development of full neoplasia other additional factors are 
required.
Constitutive expression is the result of c-myc 
activation in a chemically transformed cell (Campisi et al,
1984). How this deregulation of expression comes about is of 
central importance if we are to understand how normal
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cellular genes can when activated induce the transformed 
phenotype. There is evidence for both transcriptional and 
post-transcriptional regulatory mechanisms. The work 
presented in this thesis is centered around the analysis of 
the transcriptional regulation of c-m y c . The second part of 
this introduction therefore outlines our present knowledge 
of transcription regulation with a brief discussion of gene 
regulation in general.
1.7. Chromatin Structure of Active Genes
The nuclear DNA of eukaryotes is highly organised at 
several structural levels, from the protein coding gene unit 
to the ordering of solenoids into discrete loops (for 
reviews see North, 1984; Zehnbauer and Vogelstein, 1985).
Indeed gene expression appears to be controlled at many
stages (Efstratiadis et al, 1980) with transcriptional 
regulation the most frequent level (for review see Darnell, 
1982). It is this level of control on which the work
described in this thesis is based, and as such I will
specifically concentrate this part of the introduction on 
eukaryotic transcriptional control mechanisms, with only a 
brief outline of the other levels of expression control.
Eukaryotic chromatin has a dynamic, complex hierarchical 
structure, with active gene transcription taking place only 
on a small proportion of it at any one time. Active genes
are apparently packaged in an altered nucleosome structure
probably established and maintained by histone HI and its 
variants together with HMG proteins (for review see
Weintraub, 1985). This altered nucleosome structure is
described as being less condensed or more open than that
associated with inactive domains. Obviously there are clear 
changes in chromatin structure between open-active and 
inactive domains and these can be detected by their 
sensitivity to DNase digestion (Kerem et al, 1984; Jackson,
1986). Presumably this open state allows the association of 
the transcriptional factors including the RNA polymerase
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with the DNA, an association prohibited by the condensed 
state.
These active chromatin regions appear to be 
compartmentalised to certain regions within the nucleus. 
Many lines of evidence indicate that active regions are 
associated with the nuclear substructure (for review ses 
Jackson, 1986), and that transcriptionally active genes are 
apparently specifically anchored to the nuclear 
matrix/scaffold (for review see Zehnbauer and Vogelstein,
1985). Whether specific sequences are involved in this 
attachment is still under debate (for review see Jackson,
1986). If this is indeed the case, and transcription occurs 
in a complex tightly associated to the nuclear 
matrix/scaffold, then gene units could be activated by 
selective attachment, perhaps through specific sequences. 
Recent evidence has also implied that these 
transcriptionally active regions are under local torsional 
strain (for reviews see Weintraub, 1985; Lucknick, 1986; 
Jackson, 1986). From the data amassed to date, it seems 
plausible that it is the interaction of specific proteins to 
specific sequences located near to the gene unit, which 
induces this change in the level of supercoiling (for review 
see Weintraub, 1985). Indeed, Gasser and Laemmli, (1986), 
have identified specific DNA fragments which are selectivly 
attached to the nuclear scaffold (SARs), and that these are 
located 5' and 3 ’ to three Drosophila genes. Within these 
regions there are both enhancer core consensus sequences and 
sequences closely related to the cleavage consensus of 
topoisomerase II.
In summary, active genes seem to be located in less 
condensed DNA chromatin domains associated with the nuclear 
matrix/scaffold. This association is probably mediated
through specific protein-DNA interactions. In addition
active regions of DNA are probably under local torsional 
stress (Cocherill and Gerrard, 1986). Regulation of this
association is more than likely involved in the
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developmental- and differentiation- specific control of 
expression.
1.7.1. DNase Sensitivity
Alterations in DNA chromatin structure may be identified 
by the presence or absence of DNase 1 sensitivity (Larsen 
and Weintraub, 1982; for a review see Elgin, 1984) and as a 
correlation, active genes can be functionally defined by 
their increased sensitivity to these nucleases. In 
addition, there have been many reports concerning DNase 1 
hypersensitive sites which are associated with specific 
gene units. Such sites are generally found within the 5'and 
3' flanking regions of active genes (McGuinnis et al, 1983; 
Peterson, 1985; for a review see Weintraub and Groudine,
1986) and their presence precedes transcription (for reviews 
see Weintraub et al, 1982; Elgin, 1984). As such they 
appear to represent a potential for transcription (Fritton 
et al, 1984; for a review see Reeves, 1984). Such sites are 
correspondingly lacking in 'silent' genes (for a review see 
Reudelhuber, 1984).
This sensitivity is considered to reflect the positions 
of potential interactions between specific effector proteins 
and DNA. In this respect specific proteins have been shown 
to bind to the upstream sequences of several genes, thereby 
inducing their DNase sensitive sites (Weisbrod and 
Weintraub, 1979; Emerson and Falsenfeld, 1984; Wu, 1984).
DNA-protein interaction may not be the only way in which 
DNAase 1 hypersensitive sites can be generated. Actively 
transcribed DNA is thought to be in the B-configuration, but 
DNA sequences of an alternating purine-pyrimidine nature 
have the potential ability to form the Z-DNA configuration 
(for review see Neidle, 1983; Ellison et al, 1985). Such a 
configuration causes a perturbation in the supercoiling of 
DNA and sequences with this potential have been noted in 
some DNase 1 hypersensitive sites (Benoist et al, 1980). The
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switch from the B- to Z-configuration may be brought about 
by seguence-specific Z-DNA binding proteins (for review see 
Rich, 1982). There is, however, relatively little actual 
evidence for the in vivo presence of the alternative forms 
of DNA. Like Z-DNA, any structure mediated by the energy of 
DNA supercoiling, e.g. the ability of inverted repeats to 
form a cruciform formation (Lilley, 1983), may be of 
relevance in the regulation of gene expression.
1.7.2. DNA Methylation
DNA methylation patterns appear to correlate with 
nuclease sensitivity (Reeves, 1984; Keshet, Lieman-Hurwitz 
and Leder, 1986), and correspondingly active regions of 
chromatin are selectively hypomethylated (Davis et al,
1986). Whether methylation is a cause or consequence of 
gene activation is still open to debate.
1.8. Post-Transcriptional Control of Gene Expression
Gene expression can be regulated post-transcriptionally 
by a variety of mechanisms: formation and processing of the 
primary transcript, transport and stability of the mRNA and 
translational efficiency (for review see Nevins, 1983). 
Regulation at the level of processing of the gene products, 
although of considerable importance, is outwith the scope of 
this thesis and as such will not be discussed further.
(i). Formation and Processing of the Primary Transcript
The 5' mRNA terminus (transcription initiation site) 
is comprised of a terminal 7-methylguanosine residue (added 
post-transcriptionally) linked to a triphosphorylated purine 
(m7GpppPu), and is termed the cap site. Translation is 
mediated through cap-binding proteins and usually initiates 
from the first AUG codon encountered downstream from the 
transcription initiation site (for review see Shatkin, 1985; 
Kosak, 1986). The precise sequence surrounding the AUG
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appears to exert some control over the site of translation 
initiation, with the optimal sequence being 5'-ACCAUG-3' 
(Kosak, 1986). There is evidence that false translational 
starts may be involved in control of gene expression (for 
review see Hunt, 1985).
The 3' terminus of the mRNA, unlike the 5' terminus does 
not correspond to the transcription termination site and in 
eukaryotes a shift in emphasis from transcription 
termination towards RNA processing can be perceived (for 
review see Nevins 1983). The polyadenylation signal has been 
identified as AATAAA (Nevins, 1983, Mason et al, 1985). 
While additional elements (located 3' to the polyadenylation 
signal) have been identified as essential for the correct 
formation of 3' termini in several genes (Georgiev and 
Birnstiel 1985; McLauchlan et al, 1985). Polyadenylation 
may require the presence of certain small nuclear 
ribonucleoproteins (Birnstiel, Busslinger and Straub, 1985; 
Hashimoto and Steilz, 1986).
The primary transcript can be further processed by 
splicing to remove non-coding sequences. In contrast to the 
rapid polyadenylation addition process the subsequent 
splicing of a precursor RNA to the mature mRNA is a 
relatively slow process (for review see Nevins, 1983), and 
probably occurs through consensus sequences by lariat 
formation (Reed and Mannatis, 1985). Thus, the ability to 
achieve alternative splicing obviously allows the cell to 
alter the output of a gene without affecting the 
transcriptional control.
(ii). Transport and Stability of RNA
Once the fully processed, mature, eukaryotic mRNA is 
formed, transport to the cytoplasm must take place to allow 
function (translation). Control of this transport and the 
subsequent stability of the message are both important 
levels of regulation. The poly(A) segment plays a role in
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determining mRNA stability and transport efficiency (for 
review see Nevins, 1983). However, there is some data to 
suggest that other elements within the message are involved 
in stability (Garshi et al, 1985; Piechaczyk et al, 1985) 
and the mRNA cap may also play some role in protecting the 
message from enzymatic degradation (for review see Shatkin,
1985). Recent studies have started to implicate specific 
transcribed sequences which can confer instability to a 
message (Shaw and Kamen, 1896).
(iii). Efficiency of Translation
Even after the myriad of steps, each with its own level 
of control, involved in getting the mature mRNA to the 
polysomes, the level of translation efficiency may be 
regulated. Although no specific consensus sequences have 
been identified which modulate the efficiency of 
translation, 5' untranslated leader sequences have been 
implicated (McGarry and Lindquist, 1985; Pelletier and 
Sonenberg, 1985; Shpaer, 1985).
1.9. Promoter Signals for Genes Transcribed by RNA 
Polymerase II
The molecular mechanisms which underlie the regulation 
of transcription in eukaryotes are still a mystery. 
However, it has been established that eukaryotic cells 
contain three distinct classes of RNA polymerase (for review 
see Chambon, 1975): Class 1, which catalyses synthesis of
ribosomal RNA; Class II, that of mRNA and Class III, that of 
tRNA, 5sRNA and some highly repeated sequences, e.g. B2 
family. The efficiency of transcription of eukaryotic 
protein coding genes is thus dependent on the interaction of 
RNA polymerase II with the transcription cofactors and their 
regulatory sequences within the genes' promoters. Thus the 
mechanisms of this process are dependent on the precise DNA 
sequence of the regulatory regions.
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Therefore defining transcription regulatory signals 
represents an essential step in our understanding of 
eukaryotic gene expression. Analysis of genes transcribed 
by RNA polymerase II has revealed a complex and interrelated 
set of promoter elements. By the comparison of the 5' 
flanking DNA sequences of a large number of eukaryotic 
genes, the concept of a functional promoter domain has been 
formed on the basis of the conserved sequences identified. 
Not all sequences identified are homologous between groups, 
or even present at all in some genes, and as such individual 
promoters are neither structurally nor functionally 
identical. In the following chapters the regions which make 
up the promoter domain and their interactions are discussed.
1.9.1. Transcription Initiation Site
The transcriptional initiation site may, although it has 
not been formally proven, correspond to the 5' terminus of 
the primary transcript (for review see Nevins, .1983). The 
location of transcription initiation is defined by the 
upstream control elements (Mathis and Chambon, 1981). Even 
though certain non-coding conserved sequences surrounding 
the initiation site have been identified (Efstratiadis et 
al, 1980; Sures, Levy and Kedes, 1980), and although not 
directly comparable to each other, they do imply common but 
as yet unknown functions. Several deletion studies have 
shown this short sequence of DNA around the cap to be 
non-essential for efficient gene expression (Benosit and 
Chambon, 1981; McKnight and Kingsbury, 1982; Grosveld et al, 
1982), however recent contrasting data implies that the 
relative positioning with respect to helical periodicity may 
be important (Kovacs and Butterworth, 1986). In addition to 
this major start site, several minor upstream starts have 
been identified in the globin gene family (Zhu, Allan and 
Paul, 1984) and human dihydrofolate reductase gene (Masters 
and Attardi, 1985). The functional significance of such 
transcripts is not understood, although they appear to 
initiate from within putative upstream regulatory sequences
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(Zhu, Allan and Paul, 1984).
Although the presence of only one major transcription 
start site is common, some genes possess two major starts, 
e.g. human c-myc. The best example analysed is that of the 
a-amylase gene where differential usage of the two start 
sites is regulated in a tissue-specific manner (Schibler et 
al, 1983). Additionally, the differential usage of start 
sites has been shown to vary within the adenovirus
replication phase (Osborne and Berk, 1983). Perhaps the
differential usage of start sites will be found to be more
common than considered at the moment.
1.9.2. The TATA Consensus Sequence.
By studying the putative promoter regions of the 
Drosophila histone genes, Hogness (1979) first identified a 
conserved AT-rich sequence 70bp upstream from the ATG
initiation codon. Then by comparing the upstream sequences 
of a number of viral and eukaryotic genes similar AT-rich 
consensus sequences were shown to be located 20-30 bp 
upstream from the transcription initiation sites in these 
genes (Gannon et al, 1979). This, the first RNA polymerase 
II promoter element to be identified, is usually termed the 
TATA consensus sequence (or sometimes the Goldberg-Hogness 
box), and has been regarded as analogous to the Pribnow 
sequence of prokaryotic organisms (Pribnow, 1975).
By comparison of the promoter sequences of 60 eukaryotic
protein coding genes a consensus sequence of the form 
T
5'- TATA^A -3' has been compiled (Breathnach and Chambon, 
1981). The exact position of the TATA-consensus varies 
slightly between genes. However, there are some eukaryotic 
coding genes and some viral genes which do not have an 
analogous sequence (Baker et al, 1979; Flavell et al, 1979; 
Brady ey al, 1982; Dynan, 1986).
There has been extensive in vitro (Grosscheld and
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Birnstiel 1982) and in vivo analysis (Benoist and Chambon, 
1981; Dierks et al, 1983), by deletion and point-mutation, 
with the general consensus that this element functions to 
fix spatially the initiation of transcription. This can be 
correlated with the naturally occuring 5' heterogeneity 
found within certain virus mRNA species, where no 
TATA-consensus is present (Brady et al, 1982). In addition, 
studies where the TATA-consensus has been deleted have 
implicated that it may also have a role in controlling 
transcription efficiency (Dierks et al, 1983). Recently, 
naturally occuring mutations in the TATA-consensus of the 
(3-thalassaemia globin gene with a corresponding affect on 
transcription have been documented (Antonarakis et al, 1984) 
which again argues for the TATA-consensus having a role in 
governing efficiently the correct transcription initiation 
site.
How the TATA-consensus element brings about this 
regulation is not known. However, progress in understanding 
the mechanism should come soon with the isolation of a 
TATA-consensus binding protein (Wu, 1985).
1.9.3. The CCAAT Consensus Seguence
The next RNA polymerase II transcription control element 
was identified by comparison of homologous sequences within 
the 5' flanking region of a number of eukaryotic genes, and 
is termed the CCAAT consensus sequence (Efstratiadis et 
al, 1980; Benoist, et al, 1980). This sequence, 
5 ’-GGTCAATCT-3', is found 50 to 90 bp upstream from the 
transcription initiation site (Benoist et al, 1980) and in 
addition to being highly conserved amongst eukaryotic genes 
(Dierks et al, 1983) is also found in some viral genes (Han 
et al, 1982). In addition, this region shows similarity to 
the -35 region of some Escherichia coli promoters (Benoist 
et al, 1980).
In general, the CCAAT sequence appears to be essential
51
for efficient gene transcription in vivo, but is not 
ubiquitous in nature (Anagnou et al, 1986). Again, how this 
element functions is only now beginning to be analysed with 
the recent isolation of a CCAAT-binding transcription factor 
(CTF: Kadonaga, Jones and Tijan, 1986; Cohen, Sheffery and
Kim, 1986; Mcknight and Tjian, 1986). However due to its 
absence from certain genes and its non-essential role in 
certain other genes (Grosscheld and Birnstiel, 1982), the 
presence of additional upstream sequence elements is 
implied.
As data have become available on a large number of 
eukaryotic genes the 5 1 extent of the promotor sequences 
controlling transcription has become known. In general, 
sequences further upstream than the CCAAT element are 
absolutely required for efficient in vivo gene expression. 
Their identification has been a problem, as unlike the 
TATA-consensus and CCAAT element, there appears to be a lack 
of sequence homology between most of these upstream control 
regions in unrelated promoters. Thus it has not been 
possible to predict the precise location of these upstream 
regulatory elements by homology alone. In most cases, their 
initial identification has been achieved by determining the 
effect of DNA sequence alterations on the level of gene 
transcription. However, some of these regions do show a 
consensus sequence or at least a distinct repeated sequence.
1.9.4. The Upstream Promoter Elements
During the last few years the amount of data on upstream 
promoter elements has increased quite amazingly. As so many 
elements have been identified, a sub-classification can now 
begin to be made. I have grouped these elements into five 
tentative groups, which are themselves diverse in nature, 
and in some cases may indeed overlap each other. All the 
upstream promoter elements appear to have a common 
requirement for a trans-acting factor(s) to activate them. 
Most of these elements are 5' to the TATA-box, however some
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have been located 3' to the coding region or within intronic 
sequences. The first group is the CCAAT-box which has been 
already discussed. It was discussed separately for 
historical reasons only (being the first identified). The 
last group I will mention will be the enhancers, as they 
have given the best insight into how such elements may 
function. Much of the data amassed for enhancers may also be 
considered of relevance to the other upstream elements.
(a ). The GC Rich/SPl Binding Element
Located at approximately the same distance from the 
transcription start site as the CCAAT element, and first 
identified in the SV40 promoter domain, is a GC-rich element 
with the consensus sequences 5' - ^GGCGjjj^jj -3 ' (Vigneran et 
al, 1984; Dynan and Tjian, 1985). This sequence plays a 
critical role in directing efficient transcription not only 
for certain viruses (for reviews see Kadonaga, Jones and 
Tjian, 1986; McKnight and Tjian, 1986) but also for a subset 
of mammalian promoters (Das and Piatigosky, 1986; Dynan et 
al, 1986; Kadonaga, Jones and Tjian, 1986), probably only a 
few of which have been identified (see section 4.). Many of 
the so- called housekeeping genes are in this group, 
possessing numerous GC-rich elements but no obvious 
TATA-consensus (Dynan, 1986).
This upstream promoter element appears to be functional 
in either orientation (possibly bipolar), and is usually 
present in multiple copies, with the most important site(s) 
usually being those proximal to the TATA-consensus (Dynan 
and Tjian, 1985; Kadonaga, Jones and Tjian, 1986; Ishii et 
al, 1986). The trans-acting factor which recognises these 
GC-rich motifs was first identified in SV-40 and is 
designated Spl. This protein has been isolated and purified, 
and shown to exhibit a sequence-specific DNA binding 
activity. Binding of Spl enhances transcription in vitro by 
RNA polymerase II 10-50 fold. Where additional promoter 
elements are present in vivo (e.g. the CCAAT element), Spl
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appears to act in conjunction with other transcription 
factors (e.g. possibly CTF), to stimulate efficient 
transcription (for review see Kadonaga, Jones and Tjian
1986). Although possible, Spl has not been shown to be 
associated with a negative regulator of transcription.
How Spl might function is at the moment unknown. Since 
genes with no TATA-consensus but several GC-rich elements 
show heterogenous transcription start sites (for review see 
Dynan, 1986), perhaps Spl differs in its function to that of 
the TATA-consensus binding factor. The GC-rich domains of 
many promoters contain an unusually high number of GC 
nucleotides, and these dinucleotides are undermethylated 
when compared to the rest of the genome (Bird, 1986). 
Conceivably methylation of these sites may prevent Spl 
interaction. This is only a correlation of observations, but 
perhaps it may be of importance in control of expression. If 
demethylation of the GC dinucleotides is indeed an active 
process then a factor, such as Spl, may play an role in 
their generation.
(b). Receptor-Induced Elements
This, by definition, is a diverse group of upstream 
promoter elements which is basically a subset of enhancer 
elements. More than likely this group will expand as more 
investigation is undertaken. These elements are activated 
by the binding of a trans-acting factor (e.g. a hormone 
activated receptor), which can have the ability to induce an 
individual or a group of genes thus allowing co-ordinate 
control of expression.
The best example is that of the glucocorticoid receptor 
which can activate both the metallothionein gene and Mouse 
Mammary Tumour Virus enhancer (Lato et al, 1984;Karen et al, 
1984; von de Ahe et al, 1985; Moore et al, 1985). Using 
these two systems activation has been shown to be due to an 
active glucocorticoid hormone-recptor complex directly
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binding to the respective enhancer elements (Miksicek et al,
1986). This binding is through the specific recognition 
sequence, 5'- GTGTGGAAAG -3' (Sassone-Corse and Borrelli,
1986). Since this enhancer can function without receptor 
activation, other factors must be able to interact with at 
least some part of the enhancer element (Sassone-Corse and 
Borrelli, 1986), but it is the receptor complex which
confers the specificity to the system. This requirement for 
several factors is clearly seen for the metallothionein 
element where induction can be from heavy metals or 
glucocorticoids, thus impling the presence of several, 
possibly overlapping recognition elements (Sassone-Corse and 
Borrelli, 1986).
Other members of this family include the
oestradiol-receptor complex (Jost, Geiser and Seldran,
1985)and the growth factor induction of the c-fos (Treisman,
1985) and probably c-myc genes (Kelly et al, 1983). These 
elements (and probably other upstream promoter elements) 
have a modular nature, in that the interaction of several 
factors are required (thus several cis-acting recognition 
sequences) for activity. In each case the cis-acting 
response elements will probably reside close to, although 
not necessarily adjacent to the promoters they regulate. 
Recently, the serum-responsive sequence required for
transcriptional activation of the c-fos gene has been 
identified as an inverted repeat of 5'-GATGTCCATA-31 
(Treisman, 1986). It will be interesting to see if any of 
the other serum inducible genes have this (or a similar) 
element adjacent to their promoters.
(d). Enhancer Elements
It is now becoming very hard to define an enhancer 
element because the characteristics originally thought to be 
specific for them are being found to be true for other 
upstream elements. Therefore some of the data already 
amassed for enhancer elements will probably be relevant in
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the understanding of how upstream promoter elements function 
in general. However, enhancer elements can be found in 
addition to other upstream promoter elements in some 
systems.
The list of such elements has expanded rapidly since the 
prototype (the 72 bp repeat element of SV-40) was originally 
identified (Banergi, Rusconi and Schaffner, 1981) and 
includes both viral and eukaryotic examples (for review see 
Khoury and Gruss, 1983).
Although little homology exists among enhancer elements 
from different species, a core sequence has been 
identified as 5'-GTGG G-3', but even this is not 
universal (for review see Khoury and Gruss, 1983). By 
itself this sequence is not sufficient for full function, 
suggesting that neighbouring sequences contribute to enhance 
function (for review see Yaniv, 1984). These elements 
function optimally as an intact element, the regions of 
importance apart from the core element, are still little 
characterised (Cochran and Weissman,1984; Zenke et al, 1986; 
Hearing and Shenk, 1986). Thus enhancers appear to have a 
modular nature, possibly with each sub-element having its 
own specific individual role in allowing the enhancement of 
transcription (e.g. hormone receptor responsive).
In addition to their lack of sequence homology, there is 
little structural similarity between enhancers. Duplicated 
sequences are common (Laimins et al, 1984) but are not an 
absolute requirement, as related viruses without duplicated 
enhancer sequences remain viable (Khoury and Gruss, 1983). 
Of note, there appears to be an homologous duplicated 
sequence upstream from the Xenopus laevis ribosomal gene 
spacer (transcribed by RNA polymerase I: Labhart and Reeder, 
1984). However, enhancer elements do share local homologous 
twist-angle variations with a helical periodicity. This 
recurring spatial geometry may account in part for their 
similar characteristics (Nussinov et al, 1984).
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A comparison of the available data has allowed the 
following in vivo enhancer characteristics to be identified 
(for reviews see Khoury and Gruss, 1983; Serfling, Jasin and 
Schaffner, 1985).
(i).They are able to activate heterologous promoters. Due to 
this property, enhancers have been used to construct high 
level expression vectors for mammalian cells and thus 
allow genes with weak promoters to be analysed.
(ii).They function in an orientation independent manner.
(iii).Enhancers have the property of being able to exert 
their effect over relatively long distances (in some cases 
over several kilobases) although the presence of certain 
sequences may interfere with this property. When adjacent 
to more than one promoter, the enhancement was found to be 
preferentially for the most proximal.
(iv).They can initiate transcription in the absence of an 
apparent endogenous promoter.
(v).They can be located 5'or 3' to, or within an intron of 
the gene.
(vi).There is now quite considerable evidence suggesting 
that there are subtle differences between enhancer 
elements and as a consequence they can function in a 
tissue- and/or species-specific manner.
These properties had set them apart from the upstream 
promoter elements. More recent investigations however, 
suggest that enhancer and promoter elements may overlap both 
physically and functionally (Serfling, Jasin and Schaffner, 
1985; Foster, Stafford and Queen, 1985). How an enhancer may 
function is only now beginning to be understood. Several 
studies have shown enhancer activity to be due to the 
interaction of the DNA sequence with a trans-acting factor
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(Sassone-Corsi, Wilderman and Chambon, 1985; Scholer and 
Gruss, 1985; Gaffeny et al, 1985; Treisman, 1986; Ohlsson 
and Edhund, 1986). In addition, the SV-40 enhancer has been 
shown to increase directly the polymerase density within a 
linked gene, therefore, apparently increasing the rate of 
transcription initiation without influencing the specificity 
of initiation (Weber and Schaffner, 1985; Treisman and 
Maniatis, 1985). Also, DNase sensitive sites sometimes 
correlate with the presence of enhancer sequences in 
chromatin (for review see Khoury and Gruss, 1983).
From this data a speculative model of how enhancers (and 
probably other upstream promoters) may function can be 
proposed. The enhancer element could function in 
association with nuclear proteins to present an 
"open-window" thereby allowing entry of the RNA polymerase
II. Linear diffusion of the polymerase to the control 
promoter elements could then occur, (e.g. CCAAT, Spl, TATA), 
which then spacially fix transcription initiation, 
presumably through their respective trans-acting factors. 
The modular nature of enhancers allows for the interaction 
of several trans-acting factors, possibly each conferring 
its own degree of specificity upon the enhancer.
A recent report on transcription control of the SV-40 
early promoter has provided more information on this aspect. 
This promoter domain contains an enhancer element, a 
Spl/GC-rich domain and a classical TATA-consensus. Upon 
inserting odd multiples of half a DNA turn between each of 
these respective elements (in various combinations), a 
marked decrease in in vivo activity was observed (Takahashi 
et al, 1986). This indicates that the helical periodicity of 
the respective cis-acting elements is crucial, implying that 
the correct ster eospecific alignments between the 
trans-acting factors binding to these elements are essential 
for efficient transcription regulation.
The interaction of upstream elements was shown by recent
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analysis of the HSV-1 IE 4/5 gene (Gaffney et al, 1985). 
The HSV enhancer, the 5'-TAATGARAT-31 consensus sequence, 
responds to a trans-acting viral component, presumably 
opening up the chromatin adjacent to the gene, thereby 
allowing entry of the polymerase. However the GC-rich 
sequences (possibly Spl) near the transcription initiation 
site can affect the magnitude of transcription. The 
enhancer is conferring the specificity to the system.
In addition, several studies have indicated that a 
potential to form Z-DNA may participate in the formation of 
such an "open-window" (Nordhieim and Rich, 1983, Azorin and 
Rich, 1985), but there is as yet little direct evidence that 
Z-DNA actually exists. Recent studies have indicated that it 
is the helical periodicity within and between adjacent 
consensus elements which is of importance (Das and Sulzman, 
1985; Takahashi et al, 1986; Rhodes and Klug, 1986).
Since it has become apparent that full enhancer activity 
can not be achieved in vitro with soluble transcription 
extracts, it has been proposed that higher-order nuclear 
structures are also required. Recent reports give evidence 
for this by identifying nuclear matrix/scaffold-associated 
regions (SARs) associated with both enhancer consensus 
sequences and topoisomerase II recognition elements (murine 
immunoglobulin gene: Cockerill and Garrard, 1986;
Drosophila: Gasser and Laemmli, 1986).
Enhancers function as their name implies, to stimulate a 
positive enhancement of transcription. However, given the 
correct trans-acting factor these cis-acting elements can 
cause the repression of a gene (Gorman, Rigby and Lane, 
1985; Jones, 1986). How this occurs is unknown, but 
presumably it is a function of the respective trans-acting 
factors. To complicate matters the Ela gene product can both 
activate and repress enhancer action (for review see Jones,
1986).
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(d). Other Upsteam Promoter elements
This is a diverse category containing all the elements 
known to-date which do not fall into one of the other 
groups. As these elements are further analysed they will 
probably be found to be members of the other categories. To 
describe each here would be nonproductive, but there are two 
factors of interest with respect to the work presented in 
this thesis.
Firstly, the adenovirus Ela gene product (see section
1.6.4.) has been shown to regulate transcription from its 
own viral genes and from cellular genes. Surprisingly 
perhaps, this trans-acting factor functions in a 
sequence-independent manner (Hearing and Shenk, 1985; 
Kingston, Kaufman and Sharp, 1984). Here we have a 
trans-acting factor which regulates transcription without 
the requirement of an obvious promoter sequence! However, 
another possibility is that the Ela gene product functions 
in association with other sequence-specific DNA-binding 
proteins and is therefore not truly sequence non-specific 
(Nevins, personal communication).
As already mentioned (see section 1.4.1.), the c-myc 
gene may have at least one Nuclear Factor-1 (NF-1) binding 
site in its 5' flanking sequences (Siebenlist et al, 1984). 
There are now several genes (Hennighausen and Fleckenstein, 
1986) which have the consensus sequence, 5 1-TGGCANNATGCCA-3' 
and which bind NF-1 in vivo (for review see Dynan, 1985). 
Until recently no role in transcription regulation had been 
demonstrated for this element, although it had been 
associated with sites of DNase 1 hypersensitivity (for 
review see Dynan, 1985). Upon removal of the domain 
containing the NF-1 recognition sequence from the Hepatitis 
B virus surface antigen promoter there is a 10-fold decrease 
in gene expression observed by transient transfection assay. 
In this system this region has been shown to bind NF-1 
factor in vitro (Shaul, Ben-Levy and De-Medina, 1986).
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Although this is not proof of an in vivo functional 
interaction, it implies that it may occur. NF-1 has been 
shown to stimulate adenovirus DNA replication (de Vries et 
al, 1985). If a role in transcription is positively 
assigned to this factor, it is currently thought likely that 
it would function similarly to Spl and CTF in that it would 
augment expression control, and not confer specificity to 
the system directly (see section 4.). Since these studies 
another factor, NF-III which, has similar characteristics, 
and binds to a sequence which overlaps the NF-I consensus 
has been identified (Pruijin, van Driel and van der Vliet, 
1986).
1.9.5. Summary of Upstream Promoter Elements
Both upstream promoters and enhancer elements may have 
the ability to confer specificity to their individual genes, 
through interaction with specific trans-acting factors. 
They both probably act, enhancers almost certainly do, by 
altering the chromatin state around the gene to be 
transcribed into a more open conformation, thus presumably 
allowing easier access of RNA polymerase II and any 
attendant transcription cofactors. In addition, there would 
appear to be a subclass of upstream promoter elements, with 
their respective trans-acting factors (Spl, CTF and possibly 
NF-1) which somehow augmentt the level of transcription.
Although in the above discussion these elements have 
been termed upstream promoter elements, it must be 
remembered that transcription regulatory elements can be 
located 3' to or within the transcribed unit.
1.10. Negative Regulatory Elements
Specific sequences which promote transcription may only 
be one side of cellular transcription control mechanisms. 
Recent data from several systems has shown that repression 
of transcription may be just as an important mechanism with
61
which cellular integrity is maintained. Two viral gene 
products are known to repress their own synthesis by 
interacting directly with their own promoters: HSV-VP175
(Dixon and Schaffner, 1980) and the SV-40 large T-antigen 
(Rio and Tjian, 1983).
Recently, several genes have been shown to be regulated, 
at least in part, by some form of repressor : the Beadex
locus of Drosphila (Mattox and Davidson, 1984), the H-l 
region of (3-globin (Gilmour et al, 1984), p53 (Bienz-Tadmor 
et al, 1985), rat insulin-1 gene (Laimins, Holmgren-Konig 
and Khoury, 1986), human immunoglobin heavy chain locus 
(Gough, 1985), HMG coenzyme A reductase gene (Gaub et al,
1985), ovalbumin gene (Osborne, Goldstein and Brown, 1985) 
and the yeast mating type locus (Brand et al, 1985). The 
name given to these regions varies (negative regulatory 
element, dehancer, blocker, silencer), however, in each case 
they function similarly to repress transcription (albeit to 
various degrees). The cases which have been studied in 
greater detail show that these negative regulatory elements 
are cis-acting, orientation independent and relatively lax 
about their positioning to homologous or heterologous 
promoters (Gilmour et al, 1984; Brand et al, 1985; Laimins; 
Holmgren-Konig and Khoury, 1986).
At the present moment we can only speculate at how they 
function, although several candidate properties have been 
postulated to be of possible importance. The Hi locus
(Gilmour et al, 1984) has the potential to form Z-DNA while
the rat insulin locus (Laimins, Holmgren-Konig and Khoury,
1986) was identified as a member of a large interspersed
repetitive family. In addition, transcription of the HMG
CoA reductase gene (Reynolds et al, 1984) appears to be 
inhibited by sequences present in the untranslated leader 
sequences. Whether these properties are of any relevance to 
the repression function awaits analysis. Although the 
individual DNA sequences will be essential, the effector 
must be a trans-acting factor. This has been clearly
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illustrated by the extinction experiments in cell hybrids 
(Killary and Fournier, 1984) where the extinction 
(repression) of a given tissue-specific trait was correlated 
to a specific locus.
Transcription repression requires cis-acting sequences 
(negative regulatory elements: NRE) to be postulated (Renan, 
1985). More than likely these sequences will only function 
when the correct trans-acting factor (repressor) interacts 
with them. In possibly analogous bacterial systems, more is 
known about this repressor-NRE interaction (for review see 
Papo and Sauer, 1984). The bacterial repressor is thought to 
be a symmetrical protein which binds to one side of the 
double helix (i.e. the recognition sites are lObp apart). 
This recognition sequence (to which the repressor interacts) 
is thought to reside in the major groove of the B-DNA double 
helix (Pabo and Sauer, 1984). The periodicity and thus the 
relative positioning of the recognition sequence may be 
crucial for repressor binding, similar to what is currently 
thought for positive regulators. Activation of the gene 
would then require removal or inactivation of the repressor, 
or the presence of an activator.
The work described in this thesis identifies a NRE in 
the 5' flanking sequences of the human c-myc gene and as 
such this topic will be expanded in section 4 of this 
thesis.
1.11. The Transcription Termination Signal
Transcription 3' end processing in eukaryotes is 
heterogeneous, but regulated, and depends on specific DNA 
sequences downstream of the 3' processing site (s) 
(McLauchlan et al, 1985; Birnsteil, Busslinger and Strub,
1985). The factors which regulate termination of 
transcription and subsequent 3' end processing are as yet 
only vaguely understood.
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Since alternative 3' ends can be generated, and the 
actual 3' end achieved may in turn control processing events 
or affect the stability of the transcript, this is, an 
obvious point at which expression could be controlled. 
However, this is not at the level of control of 
transcription. There are examples where 3' sequences affect 
the level of expression of a gene but this is presumably due 
to post-transcriptional effects (Triesman, 1985). As of yet 
there are no examples where 3' sequences regulate the level 
of transcription initiation.
1.12. The Promoter Domain : A Summary
Although I have described each transcriptional element 
individually it cannot be over-stressed that they function
together as a whole to form the full functional promoter 
domain of a gene. Although individual elements have been 
identified how they function is still unknown, but
speculations can be made.
One interpretation of what happens in the promoter 
domain could be as follows. Upon activation of the upstream 
promoter/enhancer elements, mediated by a trans-acting 
factor, an open chromatin state is induced, which we can
detect due to its increased sensitivity to DNase 1
digestion. Somehow these active regions are associated with 
the nuclear substructure and there is now some evidence that 
this may involve enhancer-like elements. This state then 
allows entry of the RNA polymerase II, and any required 
cofactors, onto the DNA. The polymerase then diffuses along 
the DNA until recognising the transcription initiation 
control elements; possibly the TATA- , SPl- or CCAAT- 
elements as they are in nature conserved sequences. These 
elements (and thus the trans-acting factors which recognise 
them) may help to regulate the magnitude of transcription. 
The specific sequences of the individual upstream 
promoter/enhancer elements probably confer the species, 
tissue and temporal regulation upon specific genes.
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Negative regulatory elements could function to prevent the 
binding or movement of the polymerase, presumably by the 
binding of a specific factor (repressor) to this site. At a 
higher level nucleosome spacing could form the basis of the 
selective gene expression during development and 
differentiation (Stein and Kunzler, 1983).
Co-ordinate control of an individual or group of genes 
could be mediated by trans-acting factors binding to gene 
specific upstream control sequences. Specificity in these 
systems could be conferred by the specific cis-acting 
element, the trans-acting factor or the presence of several 
trans-acting factors (repression or activation).
1.13. RNA Polymerase II Associated Factors
These are general factors unlike the specific proteins 
previously discussed, which are involved in generating a 
transcription complex and not transcription activation. By 
definition, RNA polymerase II must be capable of binding to 
DNA to function, but it lacks any inherent ability to 
recognise specific sequences and as such will initiate 
transcription totally at random (for review see Lewis and 
Burgess, 1982). Initiation only occurs at specific sites 
upon the presence of the previously discussed 
promoter-associated factors. It is now thought that there 
are other factors which interact with the polymerase to form 
preinitiation and initiation complexes, and only then 
transcription occurs (Culotta, Wides and Sollner-Webb, 1985; 
Safer et al, 1985; Sawadogo and Roeder, 1985).
1.14. Rational for Work Presented in this Thesis
Since aberrant expression of the human c-myc oncogene is 
observed in transformed cells, and expression of c-myc in 
conjunction with the c-ras oncogene induces transformation, 
the regulation of its expression can be expected to be 
tightly regulated in the normal cell. From serum induction
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studies (Kelly et al, 1983) and the expressional silence of 
the normal allele in Burkitt's lymphoma cells (for review 
see Leder et al, 1983), a repressor has been postulated to 
control, at least in part, c-myc transcription. As
previously discussed, most transcriptional regulatory 
elements are located 5' to a gene, but elements 3' or even 
within introns have been identified (but current data would 
implicate the 5' region in c-myc: for review see Leder et
al, 1983). DNase I sensitivity analysis (Siebenlist et al, 
1984) correlates with the location of chromosome
translocation breakpoints (for review seee Leder et al, 
1983) to locate the hypothetically reguired cis-acting 
negative regulatory element to the 5' flanking sequences of 
the c-myc oncogene. However it is possible that a 
non-specific interaction could occur thus negating any 
requirement for a cis-responsive sequence element.
The aim of the work described in this thesis was to 
identify and localise such a negative regulatory element 
(NRE), if one was present, by analysis of the 5' flanking
sequences of the human c-myc oncogene with functional
expression assay, in cell cultures growing in log phase. As 
a consequence of such a search other cis-acting elements 
present in this region could be identified (as described 
c-myc expression is regulated by several factors: serum,
interferon, the differentiation state). In addition, 
although the dual promoter region contains two TATA-boxes 
(Battey et al, 1983) there is no easily identifiable 
upstream promoter, although there are candidate domains. 
The presence of such a promoter (again if one was present), 
or any additional transcriptional regulatory element, would 
also be identified in the line of this research.
By identifying the transcriptional regulatory elements 
involved in c-myc expression a greater insight into how 
c-myc is deregulated in the transformed cell will hopefully 
be achieved.
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Figure 1.
Comparison of the Sequenced Genomic c-myc Genes.
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M
Depicted in this diagram is the genomic structure, to 
scale, of the various cellular myc genes sequenced. H = 
human c-myc; N = human N-myc; F = feline c-myc; M = murine 
c-myc; C = chicken c-myc (Bernard et al, 1983"; Nottenburg 
and Varmus, 1986; Stewart et al, 1986; Kohl et al, 1986).
Boxes represent exons; open being untranslated, shaded being 
translated. The known transcription initiation sites are 
indicated by arrows (with the human major start sites 
designated PO, PI and P2); where heterogeneous starts occur 
these have been shown by an open end (dots) to the first 
exon.
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Figure 2.
Human c-myc 5' Flanking Region.
Shown below (A.) are the in vivo DNase I hypersensitve 
sites (indicated by Roman numerals and solid arrows, 
Siebenlist etal, 1984) within the human c-myc region, and 
relevant restriction sites (see figure 8 tor key). The 
relative intensities of the DNase I hypersensitve sites are 
indicated by the width of the arrow. The sequence 
corresponding to the indicated region (sequence) is shown on 
the next page (B.). PI and P2 refer to Oie two major 
transcription' initiation sites (PO has not been localised 
accuratly; Bentley and Groudine, 1986).
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B -2261TTTTTTTCGTCTATGTACTTGTGAATTATTTCACGGTTTGCCATTACCGGTTCTCCATAGGGTGATGTTCATTAG-2186CAGTGGTGATAGGTTAATTTTCGACCATCTCTTATGCGGTTGAATAGTCACCTCTGAACCACTTTTTCCTCCAGT
-2111
AACTCCTrTTTCTTCGCACCTTCTGCAGCCAACCTGAAAGAATAACAAGGAGGTGGCTGGAAACTTGGTnTAAG
~PsTT- ■ '
-2036
GAACCGCCTGTCCTTCCCCCGCTGGAAACCTTGCACCTCGGACGCTCCTGCTCCTGCCCCCACCTGACCCCCGGC
-1986
CCTCGTTGACATCCAGGCGCGATGATCTCTGCTGCCAGTAGAGGGCACACTTACTTTACTTTCGCAAACCTGAAC 
Hind I
-1911 I
GCGGGTGCTGCCCAGAGAGGGGGCGGAGGGAAAGACGCTTTGCAGCAAAATCCAGCATAGCGATTGGTTGCTCC 
---- > I- I
-1836
CGCGTTTGCGCAAAGGCCTGGAGGCAGGAGTAATTTGCAATCCTTAAAGCTGAATTGTGCAGTGCATCGGATTTG 
I 761
GAAGCTACTATATTCACTTAACACTTGAACGCTGAGCTGCAAACTCAACGGGTAATAACCCATCTTGAACAGCGT
ACATGCTATACACGCACCCCTTTCCCCCGAATTGTTTTCTCTTTTGGAGGTGGTGGAGGGAGAGAAAAGTTTACT
 >
-1611
TAAAATGCCTTTGGGTGAGGGACCAAGGATGAGAAGAATGTTTTTTGTTTTTCATGCCGTGGAATAACACAAAAT
-1536
AAAAAATCCCGAGGGAATATACTATTATATATTAAATATAGATCATTTCAGGAGCAAACAAATCATGTGTGGGGC
Aval
-1461
TGGGCAACTAGCTAAGTCGAAGCGTAAATAAAATGTGAATACACGTTTGCGGGTTACATACAGTGCACTTTCACT 
-1386 II-l
GATATTCAGAAAAAATTGTGAGTCAGTGAACTAGGAAATTAAATGCCTGGAAGGCAGCCAAATTTTAATTAGCTC
- 1311
AAGACTCCCCCCCCCCCAAAAAAAGGCACGGAAGTAATACTCCTCTCCTCTTCTTTGATCAGAATCGATGCATTT
Clal
-1236
TTTGTGCATGACCGCATTTCCAATAATAAAAGGGGAAAGAGGACCTGGAAAGGAATTAAACGTCCGGTTTGTCCG
-1161
GGGAGGAAAGAGTTAACGGTTTTTTTCACAAGGGTCTCTGCTGACTCCCCCGGCTCGGTCCACAAGCTCTCCACT
HincII
-1086 Rsal
TGCCrCTTTTAGGAAGTCCGGTCCCGCGGTTCGGGTACCCCCTGCCCCTCCCATATTCTCCCGTCTAGCACCTTT
Kpnl------- *----
-1011
GATTTCTCCCAAACCCGGCAGCCCGAGACTGTTGCAAACCGCCACAGGGCGCAAAGGGGATTTGTCTCTTCTGAA
-936
ACCTGGCTGAGAAATTGGGAACTCCGTGTGGGAGGCGTGGGGGTGGGACGGTGGGGTACAGACTGGCAGAGAGCA 
*-• 1 Rsal
-861
GGCAACCTCCCTCTCGCCCTAGCCCAGCTCTGGAACAGGCAGACACATCTCAGGCTAAACAGACGCCTCCGCACG 
-786 H -2
GGGCCCCACGGAAGCCTGAGCAGGCGGGGCAGGAGGGGCGGTATCTGCTGCTTTGGCAAGAATTGGGGGACTCAG
-711
TCTGGGTGGAAGGTATCCAATCCAGATAGCTGTGCATACATAATGCATAATACATGACTCCCCCCAACAAATGCA
-636
ATGGGAGTTTATTCATAACGCGCTCTCCAAGTATACGTGGCAATGCGTTGCTGGGTTATTTTAATCATTCTAGGC 
Thai AccI
-561
ATCGTTTTCCTCCTTATGCCTCTATCATTCCTCCCTATCTACACTAACATCCCACGCTCTGAACGCGCGCCCATT
-486
AATACCCTTCTTTCCTCCACTCTCCCTGGGACTCTTGATCATAAGGCGCGGCCCTTTCCCCAGCCTTAGCGAGGC
-411
GCCCTGCAGCCTGGTACGCGCGTGGCTGGCGGTGGGCGCGCAGTCGTTCTCGGTGTGGAGGGCAGCTGTTCCGCC
PstI  ^PvuII
-336
TCGGATGATTTATACTCACAGGACAAGGATGCGGTTTGTCAAACAGTACTGCTACGGAGGAGCAGCAGAGAAAGG
-261
GAGAGGGTTTGAGAGGGAGCAAAAGAAAATGGTAGGCGCGCGTAGTTAATTCATGCGGCTCTCTTACTCTGTTTA
-186 III-l
CATTCCTAGAGCTAGAGTGCTCGGCTGCCCGGCTGAGTCTCCTCCCCACCTTCCCCACCCTCCCCACCCTCCCCA<  <---
- 1 1 1
TAAGCGCCCCTCCCGGGTTCCCAAAGCAGAGGGCGTGGGGGAAAAGAAAAAAGATCCTCTCTCGCTAATCTCCGC
Smal  .
*36   fp"l^
CCACCGGCCCntflVTAjjTGCGAGGGTCTGGACGGCTGAGGACCCCCGAGCTGTGCTGCTCGCGGCCGCCACACCG 
-U) III-Z
g gccccggccgtccctggctc^c ct cc t g c ct c ga ga a gg g ca gg g ct tc t ca ga g gc t t g g c g g^aaaaagaac
-115 f~P2
GGAGGGAGGGATCGCGCTGACffATA^AAGCCGGTTTTCGGGGCTTTATCTAA
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Figure 3.
The Cell Cycle.
There are three phases to within the G0-G1 period of 
the cell cycle. There is GO, where the cells are quiscent. 
Certain growth factors can stimulate cells in GO to enter 
Gl. They are termed Competence Factors (e.g. PDGF, 
platelet-derived growth factor; EGF, epidermal growth 
factor; FGF, fibrobast growth factor; IL-2 and IL-3, 
interlukin 2 and 3). The Progression Factors are then 
required to allow traverse of the Gl phase (through a 
restriction point, RP - still ill defined). In the final 
phase the cells are commited to finish the cell cycle 
(although there may be another restriction point within G 2 ). 
Where the expression of an oncogene is transiently effected 
within the cycle, it has been indicated. A 68K protein has 
been proposed to be involved in the overcoming of the Gl 
restriction point. (Stiles et al, 1979; Kelly et al, 1983; 
Reed et al, 1985; Conscience, Verrier and Martin, 1986; 
Treisman, 1986; and data presented at a UCLA Symposium,
1986).
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Figure 4.
Selected Burkitt's Lymphoma Breakpoints.
Depicted in the diagram are some (not all) of the known 
Burkitt's lymphoma (BL) breakpoint locations. The Roman 
numerals indicate the appropriate DNase 1 hypersensitive 
sites (Siebenlist et al, 1984). The arrows indicate the two 
major human transcription start sites (PI and P2). The 
individual BL cell lines are as described in Bernard et al, 
(1983); Saito et al, (1983); Taub et al, (1984a and 1984b); 
Rabbits et al, (1984); Denny et al, (1985); Show et al, 
(1985).
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Figure 5.
Selected Murine Plasmacytoma Breakpoints.
Depicted in the diagram are some (not all) of the known 
murine plasmacytoma (MPC) breakpoint locations. The Roman 
numerals indicate the appropriate DNase 1 hypersensitive 
sites (Fahrlander, Piechaczyk and Marcu, 1985). The arrows 
indicate the two major murine transcription start sites (PI 
and P2). The individual MPC cell lines are as described in 
Bernard et al, (1983); Cory, Gerondakis and Adams, (1983); 
Yang et al, (1985); Fahrlander, Piechazyk and Marcu, (1985); 
Calibi and Neuberger, (1985).
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CHAPTER TWO
MATERIALS AND METHODS
73
2.1. Materials
Unless othrewise stated, all chemicals were obtained
from BDH Chemicals, Poole, Dorset, UK, or Sigma Chemical Co,
St Louis, Missourri, USA.
Biorad Laboratories, Richmond California, USA:
Ammonium persuphate, TEMED, protein assay kit II.
Pharmacia Fine Chemicals, Uppsala, Sweden:
Sephadex G50, polynucleotide kinase.
Vestric, Glasgow, Scotland, UK: '
Ampicillin.
Fluka, Buchs, Switzerland:
Piperidine.
Aldridge Chemical CO Ltd, Gillingham, Dorset, UK: 
Dimethylsulphate.
Schwarz Mann Biochemicals, Wembley, Middlesex, UK:
Urea.
BRL, Rockville, Maryland, USA:
Agarose, low melting point agarose, all restriction 
endonucleases, bacterial alkaline phosphatase, Klenow 
large fragment, T4 DNA polymerase.
Amersham International, Ailesbury, UK 
■^C chloramphenicol.
Collaborative Research Inc, Massachusetts, USA:
Molecular linkers.
Boehringer Mannheim, Lewes, East Sussex, UK:
DNase I .
Gibco Ltd, Paisley, Scotland, UK:
Special liguid medium.
Fisons PLC, Loughborough, UK:
Ethyl acetate.
Difco Laboratories, Detroit, Mitchigan, USA:
Bactopeptone, yeast extract.
Northumbrian Biologicals Ltd, Cramlington, UK:
Foetal bovine serum, glutamine.
Camlab, Cambridge, UK:
Chromatography plates.
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2.2. Construction of Recombinant Plasmids
All recombinants used in this thesis were constructed 
by manipulation of one of three existing plasmids; pMC41 
(kindly given by T.Papas), pLW2 (kindly given by B.Clements) 
and peO-1 (kindly given by J.Lang). The vector plasmids used 
were pUCl2, pUC18 (Messing and Vieira, 1982) and pAT153 
(Twigg and Sherrat, 1980).
2.2.1. Growth and Storage of Parental Plasmids
10 ml of L-broth (1% tryptone, 0.5% yeast extract, 1% 
NaCl) containing 100 pg/ml ampicillin was inoculated with 
host bacterium Esherichia coli K12 strain JM83 containing 
parental plasmiids (containg the amp^ gene) and incubated 
overnightat 37°C in an orbital shaker. 9 ml of the resulting 
culture were centrifuged at 2 G for 15 min and resuspended 
in 1 ml of 80% glycerol, 2% bactopeptone, therefore allowing 
storage at -20°C. The remaining 1 ml was then used to 
inoculate 1-2 volumes 500 ml L-broth, and incubated for 20 
hr at 37°C in an orbital shaker. Bacterial cultures were 
subsequently harvested by centrifugation for 1 min at 8000 G 
and 4°C.
2.2.2. Extraction of Plasmid DNA
Plasmid DNA was isolated by modification of a 
previously described method (Clewell and Helinski, 1970). 
The pellets were resuspended in 10 ml of 25% (w/v) sucrose 
in 50 mM Tris-HCl pH 8.0, 5 ml 5 mg/ml (w/v) lysozyme and
5 ml 0.2 M EDTA pH 8.0 added respectively, and the bacterial 
lysate left for 30 min at room temperature. 600 pi of 10% 
Nonidet P-40 in 50 mM Tris-HCL pH 8.0, was then added and 
the tubes inverted until the lysate became viscous. The 
lysate was spun at 15000 G and 4°C for 30 min. The 20 ml 
supernatant was removed and extracted once with an equal 
volume of phenol, equilibrated in 50 mM Tris-HCl pH 8.0, and 
once with an equal volume of chloroform : isoamyl alcohol
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(24:1 v/v). The supernatant was removed, 50 pi of pre-boiled 
(10 min) RNase A (1 mg/ml): RNase T1 (10000 unit/ml) added
(Lonsdale et al, 1979), and incubated at 37°C for 30 min. 
The plasmid preparation was then extracted once with an 
equal volume of equilibrated phenol, and once with an equal 
volume chloroform : isoamyl alcohol (24:1 v/v). The purified 
plasmid was then precipitated for 90 min by the addition of 
1/10 volume 7.5 M ammonium acetate pH 7.5, and an equal 
volume of isopropanol (Marmur, 1961). The DNA pellet was 
quickly washed with 100% ethanol, lyophilised and 
resuspended in 500-1000 pi of 0.1 M TrisHCl pH 8.0, 0.1 M
EDTA. The resulting DNA preparation contains mostly 
supercoil plasmid, some relaxed circle plasmid and very 
slight traces of contaminating E .coli DNA.
2.2.3. Identification of Plasmids by Restriction
Endonuclease Digestion and Gel Electrophoresis
All recombinant plasmids constructed were confirmed 
by extensive restriction enzyme digestion, and subsequent 
identification by either agarose or polyacrylamide gel 
electrophoresis.
(i) Restriction Endonuclease Digestion
An appropriate amount (1-3 pg) of plasmid DNA was 
digested by incubation for 3 hr at 37°C in the suppliers 
recommended buffers with spermidine added to 1 mM. Digestion 
was terminated by the additon of 1/10 volume gel loading dye 
containing, 10% w/v Ficoll 400, 0.1 M EDTA and 0.05 w/v
bromophenol blue.
(ii) Agarose Gel Electrophoresis
DNA samples were electrophoresed on 0.5-2.0% 
horizontal gels (depending on expected molecular weights of 
DNA fragments generated) containing 0.5 pg/ml ethidium 
bromide at 2-5 V/cm for 1 hr-overnight, at room temperature
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in 1 x TBE buffer (0.089 M Tris-borate, 0.089 M boric acid, 
10 mM EDTA pH 8.0).
(iii) Polyacrylamide Gel Electrophoresis
Gels were formed by the addition of an appropriate 
volume of 29% w/v acrylamide : 1% w/v N,N’-methylene-
bisacrylamide stock solution diluted as required by the 
addition of water, 1 x TBE buffer, and 500 pi 10% ammonium 
persulphate, and gel formation catalysed by the addition of 
50 pi N,N,N',N'-tetramethylethylenediamine (TEMED) / 100 ml. 
DNA samples were electrophoresed on 4-8% gels in 1 x TBE 
buffer at 20 V/cm and room temperature. Gels were stained in 
1 x TBE buffer containing 1.0 pg/ml ethidium bromide.
(iv) Gel Photography
Gels were photographed under UV irradiation (365 nm) 
using Polaroid type 55 or type 57 film.
2.2.4. Isolation of Purified Restriction Fragments
Restriction endonuclease digested DNA was 
electrophoresed on low melting point agarose (LMA) gels in 1 
x TBE buffer in the presence of 0.3 pg/ml ethidium bromide. 
The appropriate DNA fragments were then excised and 
extracted by a modification of the method of Weislander, 
(1979). The excised LMA fragment was heated to 70°C for 5-10 
min in 1 volume distilled water and then allowed to cool to 
40°C. The DNA solution was extracted once with ice cold 
phenol, then twice with room temperature phenol, and the 
volume reduced to 200 pi with butan-2-ol. The DNA was then 
precipitated with 1/10 volume 7.5 M ammonium aetate pH 7.5, 
and 1 volume isopropanol at -70°C for 60 min. The purity of 
the DNA fragment was checked on an agarose gel (see section
2.2.3.).
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2.2.5. Preparation of Vector DNA
Vector DNA was subjected to appropriate restriction 
enzyme digestion and electrophoresed on a low melting point 
agarose gel at 3 V/cm for 1 hr at 4°C, and purified as 
previously described. Because the colour selection technigue 
(pUC vectors: Messing and Vieira, 1982) was used, there was 
no requirement to phosphatase the vector DNA. However, when 
very small fragments were to be cloned and the colour 
selection technique was not available, the vector was 
phosphatased. Rather than putting the digested vector DNA 
through a LMA gel, the digestion solution was diluted with 
one volume 50 mM TrisHCl pH 7.5, and incubated at 65°C for a 
further 2 hr with bacterial alkaline phosphatase (BAP) as 
recommended by the suppliers. The phosphatased DNA was 
extracted twice with phenol, once with chloroform and 
ethanol precpitated. Subsequently, the prepared DNA was 
ligated as described in section 2.2.7.
2.2.6. Use of Molecular Linkers
The presence of fortuitous restriction enzyme sites 
correctly positioned to allow constuction of particular 
recombinant plasmids is a rare event, and more often it is 
necessary to convert undesirable restriction sites to those 
required by the addition of synthetic molecular linkers 
(Heyneker et al, 1976). For this thesis only BamHI and 
Hindlll linkers were used.
(i) Molecular Linker Addition to Blunt Ended DNA
0.5-2 pg purified DNA previously cut with restriction 
enzymes which generate blunt-ended molecules (HincII, Rsal, 
Smal, Thai and PvuII for this thesis) was ligated with 50 x 
excess of phosphorylated synthetic linker molecules under 
conditions descibed in section 2.1.7. Ligation was 
terminated by heating at 65°C for 10 min, and the DNA 
cleaved with the appropriate restriction endonuclease to
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remove excess copies of the linker molecules. DNA was then 
separated from unused linkers by low melting point agarose 
gel electrophoresis, or by precipitation with 1/2 volume 
isopropanol at room temperature (a technique which allows 
selective precipitation of DNA while the molecular linkers 
remain in solution : J.Lang, personal communication).
(ii). Molecular Linker Addition to 'Sticky End' DNA 
(5'Overhang)
On DNA cleavage certain restriction enzymes produce a 
5' overhang which must be removed before molecular linker 
addition is possible. This was done by the addition of the 
nucleotides complementary to those of the 5' overhang, 
catalysed by Klenow large fragment DNA polymerase. 2-3 pg of 
cleaved DNA was incubated for lhr at 15°C in 50 pi reaction 
volume and 50 mM TrisHCl pH 7.8, 5 mM M g C^, 1 mM DTT, with 
complementary nucleotides to 20 pM and 5 units Klenow. The 
reaction was terminated by phenol extraction and the DNA was 
selectively precipitated with isopropanol at room 
temperature.
(iii) Molecular Linker Addition to Vector DNA
When molecular linkers were ligated to a restriction 
site within vector DNA molecules, removal of excess linker 
molecules by restriction enzyme recleavage was considered 
unnecessary. Under these circumstances, the ligated product 
was transfected directly into the host bacteria. Routinely, 
a high proportion (up to 80%) of the recombinant clones 
contained the linker insert, either produced by 
circularisation of the vector molecules in vitro after 
linker addition, or by homologous recombination across a 
ladder of linker inserts in vivo. This method has allowed 
the generation of recombinant clones containing analogous 
linker inserts at a number of sites.
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2.2.7. Ligation of 'Target' and Vector DNA
Ligation was performed by a modification of a 
previously described method (Tanaka and Weisblum, 1975). 
50-100 pg of vector DNA was mixed with a 3 molar excess of 
'target' DNA (fragments to be recloned) and ligated in the 
presence of 10 mM TrisHCl pH 7.6, 10 mM MgC^, 10 mM DTT,
0.5 mM ATP and 1-2 units T4 DNA ligase in a 10 pi reaction 
volume, for 5-16 hr at room temperature. For all such 
ligations the plasmid vector was pAT153 (a deletion mutant 
of pBR322; Twigg and Sherratt, 1980), or more often one of 
the pUC family of plasmids (Messing and Vieira, 1982).
2.2.8. Transformation of Competent Bacterial Host Cells
Host JM83 bacteria were transformed with ligated 
plasmid as previously described (Cohen et al, 1972). 100 ml
of E .coli K12 strain JM83 bacterial cells were grown to an 
optical density of 0.4 at 600 nm, harvested by
centrifugation for 1 min at 8000 G and 4°C, washed by 
resuspending in 1 volume of ice cold 10 mM TrisHCl pH 7.5, 
100 mM MgCl 2 , and swirled gently for 5 min, before 
harvesting as before. The bacterial pellet was resuspended 
in 1 volume 10 mM TrisHCl pH 7.5, 100 mM CaC^, and left on 
ice for 1 hr. The cells were harvested as before. The cells 
were then resuspended in 1/50 volume 10 mM TrisHCl pH 7.5,
100 mM CaCl2 , and if kept at 4°C were found to be viable for
up to 5 days (with the highest effiency after 12-24 hr). 
Ligated plasmids were then added to 200 pi of competent 
cells and left on ice for 30 min, to allow the DNA to come 
into contact with the bacterial cells. To facilitate entry 
of the DNA into the bacteria, the cell-DNA mixture was 
heat-shocked at 37°C for 5 min. The cell suspension was
incubated with 800 pi of L-broth for 90 min at 37°C. 300 pi
aliquots were then spread over 90 mm L-broth 1.5% agar 
plates containg 100 pg/ml ampicilin, 25pg/ml X-gal 
(5-bromo-4-chloro-3-indolyl-P-galactoside : chromogenic
substrate for (3-galactosidase) and incubated overnight at
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37°C.
2.2.9. Screening Bacterial Colonies for Specific
Recombinants
Ampicillin resistant colonies were screened for the 
desired recombinant plasmids by 'mini-preps' analysis. This 
method was thought to be more efficient than filter 
hybridisation.
(i) Mini Preps
12-48 single bacterial colonies were picked from the 
original plates with sterile cocktail-sticks, and shaken 
into 1ml of L-broth containing 100 pg/ml ampicillin, and 
grown overnight at 37°C in an orbital shaker. The cells were 
harvested by spinning at .16000 G for 20 sec. The pellets 
were resuspended in 75 pi STET buffer (8% w/v sucrose, 50 mM 
TrisHCl pH 8.0, 50 mM EDTA, 5% v/v Triton X-100) with fresh
lysozyme added to 1 mg/ml. This solution was placed in a 
boiling water bath for 50 sec. The bacterial lysate was then 
centrifuged at 16000 G for 8 min. The supernatant was 
recovered, and plasmid DNA precipitated by addition of 1 
volume isopropanol on dry ice for 5 min. The DNA was
recovered by centrifugation at 16000 G for 10 min. The
pellets were then lyophilised for 1 hr, and resuspended in 
50 pi of water. This method yields about 6 pg of plasmid 
DNA.
(ii). Identification of Correct Recombinant by Gel 
Electrophoresis
Recombinant clones identified by the 'mini-prep' 
method were then digested with appropriate restriction
enzymes and electrophoresed on agarose gels at 4.5 V/cm for
1-3 hr, or after a 30 min treatment with RNase A/Tl (see 
section 2.2.2.), followed by phenol extraction on
polyacrylamide gels at 20 V/cm for 1-2 hr.
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2.3. Transient Expression Assays
In the studies presented within this thesis various 
DNA domains were used to drive the expression of a reporter 
gene (CAT) in transient transfection studies.
2.3.1. Recipient Cells
All the cell lines described were obtained from the 
Beatson Institute reference stocks. During these studies the 
following cells were used.
(a). LaTK" cells, (Kit et al,1963); a thymidine kinase 
negative varient of the mouse fibroblast derived cell line 
(L cells).
(b). HeLa cells, (Scherer, Syverton and Gey, 1953); derived 
from a human epithelial carcinoma.
(c). K-562 cells, (Lozzio and Lozzio, 1975); derived from a 
human erythroid leukaemia, the actual varient used was 
selected for its increased adhesive property (D.Spandidos).
(d). NIH-3T3 cells (Jainchill, Aaronson, and Todaro, 1969); 
a fibroblastoid contact-inhibited varient derived from a NIH 
Swiss mouse embryo.
(e). GM468 cells (NIGMS, Human Genetic Mutant Cell 
Repository); derived from normal human fibroblasts.
(f). MRC-5 cells (Jacobs, Jones and Bailie, 1970); a human 
primary fibroblast culture, capable of attaining 42-46 
population doublings before onset of decline in 
proliferation.
2.3.2. Cell Culture
Cells were grown in Special Liquid Medium (SLM) 
supplemented with glutamine to 4 mM and foetal calf serum to 
13% at 37°C, in 10% C02/air. Cells were refed every 2 days 
to ensure optimal health and were passaged by sequential 
washes in phosphate buffered saline (PBS), 10% trypsin/ 
citruline and finally resuspended in an appropriate volume 
of medium. Cell numbers were measured in a coulter counter.
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Cell stocks were made by resuspending 10^ cells in medium 
plus 10% glycerol, and immediatly placing them at -70°C, 
with final storage being under liquid nitrogen.
2.3.3. DNA Mediated Gene Transfer
The introduction of CAT recombinant plasmids into 
mammalian cells in culture (DNA mediated gene transfer) was 
performed by the calcium phosphate co-precipitation 
technique (Graham and Van Der Eb, 1973), using a 
modification of the method described by Wigler et al, 
(1977). The levels of CAT expressed was then measured by 
enzyme assay shortly after transfection (i.e. transient 
expression).
(i). Estimation of DNA Concentration
The DNA concentration was measured by obtaining an 
optical density reading. This value was confirmed by a 
visual estimation of DNA concentration. Uncut plasmid was 
electrophoresed on 0.6% agarose gels and the DNA 
'eyeballed'. By using a range of sample amounts and 1 pg of
commercial pUC12 DNA an accurate value was obtained. This
also allowed the DNA purity to be observed. Such a technique 
ensures molar equivalents of each recombinant plasmid are 
used when introducing DNA into recipient cells.
(ii). Calcium Phosphate Co-Precipitation of DNA
Recombinant plasmid DNA and commercial salmon sperm 
DNA as carrier (except in the competition experiments, where 
pUC12 plasmid DNA was used), were diluted to a final 
concentration of 20 pg/ml by the addition of an appropriate 
volume of water HEPES bufered saline (5 g/L HEPES [N- 2-
hydroxyethyl-piperazine- N ’- 2- ethenesulfonic acid], 8 g/L 
NaCL, 0.1 g/L Na2HP04 pH 6.95, and subsequently CaCL2 to 125 
mM. The solution was then left to stand for 30 min at room 
temperature, to allow a calcium-phosphate precipitate to
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form and concomitantly co-precipitate the DNA. 1 ml of the 
precipitate (in suspension) was then added, by dropping, to 
approximately 10^ recipient cells (5 x 10^ cells when using 
K-562 cells), exponentially growing at 37°C in tissue 
culture flasks of surface area 25 cm , in 9 ml of culture 
medium.
(iii). Harvesting of Cells
Cells were routinely harvested 44-48 hr after 
transfection, basically by the method of Gorman, Moffat and 
Howard, (1982). The cells were washed with PBS carefully, 
and then allowed to sit at room temperature in 1 ml TEN 
buffer (0.04 M TrisHCl pH 7.4, 1 mM EDTA, 0.15 M NaCl). The 
cells were scraped off and pelleted (2 min in microfuge at 
room temperature). Pellets were dispersed by vortexing in 
100 pi 0.25 M TrisHCl pH 7.8, and cells disrupted by 3 
cycles of freeze-thaw. The debris were spun down (8 min in 
microfuge) to give the cell extract (supernatant) ready for 
assaying. The cell extract can be stored at -20°C at this 
stage if required.
2.3.4. Chloramphenicol Acetyltransferase (CAT) Assay
Obviously, the amount of cell extract and the time of 
enzyme assay depends on the promoter domain to be assayed, 
the amount of DNA transfected and the cell type used as 
recipient. However these variables were standardised as 
discused in the result section of this thesis.
(i). Assay of Transient Expression of CAT Enzyme Levels
All reactions were done in 90 pi final volume 
containing 1 pi Chloramphenicol, 5 pi 50 mM acetyl
coenzyme A, 20-84 pi cell extract (made up to volume as 
required with 0.25 M TrisHCl, pH 7.8). Typical reaction 
times were 30-90 min at 37°C. The chloramphenicol and its 
acetylated forms were extracted with 600 pi ethyl acetate by
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shaking for 30 sec, and separated from the cell extract by 
spining in a microfuge for 30 sec. The top organic phase was 
removed (avoiding interface) and dried down using a vacuum 
aspirator (about lhr).
(ii). Thin Layer Chromatography of Labelled Chloramphenicol
The dried down chloramphenicol samples were 
resuspended in 20 pi ethyl acetate, and spotted onto silica 
gel thin layer chromatography (TLC) plates, trying to keep 
the spot size as small as possible. The TLC plates were 
developed in chloroform : methanol (95:5) ascending.
(iii). Representation and Quantification of Results
The developed TLC plates were exposed to XAR-5 Kodak 
film overnight at -70°C. These autoradiographs gave a good 
visual qualitative representation of the result (see figure 
6). Quantitative results were obtained by cutting out and 
subsequently, counting the respective acetylated 
chloramphenicol spots in a LKB scintillation counter.
2.4. In vitro 'Footprint' Analysis
This technique allows the 'footprint' of a protien to 
be localised on a fragment of DNA in vitro. By using 
purified protein extracts 'footprints' of specific proteins 
can be identified. The purified protein fractions used in 
these studies were a kind gift from R.Tjian (Kadonaga, Jones 
and Tjian, 1986). Basically, nuclei are isolated and a 
nuclear extract made. This extract is subsequently run over 
a series of differing affinity columms (the final enrichment 
step being a DNA affinity column). By this method a 
partially purified protein extract, and two highly enriched 
extracts (for Spl and CTF) were obtained (see figure 7).
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2.4.1. ^^P-Endlabellinq of DNA 5' Termini
Purified restriction fragments were labelled at their 
5' termini as described by Maxam and Gilbert, (1980). 
Approximately 4 gg of purified plasmid was linearlised with 
a selected restriction enzyme and treated with BAP (see 
section 2.2.5.). The DNA was ethanol precipitated and washed 
with 95% v/v ethanol, lyophilised and dissolved in 50 mM 
TrisHCl pH 7.6, 10 mM MgCl2 , 5 mM DTT, 0.1 mM EDTA, 0.1 mM
spermidine. 5 gl a-~^P-ATP (3000Ci/mmol) was added and the 
reaction catalysed with 10-20 units of T4 polynucleotide 
kinase in a 12.5 gl reaction volume for 30 min at 37°C. The 
reaction was then terminated by phenol extraction, the DNA 
precipitated by ethanol, and subsequently digested with a 
further restriction enzyme to generate restriction fragments 
5' labelled at one end. The fragments were then separated by 
electrophoresis on a polyacrylamide gel at 20 V/cm. The 
gels were then autoradiographed while wet using radioactive 
ink as a marker and the bands removed to Eppendorf tubes.
2.4.2. Purification of Labelled Fragment
The extraction of labelled DNA was by 
isotachophoresis (Ofverstedt et al, 1984). The 
polyacrylamide gel fragments were stained in 5% phenol red 
and placed on top of a sephadex G50 column (sealed with 
dialysis membrane), equilibrated with 40 mM TrisHCl pH 7.5, 
and overlayed with 0.1 M 6-aminocaproic acid. A current of
2-6 mA was applied until sharp focusing of the indicator dye 
is achieved (the DNA runs just ahead of the dye). The DNA 
was then collected in fractions by removal of the dialysis 
membrane, pooled and ethanol precipitated on dry ice for 
15 min. After lyophilising the labelled, purified DNA was 
resuspended in an appropriate volume of water.
2.4.3. G Residue Sequencing
G-track markers were made by using the DNA sequencing
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protocol described by Maxam and Gilbert, (1980). 200 pi of
DMS buffer (50 mM sodium cacodylate pH8.0, 10 mM M g C ^ ,  1 mM 
EDTA) and 1 pi calf thymus carrier DNA (1 mg/ml) were added 
to 5 pi -^P-DNA chilled on ice, 1 pi dimethylsulphate (DMS) 
added, and incubated at 20°C for 10 min. The reaction was 
then chilled, 50 pi DMS stop (1.5 M sodium acetate pH 7.0, 
1 M 2-mercaptoethanol, 100 pg/ml tRNA) added, and the DNA
precipitated by the addition of 750 pi ethanol, and transfer 
to a dry-ice-ethanol bath for 75 min. The DNA was recovered 
by centrifugation at 4°C for 5 min, in an Eppendorf
centrifuge. The pellet was redissolved in 250 pi of 0.3 M 
sodium acetate pH 6.5, and ethanol precipitated as before, 
washed with 750 pi 95% ethanol and lyophilised. 100 pi 1 M
piperidine was then added, and the tubes heated to 90°C for
30 min, and the solution then frozen on dry ice and
lyophilised (5 hr-overnight). 10 pi water was added,
lyophilised as before, this step repeated, and the pellet 
dissolved in 6-20 pi formamide dyes (80% v/v formamide, 1 x 
TBE, 0.1% w/v xylene cyanol FF, 0.1% w/v bromophenol blue), 
heated for 1 min, and gnick chilled on ice.
2.4.4. DNase I Digestion
End-labelled DNA restriction fragments (10-30 cpm), 
10 pi 10% polyvinyl alcohol, 1 pi 1 mg/ml calf thymus DNA 
(with 10A2£0nm unit/ml poly d(I-C) unless purified protein 
extracts were used) made up to 25 pi with water, were 
incubated with protein extract (0-25 pg), and adjusted to 
25 pi volume with Z'Buffer (25 mM HEPES (K+) pH 7.8, 12.5 mM 
MgCl2 , 1 mM DTT, 20% v/v glycerol, 0.1% v/v Nonidet P-40 
plus 0.1 M KCl) for 15 min, on ice. The sample was left at 
room temperature for 1 min, then 50 pi (10 mM MgC ^ ,  5 mM 
CaCI2 ) was added, and mixed at room temperature for 1 min. 
DNase I (0.5 pi; 2.5 mg/ml) was added to 1 ml ice cold 
water, and dilutions (1:1000 or 1:2000) were added to the 
DNA-protein solution, mixed and left at room temperature for 
1 min. The reaction was terminated with 90 pi Stop Solution 
(20 mM EDTA pH 8.0, 1% w/v SDS, 0.2 M NaCl, 250 pg/ml tRNA).
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The samples were then extracted first with phenol, then 
chloroform : isoamyl alcohol, and then ethanol precipitated
on dry ice for 10 min. After a 75% ethanol wash and 
lyophilising, the pellet was dissolved in 7.5 pi formamide 
dye, boiled for 3.5 min, and chilled on ice ready to be 
loaded onto the gel.
2.4.5. Polyacrylamide Gel Electrophoresis
The footprinted samples, plus G-track marker, were 
then loaded onto a 6% or 12% polyacrylamide sequencing gel, 
made by dilution of stock deionised 20% acrylamide solution 
(29:1 w/w acrylamide: N N '-methylenebisacrylamide) with 10 M
urea in 1 x TBE and 0.07% w/v ammonium persulphate, and 
polymerisation was catalysed by the addition of 27 pi TEMED. 
The gels were pre-electrophoresed for 1-2 hr, at 35 W, and 
subsequently electrophoresed at 35 W until optimal 
positioning was acheived. These gels were autoradiographed 
by exposure overnight to XAR-5 Kodak film at -70°C.
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Figure 7.
Basic Protocol used to Purify Protein Extracts for 
in vitro DNase 1 Footprinting.
The respective sequences of the two consensus elements 
are shown (for a more detailed description see sections 2.4,
3.4.6., and Kadonaga, Jones and Tjian, 1986).
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CHAPTER THREE
RESULTS
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3.1. Optimisation of CAT Assay
3.1.1. The Chloramphenicol Acetyltransferase Assay
Although RNA levels represent the most definitive gauge 
of promoter activity, quantification of RNA is tedious and 
it is often difficult to obtain accurate measurements unless 
the promoter being analysed is particularly strong or
amplified. It is often preferable to determine the function 
of a promoter by joining it to a second gene segment (which 
lacks its own promoter) coding for a readily assayable 
protein, the reporter gene. In the CAT assay (Gorman,
Moffat and Howard, 1982) the bacterial chloramphenicl 
acetyltransferase (CAT) gene is used, with the enzymatic 
function of CAT being both quickly and precisely assayable.
Two assays for CAT activity have been developed. The 
first, a spectrophotometric assay, unfortunately depends on 
the cell type used and as such requires a control to be run
for each cell type used. A better assay (Gorman, Moffat and
Howard, 1982) involves the measurement of the conversion of 
C-chloramphenicol to its acetylated forms by thin layer 
chromatography (see figure 6). The great advantage of this 
assay is that any cell type can be used, the only restraints 
being those imposed by the specific DNA sequences being 
analysed. It is now the most common transient functional 
assay used to analyse gene expression.
This assay shows a high level of specificity due to the 
CAT gene being absent from all mammalian cells looked at, 
(metabolism of chloramphenicol being via glucosyl 
transferase). Thus there is no endogenous background CAT 
activity. In addition, there is no interference from other 
endogenous enzymatic activities which could compete for the 
substrate or cofactors. The assay is rapid, sensitive and 
reproducible, as well as requiring only a low grade 
radioisotope. Finally, quantification of the result can be 
easily and accurately carried out in a scintillation
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counter. These advantages make the CAT gene marker, at the 
moment, the most convenient developed assay for transient 
expression studies. There are other transient assay systems 
available, eg. (3-galactosidase, but they are either more 
cumbersome or less sensitive than the CAT assay.
3.1.2. Standard Positive CAT Construct
Figure 8 shows the Key for all the figures in this 
section.
Before undertaking any functional experiments on the 
c-myc-CAT plasmid recombinants, characterisation of the 
obtainable expression levels is required. For this, and as 
a positive control in subsequent experiments, a strong 
promoter-driven CAT recombinant was kindly obtained from B. 
Clements, pLW2 (Gaffney et al, 1985). The 210bp BamHI 
fragment of pLW2 (see figure 10) contains the promoter 
domain (TATA-consensus and two GC-elements) plus a small 
part of the 5' mRNA leader sequence from the HSV-2 
immediate-early 4/5 gene (HSV-IE). This promoter directs a 
high level of activity when compared to other promoters, 
e.g. HSV-tk (J. Lang, personal communication) and e-globin 
(this thesis). Although an enhancer element has been 
described which controls this gene it is not present in pLW2 
(Gaffney et al, 1985). The first ATG initiation codon lies 
within the CAT gene.
Transcription 3' end processing is regulated by a lOObp 
Smal/Xbal fragment derived from the 3' terminus of the HSV-2 
IE gene-5 (Gaffeny et al, 1985), which makes this construct 
differ from the more commonly used prototype CAT vector, 
pSV2-CAT (Gorman, Moffat and Howard, 1982). The HSV-derived 
termination sequence appears to allow a slighly higher level 
of activity, in mouse fibroblasts, when compared to the 
SV-40 derived recombinant (unpublished results).
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3.1.3. Generation of CAT Vector
By deleting the 210bp BamHI fragment from pLW2 (Gaffney 
et al, 1985), the CAT vector pB9 (containing no obvious 
promoter or cap site), was generated (see figure 11). This 
plasmid was used as the basic vector for all the 
recombinants described in this thesis, and as a negative 
control in all the experiments.
3.1.4. Restriction Analysis of Basic CAT Recombinant
Hindlll or EcoRI digestion of both pB9 and plW2 results 
in a linear plasmid, of respectively 3.6 and 3.8Kb as seen 
in figures 12. To confirm that the 210bp HSV-IE promoter 
domain had been deleted in the CAT vector, pB9 was digested 
with Hinfl (see figure 12). As expected the pUC-derived 
fragments of 1413, 517, 396, 75 and 65bps are seen. In
addition, the 214bp pUC fragment containing the polylinker 
domain is replaced by a 301bp (HSV-IE termination domain) 
and a 793bp (most of CAT structural gene), due to the 
presence of a Hinfl site being present within the CAT 
sequence. PstI digestion of pLW2 gives a lOOObp fragment, 
containing the 780bp CAT gene and the 210bp HSV-IE promoter 
domain (see figure 12).
3.1.5. Optimisation of Expression Time
The activity time course observed when cells were 
harvested at intervals of 8 hours from when the 
DNA-calcium-phosphate precipitate was washed off is shown in 
figure 13. In each experiment the positive control pLW2 
(5pg) was used. For LaTK'cells CAT enzyme levels start to 
decrease after 48 hours, while a plateau of activity is 
observed for NIH-3T3 cells with a slight maximum occuring at 
40 hours. This time course is in agreement with results 
using the tk enzyme as a marker (Spandidos and Wilkie, 
1984a; Lang, 1985). Hela cells (result not shown) show 
maximal activity at 40 hours in this assay. Since the
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absolute activity levels observed in LaTK- cells was far 
greater than those observed in NIH-3T3 cells, the former 
were the cells of choice for the majority of experiments 
described in this thesis. NIH-3T3 cells have been found to 
be poor transient transfection recipients by other workers 
(Alwine, 1985; see section 3.1.8.).
3.1.6. Tranfected DNA Titration
To investigate the effect of varying the amount of 
transfected DNA, increasing amounts of pLW2 DNA (the 
positive control) were transfected into LaTK""cells. As shown 
in figure 6, the acetylated chloramphenicol has 2 forms, the 
mono-acetylated (primary and secondary) and di-acetylated, 
both of which are plotted along with total activity in 
figure 14. Clearly, although at higher DNA transfected 
amounts the production rate of the diacetylated (C) form is 
in the linear part of the curve with respect to increasing 
DNA amounts, at the lower DNA amounts it is not an accurate 
representation of CAT activity. Since in the studies 
described in this thesis repression of an active state is 
analysed, many results would presumably involve relatively 
low CAT levels, the measurement of the diacetylated form 
alone would be an inappropiate representation of enzyme 
activity (expression). Summation of the two mono-acetylated 
forms (A + B) seems unreliable, since at high rates of 
conversion the di-acetylated form was produced from the 
mono-acetylated forms in preference to mono-acetylation. 
However, total counts (A + B + C) gave a reproducible 
representation of CAT activity, above 1 ug of transfected 
DNA. In addition, total counts gave at the lower DNA 
amounts a high enough value to allow easy and reproducible 
values to be obtained.
Since the absolute value between experiments using the 
same recipient cell line vary, results are expressed as 
averages of total counts or as relative ratios (from a 
standard positive). Experiments with less than 15% variation
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in duplicate samples from control plasmids were deemed 
representative and tabulated. In this way, the different 
cell lines can be qualitatively compared for relative 
differences between test plasmids. The variation observed 
between experiments is probably due to a complex interaction 
of many factors, (e.g. subtle changes in temperature or pH, 
slight differences between various medium preparations) 
which compoundly affect the growth of the recipient cell. 
Thus this variation probably reflects the growth state of 
the recipient cell at time of transfection.
In the experiments described here, the minimum amount of 
DNA to be transfected was taken to be lug, since below this 
amount non-reproducible results were obtained. In addition, 
when more than 10gg were transfected only very slight 
increases (if any) in activity were observed, probably 
indicating an "assay-saturation" (Weintraub, Cheng and 
Conrad, 1986; and see figure 30). Whether this saturation is 
relative to DNA uptake by the cells, or to the cells ability 
to express (titration of cellular pool of transcription 
factors) the exogenously introduced DNA is not known. 
Although not seen in this experiment, when DNA amounts of 
greater than lOgg were used a near plateau of activity was 
observed (see section 3.2.6.). Thus the linear part of the 
expression curve for LaTK cells in these experiments was, 
taken to be, between lgg and lOgg. To ensure equal numbers 
of available plasmid molecules equimolar-amounts 
(standardising all plasmids to the 3.3Kb pB9,i.e. pB9=l) 
were used in all experiments.
The amount of DNA transfected could play a crucial role 
in the outcome of an experiment. Therefore experiments were 
carried out using a DNA titration wherever possible, thus 
hopefully allowing any biologically relevant variation in 
activity due to DNA concentration to manifest itself. In 
experiments where only a single DNA amount was used, a low 
amount was considered the most appropriate to avoid the 
possible saturation effects in the assay.
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3.1.7. Optimisation of CAT Assay Parameters
To allow optimisation of the CAT enzyme activity assay 
LaTK~ and NIH-3T3 cells were transfected with 5pg of pLW2 
(the positive control), and the cell extract aliquoted 
accordingly such that the effect of varying the ammount of 
extract, or the time of incubation in the enzyme assay could 
be examined (see figure 15). The cell extract containing CAT 
enzyme activity was stable at -20°C for several months.
Again the graphs obtained for the various acetylated forms 
were compared (results not shown) and the previous 
conclusions were confirmed (see section 3.1.6.).
An assay time course of 20 to 120 minutes for cell 
extracts from both LaTK and NIH-3T3 cells and the resultant 
CAT activity plotted in figure 15. The assay was linear 
between 60 and 120 minutes for both LaTK-and NIH-3T3 cells, 
and longer if additional coenzyme A was added at 100 minutes 
(data not shown). The tail-off after 120 minutes is 
probably due to substrate exhaustion, but the presence or 
accumulation of inhibitors cannot be excluded. It was noted 
that reproducible results were not obtained if a time point 
of less than 30 minutes was taken.
Even though the time of assay incubation was doubled
(i.e. betwwen 40 and 80 minutes) the resultant CAT activity 
did not. This may reflect the effect of progressive 
substrate exhaustion. To exclude any possible discrepancies 
between results due to this effect, for the studies
presented within this thesis the CAT assay was routinely run
for 60 minutes.
A linear graph (see figure 15) was obtained when the 
amount of extract was varied for LaTK- cells. In these 
experiments the observed CAT activity was always 
substantially lower for NIH-3T3 cells than for LaTK- cells. 
In addition, the curve seen for NIH-3T3 cells was linear but 
even though the amount of cell extract used was quadrupled,
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the corresponding CAT enzyme activity was only doubled. This 
could be due to an endogenous enzyme (which is present at 
high levels in NIH-3T3 cells), which is utilising the
substrate. However, since no spurious chloramphenicol spots 
were observed on the chromatogram (although this does not 
exclude the possibility), it is unlikely that such an enzyme 
exists. Chloramphenicol is broken down in mammalian cells by 
glucosyl transferase, but even if no spurious spots were 
produced during this reaction a decrease in substrate amount 
would (but is not) be seen. Possibly the most likely
explanation for the observed NIH-3T3 cells activity curve 
may be the presence of an inhibitor. A preliminary 
experiment involving the mixing of NIH-3T3 and LaTK~ cell 
extracts indicates that such an inhibitor may exist within 
the NIH-3T3 cell extract (unpublished results). Mixing cell 
extracts has indicated that Friend erythroleukaemia cells 
may also contain an inhibitor (G.Sibbet, personal 
communication). Due to the low transfection efficiency and
possible assay inhibitor, NIH-3T3 cells were only rarely
used as transfection recipients in the work presented in 
this thesis.
3.1.8. Reproducibility of CAT Assay
The fact that with at least 8 separate transfections of 
pB12 and pB14 during these studies (see section 3.2.3), 
using several plasmid preparations, similar results 
(comparable ratios) were obtained for LaTK cells, implies 
reproducibility within this assay. Several additional 
experiments confirmed this reproducibility. In the early 
experiments, quadruplet samples were assayed, with only a 
15% variation between samples being observed. To ensure 
that this was not due to cell harvesting variations (i.e. 
total cell number harvested), the protein extract amount was 
quantified with only a 11% variation being present (see 
table 1). However, this variation was not directly 
accountable for the 15% variation in activity, as assays 
performed after protein equalisation still showed variation.
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When duplicate assays were performed on the respective 
halves of the same cell extract there was still a slight 
variation observed (12%). Thus an approximately 10-15% 
error would appear to be inherent in this assay which may be 
due to slight variations in the individual assay sample 
handling (i.e. human error, loss during ethyl acetate 
extraction).
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Figure 8.
Restriction Enzyme Maps for
Recombinant Plasmids.
Maps represent recombinant plasmids characterised by 
restriction endonuclease digestion in the relevant sections 
of this thesis. The specific gel photograph corresponding to 
each restriction map is indicated by reference to the 
appropriate figure. The type of gel (and percentage) is 
shown along side each photograph. Only the relevant 
restriction sites are shown (see sections
3.2.2.,3.3.2.,3.4.2.,3.5.2. and 3.6.2.). Hindlll and
Hinf I pAT153 were the size markers used. Fragment size is 
shown to the nearest lObp only, since due to molecular 
linker additions, accurate size can only be determined by 
DNA seguencing. (The numbers inside the plasmid circle refer 
to the Hinfl fragment sizes only). PI and P2 refer to the 
two major human c-myc transcription start sites. The 
orientation of the respective fragments of the recombinants 
is indicated by an internal arrow. Roman numerals are used 
to represent the location of the in vivo DNase 1 
hypersensitive sites (Siebenlist et al, 1984). The origin of 
each fragment is illustrated as described in the key below:
Key to Plasmid Fragment Source.
Vector sequences (pUC12,pUC18 or pAT153 
as indicated in the text),
human c-myc sequences,
HSV-IE derived sequences,
human e-globin derived sequences,
bacterial CAT gene sequences,
W7/////A
Restriction Enzyme Key:
Ac Acc I Ps Pst I
Av Ava I Pv Pvu II
B BamH I R Rsa I
C Cla I S Sma I
E EcoR I Sa Sau 3A
He Hinc II T Thai
Hd Hind III Xo Xho I
Hf Hinf I Xb Xba I
K Kpn I
Linker addition. CCAAGCTTGG = HindiII 
CCGGATCCGG = BamHI
An unbound copy of this figure can be found in the sleeve of 
this thesis.
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Figure 9.
Structure of Basic Cloning Vector.
The structure of pUC18 (Messing and Vieira, 1982) is 
depicted in the diagram. The hatched bar represents the
Eolylinker cloning region and its sequence is presented elow the plasmid map, showing the single cutting 
restriction cloning sites. Also used as a cloning vector, 
pUC12 is essentially the same except that it does not 
contain the Kpnl and SphI cloning sites. For one ligation 
pATl53 was used as a cloning vector (Twigg and Sherrat, 
1980).
pUC Vector.
2 6 8 %
Pv (306)
p U C 1 8
OR^ m V
Pv(628)
(l694)Hf
Hf (1177]
396
S a c I
Xma I  
Sma I Xba I
GAATTCG AG CTCG GTACCCGGGG ATC C TC TAG A 
EcoRI K pn l Bam HI Hinf I
Pst 1 Hind UL
GTCGACCTGCAGGCATGCAAGCTT-.-co  ------
HincH 
Sal I  
Acc I
S p h I
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Figure 10.
Structure of HSV-2 Genome and Derivation of 
HSV-CAT Recombinant.
A. The stucture of the HSV-2 genome. Arrows indicate the
site and direction of immediate early (IE) transcription. 
TR = terminal repeat; IR = inverted repeat; U = unique
region; L = long region; S = short region.
B. Expanded region of HSV-2 genome showing the IE-5 gene 
transcription unit. T = 3 '  end processing signal; P 
promoter domain.
C. Map of pLW2. The 210bp Smal Sau3a promoter domain was
inserted 5' to the bacterial CAT gene, with transcription 3' 
processing being regulated by, the lOObp IE-5 region (Gaffeny 
et al, 1985).
D. The sequence of the 210bp promoter domain showing Spl
consensus sequences (underlined), the TATA-consensus (boxed) 
and the cap site (arrow).
a. □ ------— --------Hj rP Us rn hsv - 2
IE
pLW2
D
GCCCGGGGCCCGCGTCATCCCGCGGGCCCGCCCGAGGCGGGCCC
GGACG 6G GGGCGGGCCGT T CC TCGCGCefc A T A A A b GGCCGGCGT
5* and « «
CCC6GTCGCCGCCGCACCAGGGGCACACCGGC T GCGCGGCGGAG
a c c g g g a c g g c a g c g g c g g c a t c g c g a a g g g g g c c a c a g c g a g A
CAGAGACGCCGGCGGCGAGCGGGGCACCGACGCACCCCGGATCC
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Figure 11.
Derivation of the Basic CAT Vector.
By digesting pLW2 with BamHI and subsequent 
self-ligation of the resultant linear (after removal of the 
210bp promoter fragment by low melting agarose 
electrophoresis), the CAT vector pB9 was generated. This CAT 
vector does not contain an obvious promoter domain, nor a 
cap site. Transcription 3* processing is regulated by the 
HSV-2-IE termination signal (Gaffeny et al, 1985). The arrow 
indicates the direction and extent of transcription. See 
figures 8a and 12.
PLW2 Xb
Ho
Ad
XbPB9
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Figure 12.
1 % agarose ge'-
23
20
114
Figure 13.
Standardisation of Transient CAT Assays 
Expression Time.
CAT 
Activity
30
Recipient 
Cell Line
25
20
15
10-
NIH-3T3
8 16 24 32 40 48 5 6 64
T
Time (hours)
a. Average total counts (ICHcpm) from two experiments of
duplicate flasks. Vertical bars indicate the range of values 
observed.
b. Hours post transfection (i.e. post addition of
precipitate). The arrow indicates the time point of removal 
of precipitate and refeeding of cells with medium.
c. 5pg of pLW2 was transfected into LaTK and NIH-3T3 cells
as described in Materials and Methods. The resultant CAT
activity was assayed as described in Materials and Methods.
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Figure 14.
Standardisation of Transient CAT Assay: 
DNA Titration,
16
12
CAT 
Activity 8
/?•
4
1 2 3 4 5 6  7 8 9  10
A + B + C
C
A + B
DNA Amount (pg)
a. Average total counts (lO^cpm) from two experiments of 
duplicate flasks. Vertical bars indicate the range of values 
observed.
b. l-10pg of pLW2 was transfected into LaTK*~ cells as 
described in Materials and Methods. The resultant CAT 
activity was assayed as described in MAterials and Methods.
c. The various acetylated forms of chloramphenicol (see 
figure 6.).
A and B = monoacetylated chloramphenicol.
C = diacetylated chloramphenicol.
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Figure 15.
Standardisation of Transient CAT Assay.
A. Cell Extract Titration.
B. Assay Time Course.
a. Average total counts (lO^cpm) from two experiments of
duplicate flasks. Vertical bars indicate the range of values 
observed.
b. lOpg of pLW2 was transfected into LaTK'and NIH-3T3 cells
as described in Materials and Methods. The resultant CAT
activity was assayed as described in Materials and Methods.
c. Incubation time of CAT assay. 20pl of cell extract was 
assayed for CAT activity.
d. Volume of cell extract assayed. The CAT assay was
incubated for 60 minutes.
A. CAT Assay Time Course.
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Table 1.
Comparison of Cell Extracts after Protein Estimation
a b
Protein CAT
Concentration Activity
A. 130|ig 2367
130pg 2409
130|ag 2278
130pg 2331
B. 555|ig 9067
560pg 9409
530pg 8799
515pg 9110
A. The cell extract from one flask of LaTK cells was 
aliquoted into 4 samples and assayed for CAT activity as 
described in Materials and Methods. The protein 
concentration (Biorad protein assay, gave values to the 
nearest 5pg) was measured.
B. The protein content of 4 duplicate flasks was determined 
(Biorad assay), and the CAT activity of the total cell 
extract was assayed for as desrcibed in Materials and 
Methods.
a. Protein concentration as measured by the Biorad assay, as 
recomended by the suppliers.
b. CAT activity as total counts (cpm) of acetylated forms.
(see figure 6.).
c. In each case 5pg of pLW2 was transfected into LaTK~cells 
as described in Materials and Methods. The CAT activity was 
assayed as described in Materials and Methods.
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3.2. Identification and Localisation of a Negative
Regulatory Element Within the 5' Flanking Sequences 
of the Human c-myc Gene
If a cis-acting negative regulatory element (NRE) exists 
in the 5' flanking region of the human c-myc, as postulated, 
then progressive 5' deletions of this region might allow its 
identification. CAT activity driven by various c-myc 5' 
deletion fragments was analysed in the various cell lines 
previously described (2.3.1.), and such a domain localised 
within the human c-myc 5' flanking region.
3.2.1. Recombinant Plasmid Constructions
All recombinant plasmids in this series, were 
constructed using the CAT vector (pB9) and various regions 
of the c-myc 5' flanking sequences plus exon 1 derived from 
pMC41 (see figure 16), kindly given by T.Papas (Dalla-Favera 
et al, 1982b).
(i). Isolation of c-myc 5' fragment
The 3.6Kb Hindlll-Xbal fragment from pMC41 was inserted 
into Hindlll-Xbal digested pUC12 (pBl; see figure 17) and 
subsequently the resulting 3.6Kb Hindlll-BamHI fragment (the 
BamHI site derived from the pUC polylinker) was cloned into 
Hindlll-BamHI digested pATl53 (pB2; see figure 18). These 
steps were required to reduce the number of PvuII sites
present to two (pB2) thereby allowing easy partial digestion 
with PvuII and subsequent Hindlll molecular linker 
modification to give pB3 (see figure 18). The dual c-myc
promoter region, plus the majority of exon 1 and 2.3Kb of 5'
flanking sequences (originally encompassed within the 2.8Kb 
Hindlll-PvuII fragment of pMC41) is now present in pB3 as a 
2.8Kb Hindlll fragment. This conversion of a PvuII site to a 
Hindlll site was done to enable easy construction of the 5' 
deletion recombinants. Hindlll linker or BamHI linker 
modification after PvuII linearisation of pB3, gave
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respectively, pB7H and pB7B (see figure 18).
(ii). Construction of the 5' Deletion Recombinants
The c-myc recombinant (pB12; see figure 19), i.e. 
containing all 2.3Kb of flanking sequences, was constructed 
by inserting the 2.8Kb Hindlll fragment from pB3 into
Hindlll digested pB9. All further c-myc 5' deletion 
recombinants are variations on this plasmid, and
consequently they all contain 510 bp of exon 1 (i.e. except 
the distal 40bp), and both TATA-consensus elements.
The strategy used to construct the 5' deletion 
recombinants is described below, in order of increasing 
deleted fragment size. The Clal-Xbal fragment from pBl2 was 
inserted into Accl-Xbal digested pUCl2 to give pB29 (both 
the Clal and AccI sites being destroyed on ligation; see 
figure 20), which contains 1.25Kb of 5' flanking sequence. 
The 1.7Kb HincII fragment from pBl2 was inserted into HincII 
digested pB9 to give pB28 (see figure 20), which contains 
1.15Kb of 5' flanking sequence. By inserting the KpnI-Xbal 
fragment of pBl2 into KpnI-Xbal digested pUCl8, pB34 was
generated containing 1.05Kb of 5' flanking sequence (see
figure 20). AccI digestion of pB28 released a l.lKb 
fragment which was inserted into AccI digested pUCl2 to give 
pB45 (the 5' AccI site being destroyed as this ligation 
involved the two isoschizomeres of AccI; see figure 21). 
This allowed a 1.1Kb Hindlll fragment (the 5' Hindlll site 
was derived from the pUC polylinker), containing 610bp of 5' 
flanking sequence, to be inserted into Hindlll digested pB9 
generating pB46 (see figure 21). The final recombinant in 
this series pB14 (see figure 22), containing only 350bp of 
5' flanking sequence was generated by insertion of the 860bp 
Hindlll fragment from pB7H into Hindlll digested pB9. Figure 
28 shows these 5' deletion constructions and the location of 
relevant in vivo DNase 1 hypersensitive sites (HSS).
120
(iii)• Construction of the Upstream Internal Deletion
AccI partial digestion plus Kpnl limit digestion of 
pB29, followed by Klenow flush-ending and subsequent 
religation gave pB68 (see figure 23). This internally 
deleted recombinant (pB68) is identical to pB29 (the c-myc 
recombinant with 1.25Kb of 5' flanking sequences), except 
that the 445bp Kpnl AccI fragment containing the in vivo 
DNase 1 HSS II-2 has been deleted.
3.2.2. Restriction Enzyme Analysis of Recombinant Plasmids
Extensive restriction enzyme analysis has been used to 
identify each of the recombinant plasmids described. 
Representative digests are shown in figures 24, 25, 26,27
and relevant restriction maps in figures 8a, 8b, 8c, 8d.
(i). Plasmid with the Full 5' Flanking Region and Parental 
Plasmid pMC41.
PvuII digestion of pMC41 reveals the 5 internal human 
c-myc restriction sites (1341, 1091, 880 and 860bp) and the
plasmid vector site (4400 and 4100bp). The recombinants pBl, 
pB2 and pB3 were made to allow the number of PvuII sites 
present to be decreased as shown by PvuII digestion of the 
respective recombinants; pBl (2360, 2030, 860 and 790bp),
pB2 (6300 and 860bp) and pB3 (7160bp). The 860bp fragment of 
pBl and pB2 contains the majority of the c-myc exon 1 
sequences. This remaining PvuII site was converted to a 
BamHI site by linker modification to give pB7B, which gives 
upon BamHI digestion fragments of 5630 and 1530bp in size. 
In pB7H the remaining PvuII site (of pB3) was converted to 
H i n d u  by linker modification, which then gave upon Hindlll 
digestion fragments of 4360, 1940 and 860bp.
(ii). Plasmids with 5' Deletions of 5' c-myc Flanking Region
Since pB12 was used as the parent of all the deleted
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c-myc recombinants, its restriction map is shown in detail, 
and is a reference for the recombinants in this series. 
Hindll digestion of pB12 gives fragments containing the 
c-myc derived sequences (2790bp) and the pUC vector and CAT 
gene sequences (3575bp, basically pB9. Upon HincII 
digestion, fragments of 3865, 1670 and 830bp are produced.
AccI digestion gives two fragments of 5250 and 1115bp (this 
digest went only to partial completion, thus the upper band 
corresponds to the linear plasmid, while PstI digestion 
reveals 4 fragments of 2950bp (pUC and HSV-IE terminator 
sequences), 1710bp (c-myc 5' flanking sequences), 915 (c-myc 
5' adjacent sequences and the majority of exon .1) and 890bp 
(CAT structural gene).
The recombinants pB9 (CAT vector), pB14, pB46 and pB12 
were digested with EcoRI giving respectively 3.6, 4.4, 4.7
and 6.4Kb fragments, while pB28 and pB29 digested with Kpnl 
gave 5.2 and 5.3Kb fragments, and pB34 digested with Xbal 
gave a 5.1Kb fragment. The c-myc derived fragments were 
identified by Hindlll digestion of pB29 (1770bp), pB28 
(1670bp), pB46 (1120bp) and pB14 (860bp), while Hindlll Kpnl 
digestion of pB34 gave the c-myc derived fragment (1575bp) 
and the CAT-HSV terminator domain fragment (895bp). Hindlll 
digested pB9 is shown to indicate the basic vector size 
(3.6Kb). BamHI Smal digestion of pB14 reveals fragments of 
625 and 3795bp.
(iii). Plasmid with Upstream Internal Deletion
Since pB68 is derived from pB29 by deletion of a 445bp 
region, the restriction digests of these two recombinants 
are shown beside each other. PstI digestion of pB29 reveals 
identical fragments except for the 855bp in pB29 which is 
410bp in pB68. HincII digestion also confirms the deletion 
(1670bp in pB29 and 1225bp in pB68), as does Hindlll 
digestion (1770 and 1325bp respectively).
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3.2.3. Identification of a cis-actinq Negative Regulatory 
Element
Transient transfection studies using an equimolar ratio 
of 10pg (pB9) for pB12 (containing 2.3Kb 5' flanking
sequences), pB14 (containing 350bp 5 ’ flanking sequences), 
pLW2 (positive control) and pB9 (negative control) were 
undertaken in an attempt to identify a dominant cis-actinq 
transcription regulatory domain. The resultant CAT 
activities are presented in table 2 (and see figure 45). The 
6 recipient cell lines have been described previously (see 
section 2.3.1.). The c-myc recombinant containing 2.3Kb of 
upstream sequences (pBl2) was observed to have a relatively 
weak promoting activity when compared to pLW2. However, 5' 
deletion to the PvuII (pBl4) dramatically elevated CAT 
levels by 3-to 12-fold. Therefore the 2.0Kb Hindlll-PvuII 
fragment 5' to the c-myc dual promoter contains a cis-acting 
negative regulatory element (NRE) and deletion of this 
element relieves the promoter domain from repression. Due to 
subsequent experimentation this domain has been designated 
NRE-2. The relatively low repression ratio observed (still 
significant) is due to the amount of DNA (equimolar ratio of 
lOug) transfected. With lower DNA amounts a much greater 
repression ratio is observed (see section 3.4.4.).
There appears to be no obvious specificity to this 
element as it functions both in human and murine cells, of 
an erythroid, epithelial or fibroblastic origin. Slight 
variations in the repression ratio (2-4 fold) are seen among 
LaTKj HeLa and NIH-3T3 cells. Such small variations are 
unlikely to reflect a difference in the tissue- or 
species-specificity. As described before (see section 
3.1.6.), the observed ratios can only be qualitatively 
compared between cell lines. The repression ratio observed 
in K-562 cells is at least 2-3 times that seen in any of the 
other cell lines used as recipients in these studies. The 
presence of repression activity in K-562 cells was 
unexpected. K-562 exhibit elevated levels of c-myc RNA
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without any obvious rearrangement of the c-myc locus 
(Wong-Staal et al, 1983), and it was therefore hoped that 
they would not contain the postulated repressor and thus be 
permissive for c-myc expression. This has implications for 
the regulation of c-myc expression in K562 cells (see 
section 3.4.4.).
However, the c-myc recombinants, even though exhibiting 
the repression function (see pB14 and pB12), have only 
relatively weak activity in Hela and NIH-3T3 cells when 
compared to pLW2. By comparing absolute counts (pLW2 control 
not done) the c-myc-CAT recombinants are probably also only 
weakly expressed in MRC-5 and GM468 cells. This may imply a 
certain level of specificity between cell types, or may 
just represent differing transfection efficiencies. Other 
workers find GM468 and MRC-5 cells difficult to transfect 
into (D. Spandidos, personal communication). Irrespective 
of these differences, the repression of pBl2 compared to 
pBl4 levels is constantly observed in all these cell lines.
3.2.4. Localisation of the Negative Regulatory Element
To localise this element within the 2.0Kb Hindlll-PvuII 
5' region, equimolar amounts (of 5pg) of the various c-myc 
5' deletion recombinants were transfected into LaTK and HeLa 
cells and the resultant CAT activities are presented in 
figure 28. Deletion of the distal 1225bp (pB29, pB28 and 
pB34) which contains DNase I HSS I and II-l had only a small 
effect on the activity observed when compared to pB14 (see 
section 3.6.). A further 445bp deletion (pB46) to the AccI 
site allowed a release from repression similar to that of 
pBl4. Analysis of pBl2, pB34 and pBl4 in Hela cells gave 
similar results, however, in HeLa cells the repression 
ratio was less than that observed in LaTK cells. Whether 
such a slight difference represents cell specificity is 
questionable. It may just reflect the state of these in 
vitro cultured cells and their differing abilities to take 
up and express exogenously introduced DNA (see section
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3-2.5.)-
One anomaly which will be discussed later is the 
apparent slight release from repression observed with pB34. 
Perhaps this deletion has in some way affected the NRE-2 
element structure or conformation (see 3.4.4.).
3.2.5. Internal Deletion of the Negative Regulatory Element 
(NRE-2)
To confirm these results an internal 445bp deletion 
(Kpnl to AccI, which is the-region deleted between pB34 and 
pB46) from pB29 was constructed (pB68). Equimolar amounts of 
pB29 (containing 1.25Kb of upstream sequences), pB68 
(identical to PB29 except that the 445bp fragment is 
internally deleted), pB14 (containig 350bp upstream 
sequences) and pB9 (negative control) were transfected into 
LaTK- cells. The resultant CAT activities are plotted in 
figure 29. Although this internal deletion does not restore 
full activity (i.e. to that of pB14) its CAT levels are 
substantially greater than that of its parent, pB29. This 
indicates that at least part of the negative regulatory 
element resides within this 445bp region as implied by the 
5' deletion studies, however, flanking sequences (or indeed 
distal sequences) may be additionally required for full 
repression. Therefore this 445bp domain does define an 
essential component of the NRE-2. It is, however, possible 
that this 445bp region contains all the sequences requiired 
for repression (i.e. contains the whole NRE-2), and the 
difference between pBl4 and pB68 CAT levels could be due to 
some structural alteration in the general chromatin 
structure of the c-myc 5' control regions in the two 
recombinants (in addition to the NRE-2 deletion) brought 
about by the very nature of the internal deletion. Due to 
subsequent experimentation, the former proposal (i.e. the 
445bp region only deliniates an essential part but not all 
of the NRE-2) is favoured.
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A point to note, one which will be extensively described 
later (see section 3.4.4.), is that the magnitude of 
repression (compare pBl4 and pB29; see figure 29) decreases 
with increasing amount of DNA transfected.
From these studies, at least an essential component of 
the NRE-2 is located between the Kpnl site (-1055bp) and the 
AccI site (-610bp) upstream from the human c-myc 
transcription start site, when assayed transiently in LaTK 
cells. In addition this transcription regulatory element 
shows an apparent lack of tissue- or species-specificity. In 
subsequent experimentation 3^different fragments containing 
the NRE-2 domain were used; a 2.0 Kb Hindlll-PvuII fragment, 
a 445 bp KpnI-AccI fragment and a 270 bp Rsal-Thal fragment 
(see figure 16).
3.2.6. Characterisation of c-myc Promoter
The relative activity of pBl4, the 5' deletion which 
leaves only 350bp upstream of PI but contains all the 5 1 
flanking sequences required for promoter activity in these 
studies, was compared to that of pLW2, by DNA titration 
transfection experiments, with equimolar amounts of the test 
recombinants being transfected into LaTK- cells. The 
resultant CAT activities are plotted in figure 30. In this 
experiment pBl4 was nearly as active as pLW2. Since pLW2 
has already been characterised as a strong promoter (Gaffney 
et al, 1985; J. Lang, personal communication ;and see 
section 3.1.6.) this would indicate that pBl4, also 
contained a highly active promoter, when assayed in these 
cells.
The CAT vector alone (pB9) showed only very slight 
activity (1-2% of the full promoter) in LaTK and HeLa cells. 
However, in NIH-3T3 and K-562 cells the CAT vector alone had 
an activity value of about 10% of the c-myc promoter. Since 
no activity was observed when pMC41 was assayed, a non-CAT 
containing plasmid (data not shown), the low level activity
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seen for pB9 is not an assay artifact. This extremely low 
level of activity may be due to the presence of cryptic 
promoters within the pUC sequences, or may somehow be an 
innate property of a covalently closed plasmid DNA 
containing an ATG codon. This low level expression from a 
promoter-less / capless CAT recombinant differs from 
previously reported results. In experiments using pSVO-CAT, 
a promoter-less / capless CAT recombinant which contains a 
SV-40 polyadenylation signal, no expression (CAT activity) 
was seen (Alwine, 1985). This may reflect a function of the 
different polyadenylation signals (pB9 contains a HSV 
derived polyadenlyation signal: see section 3.1.3. and
3.1.4), or may just reflect a difference in the sensitivity 
between the two series of experiments.
However, pB14 is only 10% and 16% as active as pLW2 in 
Hela and NIH-3T3 cells respectively, while it is 2-3 times 
more active than pLW2 in K-562 cells.These differences in 
absolute values may represent tissue- and/or species-
specificity for either one of the two promoters studied.
There is no detailed data on the expression specificity of 
the HSV-IE promoters. Gross expressional variation (i.e. 
non-expression) has been taken to indicate specificity in 
transfection studies. However, where a gene is expressed but 
to differing levels depending on the cell type, absolute 
quantitation of that variation would be difficult to
achieve. It is quite hard to conceive how to unambiguously 
standardise any experimentation involving such a gene, as 
the standard control, in effect, could not itself be 
conclusively defined to have an unvarying expression 
irrespective of recipient cell line. Thus expression
patterns at the moment can only be describe^ in general 
terms: no expression, weak expression or high expression.
Applying this arguement to these studies, the differences 
seen between the relative activities of the c-myc and HSV-2 
IE promoters in the various recipient cell lines can not be 
attributed to, specifically, one or the other promoter. Of 
note, is that in all cell lines analysed the c-myc promoter
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(and repression) was active.
In these experiments, an assay saturation effect was 
observed: activity for both pLW2 and pB14 start to plateau
of when more than lOpg of DNA are used for the transfection 
experiments (see figure 30; section 3.1.6.; Weintraub, Cheng 
and Conrad, 1986).
These results identify a negative regulatory element 
within the 5' flanking seguences of the human c-myc 
oncogene. This element is active in several cell types of 
both human and murine origins. It has been localised to a 
445bp region, approximately 700bp 5' to PI (-1052 to
-607bp), when LaTK" cells were used as the transfection 
recipient. Since the transfected gene is of human origin, 
and the recipient cell of murine origin, a cross-species 
interaction is implied. In addition, the repression function 
was observed in fibroblastic, epithelial, and erythroid 
derived cells, thus implying a lack of tissue-specificity as 
well. This region contains the previously identified DNase I 
hypersensitive site II-2 (Siebenlist et al, 1984). Due to 
subsequent experimentation this region is designated NRE-2.
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Figure 16
Parental c-myc Recombinant and Restriction Map of 
5' Flanking Sequences and Exon 1.
The heavy lines represent human c-myc sequences 
(Hindlll-EcoRI). The 5' flanking region, exon 1 and part of 
intron 1 are shown at the bottom of the page, with the 
relevant restriction enzyme sites indicated. PI and P2 
correspond to the two major c-myc transcription initiation 
sites. The position of the in vivo DNase 1 hypersensitive 
sites (Siebenlist et al, 1984) are designated by Roman 
numerals.
EXON 3
MC41
l XON 2
XbHd
E x o n 1
/
/
/ Xo
/
/
An unbound copy of this figure can be found in the 
sleeve of this thesis.
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Figure 17.
Structure and Cloning Strategy of c-myc
Recombinant pBl.
To enable 5' deletion recombinants to be generated the 
5 ’ region (2.3Kb of 5' flanking sequences, the whole 550bp 
of exon 1 and part of intron 1) were cloned into pUC12 as a 
Hindlll-Xbal fragment. For a more detailed restriction map 
see figure 16. For a detailed description of the cloning 
strategy see section 3.2.1. See figure 8b and 24.
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Figure 18.
Structure and Cloning Strategy of c-myc Recombinants
pB2, pB3, pB7B and pB7H.
For a detailed description of the cloning strategy see 
section 3.2.1. See figures 8b and 24.
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strategy
Figure 20.
Structure and Cloning Strategy of 5 1 Deleted 
c-myc-CAT Recombinants pB29, pB28 and pB34.
For a detailed description of the cloning strategy 
see section 3.2.1. See figure 8c, 25, 26 and 27.
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Figure 21.
Structure and Cloning Strategy of 5 1 Deleted
c-myc-CAT Recombinant pB46, and Intermediate
Recombinant pB45.
For a detailed description of the cloning strategy
see section 3.2.1. See figure 8c and 26.
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Figure 22.
Structure and Cloning Strategy of c-myc-CAT
Recombinant pB14.
For a detailed description of the cloning strategy 
see section 3.2.1. See figure 8c, 25 and 26.
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Figure 23.
Structure and Cloning Strategy of c-myc-CAT
Recombinant pB68.
Restriction sites which are destroyed upon ligation are 
marked with a diagonal line across them. For a detailed 
description of the cloning strategy see section 3.2.1. See 
figure 8d and 27.
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Table 2.
Comparison of Basic c-myc and HSV-IE Promoter 
Recombinants Expression m  Different Cell Lines.
Donor DNA
Recipient c
511 Lines. pB9 pB14 pB12 pLW2 expts
LaTK"
a
1372
b
(1) .169523 (87) 50924 (26) 194022 (100) 8
HeLa 701 (2) 3100 (10) 805 (3) 30333 (100) 3
NIH-3T3 491 (10) 857 (17) 518 (10) 5149 (100) 3
K-562 1009 (8) 30053 (229) 3146 (24) 13117 (100) 3
MRC-5 491 (45) 1088 (100) 568 (52) ND 2
GM468 496 (19) 2661 (100) 661 (25) ND 2
a. Average of total counts (cpm) per flask (with no more 
than 15% variation).
b. Average counts (cpm) represented as a percentage of 
pLW2 ( pB14 for MRC-5 and GM468).
c. Number of separate experiments of duplicate flasks.
d. Donor DNA (equimolar ratio of 10pg) was mixed with
carrier salmon sperm DNA to a final concentration of
20(ig/ml in the calcium-phosphate precipitate and 
transfected as described in Material and Methods.
e. CAT activity was assayed as described in Material and
Methods using only 50pl of cell extract.
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Figure 28.
Analysis of 5' Deleted c-myc-CAT Recombinants.
A. Diagrammatic representation of 5' deletions and relevant 
restriction map of c-myc 5' flanking region. The location of 
the DNase 1 in vivo hypersensitive sites of Siebenlist et 
al, (1984), are represented by Roman numerals. pB9 is the 
promoterless CAT recombinant (the negative control).
B. Histogram of the results shown in A.
a. For each plasmid an equimolar ratio of 5pq was 
transfected into either LaTK"or HeLa recipient cells as 
described in Materialls and Methods.
b. Average total counts (cpm) from two to nine separate 
experiments of duplicate flasks, represented as a percentage 
of pB14.
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Figure 29.
Activity of Recombinants Containing an Internal 
Deletion of the NRE-2 Domain.
b
Donor DNA
100
B68
f  -  -80
CAT 
Activity
40
2 0
i—
1 2 3 4 5 6 7 8
b
DNA Amount (gg)
a. Average total counts (cpm) from two experiments of 
duplicate flasks as a percentage of pB14. Vertical bars 
indicate the range of values observed.
b. Equimolar amounts of each donor DNA (l-8gg) were 
transfected into LaTK"cells as described in Materials and 
Methods. The resultant CAT activity was assayed as described 
in Materials and Methods.
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Figure 30.
DNA Titration of c-jnyc and HSV-IE Promoter Driven 
CAT Recombinants in LaTK"Cells.
Donor DNAb
2-1
CAT3
Activity
1
2 4 6 8 10 12 14 16 18 20
DNA Amount^
a.Average of total counts (10-* cpm) from four_ separate 
experiments of duplicate flasks. Vertical bars indicate the 
range of values observed.
b. Equimolar amounts (l-10pg) of donor DNA were transfected 
into LaTK~cells as described in Materials and Methods. CAT 
activity was assayed as described in Materials and Methods.
_____________i pB9
144
3.3. Characterisation of the Negative Regulatory Element
Transcriptional control elements have been classified 
by their specific characteristics with respect to magnitude 
of effect, activity on heterologous promoters, orientation 
and distance dependence from the transcription start site. 
The NRE-2 was analysed with respect to these functional 
parameters to give preliminary clues to how this element 
might function.
3.3.1. Recombinant Plasmid Constructions
The basic parental recombinants have already been 
described (see 3.1.2. and 3.2.1.). In addition, pB30 (see 
figure 31) was constructed by adding BamHI linkers to the 
PvuII site of peOl (kindly given by J. Lang, Beatson 
Institute), and subsequent insertion of the 200bp BamHI 
fragment into BamHI digested pB9. This fragment contains 
the human epsilon globin gene promoter domain comprising of 
a CCAAT- and a TATA- element and the first 20bp of the mRNA 
5' leader sequence (see figure 32; Efstratiadis et al, 
1981). This construct, while containing a different
promoter sequence, has essentially the same structural 
layout as pLW2 (see section 3.1.3.).
(i). Recombinants Containing c-myc 5' Region in Both 
Orientations
The 2.0Kb Hindlll fragmennt of pB7H, containing DNase I 
HSS I, II-l, and II-2 (the NRE-2) was inserted, in both
orientations into pB9 (pBlO and pB13), pLW2 (pBl6 and pB17) 
and pB30 (pB37, only 5' to 3' orientation) all cut with 
Hindlll as shown in figure 33. To allow the "flipping" of 
the upstream region in front of its homologous promoter, the 
2.8Kb Hindlll fragment from pB7B was first inserted into
Hindll digested pB9, giving pB12B (see figure 34). Then by 
inserting the 900bp BamHI fragment from pB12B into BamHI 
digested pBl3, the same 5' region is "flipped" in pB19
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compared to pBl2 (see figure 35).
(ii). Recombinants Containing 445bp and 270bp NRE-2 
f ragments
By AccI digestion of pB34 and self-ligation of the 
resulting linear, pB51 (see figure 36) was constructed which 
contains the 445bp NRE-2 fragment (containing DNase I HSS 
II-2). EcoRI digestion of pB51 followed by Klenow treatment 
to produce flush-ends, and subsequent Hindlll linker 
modification, allows this 445bp NRE-2 fragment to reside as 
a Hindlll fragment (pB56; see figure 36). This fragment was 
inserted in both orientations into Hindlll digested pB9 
(pB72 and pB73; see figure 36) and only in the 3'-5' 
orientation into Hindlll digested pLW2 (pB63; see figure
36). The DNase I HSS II-2 is located within the 3' portion 
of the 445bp fragment, and from analysis of the sequence, 
the 270bp sub-fragment (Rsal-Thal) may define the extent of 
the NRE-2. Thus the Rsal-Thal 270bp fragment from pB51 was 
inserted into the Smal site of pUCl2 destroying each 
respective restriction site upon ligation (pB49; see figure
37). EcoRI digestion followed by Klenow flush-ending, and 
Hindlll linker modification, allowed this region to reside 
as a 300bp Hindlll fragment (pB62; see figure 37). This 
Hindlll fragment was then inserted in either orientation 
(pB65 and pB67; see figure 37) into Hindlll digested pLW2.
(iii). Recombinant Containing Splice Donor Site
The 3.6Kb Hindlll-BamHI fragment from pB2 containing 
all the 5' region, all of exon 1 and 600bp of intron 1 (to 
the Xbal site), was inserted into Hindlll-BamHI digested pB9 
to give pB4 (see figure 38).
3.3.2. Restriction Enzyme Analysis of Recombinant Plasmids
Extensive restriction enzyme analysis has been used to 
identify each of the recombinant plasmids described.
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Representative digests are shown in figures 39, 40, 41, 42,
43, 44 and relevant restriction maps in figures 8a, 8d, 8e,
8 f , 8g, 8 h .
(i). Plasmids Containing 5' Region and the e-Globin 
Promoter.
The basic 6-globin promoter-CAT recombinant (pB30) is 
defined by Hindlll linearalisation (3.8Kb), BamHI digestion 
to reveal the 200bp promoter domain, and PstI digestion to 
show the promoter-CAT fragment (985bp).
The recombinants containing the 1940bp c-myc upstream 
region 5' to heterologous promoter domains driving the CAT 
gene are defined by restriction enzymes which confirm the 
orientation of the c-myc derived sequences. PstI digestion 
of pBlO and pB37 give the diagnostic fragment of 60bp, while 
a 180bp fragment is seen for pB13. The 1710bp fragment is 
derived from the inserted c-myc sequences. Because pB37 
contains the 200bp e-globin promoter domain the CAT fragment 
is larger (990bp) than that seen for pBlO or pB13 (790bp). 
HincII digestion of pB16 gives a diagnostic fragment of 
800bp, while pB17 gives a 310bp fragment. The 830bp fragment 
is derived from the inserted c-myc sequences.
EcoRI linearalisation of pB19 and pB12 confirms their 
near identical (only lObp difference) size of 6.4Kb. To 
confirm the c-myc upstream region is in the "flipped" 
oreintation in pB19 compared to pB12, both recombinants were 
digested with HincII to give fragments of 4365, 875, 830 and 
310bp for pB19, and 3865, 1670 and 830bp for pB12. The 875bp 
and 310bp fragments of pB19 confirm the orientation of the 
upstream sequences.
(ii). Plasmids Containing NRE-2
The 445bp NRE-2 fragment is shown in pB51 by Hindlll 
Kpnl digestion, in pB56 by Hindlll digestion (apparent
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disparity in size is due to linker modification), and in 
pB72 by Hindlll digestion. Accl-Kpnl digestion of pB34 
indicates the size of the original NRE-2 fragment (445bp). 
The orientation of the NRE-2 fragment within pB51 was 
confirmed by Hinfl digestion. The 62bp fragment derived 
solely from c-myc sequences, while the 1454 and 544bp 
fragments indicating the insert oreintation. PstI digestion 
of pB72 giving fragments of 3240, 790 and lObp, and of pB73 
giving fragments of 2780, 790 and 460bp confirms the NRE-2
domain orientation in these recombinants. Since PstI 
digestion of pB63 reveals a 470bp fragment, similar to pB73, 
this confirms that the NRE-2 domain in these two 
recombinants is the same.
The 270bp sub-fragment is shown in pB49 by EcoRI 
Hindlll digestion and in pB62 by H i n d u  digestion (apparent 
disparity in size is due to linker modification). This
fragment was inserted into pLW2, where its orientation was 
confirmed by BamHI digestion: giving 3560, 300 and 210bp
(HSV-IE promoter domain) in pB65, and 3840, 210 and 20bp in
pB67 .
(iii). Plasmid Containing the Splice Donor Site.
The recombinant containing the splice donor site pB4 is 
defined by Clal linearalisation (7.3Kb), and Xbal-Hindlll 
digestion which reveals the pUC fragment (2680bp) and the 
c-myc-CAT fragment (4665bp, compare to Hindlll digested
pB12; see figure 25).
3.3.3. Effect on Heterologous Promoters
The ability of the NRE-2 to regulate (repress)
heterologous promoters was investigated. Since the greatest 
repression was observed when the Hindlll-PvuII 2.0Kb region 
was deleted, this region was used in these experiments. Two 
heterologous prmoters were used in these experiments; the 
HSV-IE gene promoter (viral) and the human e-globin gene
148
promoter (eukaryotic). Equimolar amounts of pLW2 (HSV-IE 
promoter), pB30 (e-globin promoter), pB14 (c-myc promoter) 
and the respective NRE-2 driven promoter-CAT recombinants 
(pB16, pB37, pB12) plus the negative control pB9, were 
transfected into LaTfC HeLa, NIH-3T3 and K-562 recipient 
cells. The resultant CAT values are shown in table 3 (see 
figure 45).
The 2.0Kb Hindlll-PvuII 5 ! region (containing DNase I 
HSS I, II-l and II-2) confers a 6-fold repression upon its 
own homologous promoter when orientated in the same 
direction (5'-3') to it, in LaTK cells. When placed in the 
same orientation in front of either the HSV-IE (pBl6) or 
e-globin (pB37) gene promoters their respective CAT 
activities are only halved in LaTK-cells. However, in Hela 
cells the heterologous HSV-IE promoter (pBl6) is repressed 
9-fold, while repression of the homologous promoter (pB12) 
is only 4-fold. These differences in repression ratios have 
no obvious explanation, except that they may reflect the 
different cell lines ability to express the exogenously 
introduced viral promoter, or reflect a titration effect 
(see 3.4.4.). The repression seen in NIH-3T3 cells is 
approximately the same for the homologous (pBl2) and 
heterologous (pB16) promoters. Therefore the 2.0Kb Hindlll- 
PvuII NRE-2 region can repress heterologous promoters, 
although not as efficiently as the homologous promoter, in 
this assay system.
3.3.4. Orientation Dependence of Repression
To investigate the orientation dependence of the NRE-2, 
the 2.0Kb Hindlll-PvuII 5' region (containing DNase I HSS I, 
II-l and II-2) was inserted in either orientation (pB12 and 
pB19) 5' to its homologous promoter (pBl4) and 5' to the
heterologous HSV-IE promoter (pB16,pB17; pLW2). Equimolar 
ratios of these recombinants were transfected into LaTK, 
HeLa, NIH-3T3 and K-562 cells and the resultant CAT 
activities are shown in table 3. When the 2.0Kb NRE-2 region
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was placed 5' to its homologous promoter, the 3'-5' 
orientation (i.e. the "flipped" orientation) consistently 
gave the greater magnitude of repression in LaTK'cells, the 
same level of repression in K-562 and NIH-3T3 cells, and 
slightly less repression in Hela cells. When regulating the 
HSV-IE gene promoter (pB16 and pBl7) in both LaTK" and 
NIH-3T3 cells, the 3'-5' orientation again showed the 
greater level of repression.
These orientation experiments were done on covalently 
closed plasmids, so the activity seen when the c-myc 
fragment containing the NRE-2 is in the "flipped"
orientation could be due to its function operating the
"long-way-round" the plasmid. However, the mere 
transfection of linear plasmids does not exclude this
either, due to the large probability that there is immediate 
recombination and recirculisation of transfected DNA on 
entering the cell (Weber and Shaffner, 1985), or possibly 
even before while in the co-precipitate stage.
Why the "flipped" orientation in some instances causes 
a greater repression is not obviously clear. This can not 
be due directly to the positioning of the NRE-2 element as 
it is in the 3' region of this fragment, i.e. the "flipped" 
orientation has it distal to the promoter. The presence of 
an additional negative element, although not seen in the 5' 
deletion studies, can not be excluded (see 3.6.4.).
Thus, using the 2.0Kb Hindlll-PvuII NRE-2 fragment, 
repression can be conferred upon heterologous promoters, 
both of viral and eukaryotic origin, in an apparently 
orientation independent manner. Repression ratios vary 
between 2- and 10- fold depending on both the orientation 
and cell line being analysed. These results imply that 
there is no essential interaction with c-myc sequences 
located outwith this region required for this repression, 
however, these studies do not provide evidence to say such 
an interaction definitely does not occur.
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3.3.5. Effect of Varying Distance
These results came from the strategy used to construct 
previously described plasmids, and the various experiments 
in which they were analysed (see table 3). As a consequence 
of the cloning strategy, the negative element is in a 
different location with respect to PI in each recombinant, 
from -530bp (pB16) and -700bp (pBl2) to -1670bp (pBl7) and 
-1840bp (pB19). This would imply that the exact positioning 
of the NRE-2 with respect to the transcription start site is 
relatively unimportant at these distances. However, since 
in pBl7 and pBl9 the c-myc sequences have been "flipped", 
there are other explanations for this (see 3.6.4.), and this 
conclusion has to be treated with some reserve.
3.3.6. Analysis of NRE-2 Fragments
To further analyse the repression function the negative 
element (NRE-2), as defined by the deletion analysis, was 
inserted as a 445bp KpnI-AccI or 270bp Rsal-Thal fragment 
into pLW2 and transient transfection experiments using 
equimolar amounts of the respective recombinants were 
performed. This set of experiments was done in LaTK- cells 
and the results are presented in table 4.
When placed as a 445bp fragment (pB63) or a 270bp 
fragment in either orientation (pB65 and pB67) upstream of 
the HSV-IE gene promoter no repression of CAT activity 
compared to the parental recombinant (pLW2) was observed.
This may indicate, that although this region is essential
for the repression activity, it does not contain the whole
negative regulatory element. As a corollary, sequences
outwith the KpnI-AccI fragment are required for it to 
function. Alternatively the relative positioning of the 
NRE-2 may be of crucial importance when proximal to the 
promoter, being in these constructs, too close to the 
promoter domain, or in the wrong local helical twist to
function. Analysis of this anomaly requires detailed
151
examination in the future.
3.3.7. Effect of the NRE-2 on a Promoter-less CAT Gene Alone
The recombinant pB9 contains no obvious promoter 
domain, nor a cap site, However, there is a very weak level 
of background activity (see 3.2.3.). When enhancer elements 
are placed upstream of a promoterless gene, transcriptional 
activation of that gene occurs (Lang, 1985). The NRE-2 was 
analysed for such activity. The 2.0Kb NRE-2 fragment and the 
445bp NRE-2 fragment were inserted, in both oreintations, 5' 
to the CAT structural gene and transfected into LaTK- and 
K-562 cells as before. The resultant CAT activity is 
presented in table 5.
When the 2.0Kb Hindlll-PvuII upstream c-myc region 
(containing DNase HSS I, II-l and II-2) was inserted 
upstream of pB9 in either orientation (pBlO and pB13) no 
affect on CAT enzyme activity was observed. However, when 
the 445bp fragment (KpnI-AccI), which contains at least an 
essential domain of the negative element, is inserted in 
either orientation 5' to the promoterless CAT gene (pB72 and 
pB73) there is an approximately 15-fold increase in CAT 
activity when compared to pB9. This level of activity is 
nearly half that of the c-myc promoter (pBl4). The NRE-2 
(the 445bp KpnI-AccI fragment) in these experiments is 
acting to promote expression.
These results may indicate that there are additional 
sequences outwith the 445bp fragment required to bring about 
repression. Whether pBlO and pBl3 give no activity due to 
an intact functioning negative regulatory element or that 
the element(s) conferring promotion are too distant from the 
promoter to have any activity is not known. When viewed as 
a whole the results presented (5' deletions, internal 
deletion and heterologous promoters) indicate that this 
445bp fragment contains an essential region but perhaps not 
the whole domain of the negative regulatory element, NRE-2,
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which can in specific situations act to promote expression.
3.3.8. Presence of Splice Donor Site
The recombinant (pB4) which contains all the c-myc 5' 
sequences, all of exon 1 and 600bp of intron 1 was 
originally made as a negative control. To test this 
recombinant (pB4) for activity, equimolar amounts (of 10pg) 
of it and pB9 were transfected into LaTK~and K-562 cells, 
and the resultant CAT activity shown in table 5. The CAT 
activity for pB4 is zero when compared to that of pB9. This 
was expected as the presumed splice donor site is retained 
in the construct while no obvious splice acceptor site is 
present. Presumably the CAT structural gene is spliced out, 
thus not transcribed (no data). Several other studies (D. 
Spandidos and N. Lowdnes, personal communication) and 
elsewhere (Remmers, Yang and Marcu, 1986) also retain splice 
donor sites in their constructs (c-Ha-ras and c-myc 
respectively) with no obvious effect on expression. This 
may be explained for the c-Ha-ras recombinants in that it is 
another system, but the c-myc recombinants (Remmers, Yang 
and Marcu, 1986) present a definite anomaly. A much 
smaller intronic region (approximately 20bp) is retained in 
their recombinant (compared to 600bp in pB4) and it is 
conceivable that the correct mRNA structure required for 
splicing can not therefore be attained.
The other obvious difference between pB4 and pB12, is 
the inclusion of the 3' 40bp of exon 1. This full length 
untranslated exon 1 may be involved in messenger stability 
(Piechaczyk et al, 1985), and as such its inclusion may 
confer an extreme instability upon the CAT induced message. 
If this was the case again Remmer's recombinants would (but 
do not; Remmer, Yang and Marcu, 1986) show the same lack of 
CAT enzyme activity. Thus this anomaly remains unresolved, 
but could be a point for future investigation.
The relatively high c-myc-driven CAT activity in these
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studies (compare recombinants pB14 and pLW2; see table 2) 
implies the presence of a fairly abundant CAT protein. Thus 
the inclusion of 500bp (the majority) of the c-myc exon 1 
sequences probably does not confer an extreme instability 
upon the resulting hybrid message.
154
Figure 31.
Structure and Cloning Strategy of G- Globin 
Promoter-CAT Recombinant pB30.
For a detailed description of the cloning strategy 
see section 3.3.1. See figure 8a, 32, 39 and 40.
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Figure 32
Structure of the Human Globin Gene Family and
Derivation of the S-Globin Gene Promoter Domain.
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CGATCCAGCA CACATTATCA CAAACTTAGT CTCCATCCAT CACTGCTCAC CCTCTCCGGA CCTGACTCCA
BamHI Hinfl
CCCCTGAGGA CACAGGTCAG CCTTGACCAATCACTTTTAA GTACCATGGA GAACAGGCGG CCAGAACTTC
m R N A _________
GGCAGTAAAG AATAAAAGGC CAGACAGAGA GGCAGCAGGA CATATCTCCT TGCGACACAG CTG
Pvull
The position of the human £. globin gene is depicted within 
the£ -like globin gene family, and the DNA sequence of the 
197 bp Bam HI-Pvu II promoter region shown. Shaded areas 
represent the coding regions of the gene separated by 
intervening introns. Underscored black bars represent the 
CAAT and TATA consensus sequences.
See figure 31•
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Figure 33.
Structure and Cloning Strategy of Recombinants
pBlO, pB13, pB16, pB17 and pB37 .
For a detailed description of the cloning strategy 
see section 3.3.1. See figure 8e and 40.
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Figure 34.
Structure and Cloning Strategy of
c-myc-CAT Recombinant pB12B.
For a detailed description of the cloning strategy 
see section 3.3.1. See figure 8d.
B 7 - B Xb
Hd
Hd
PI P2 
e xon 1\
Hd
P B 9
Ps
Xb
p B 1 2  B
158
Figure 35.
Structure and Cloning Strategy of c-myc-CAT 
Recombinant pB19.
The comparable recombinants pB12 and pB19 are shown 
diagrammatically at the bottom of the page. In effect the 
major difference between them is the "flipping" of the 2.0Kb 
Hindlll-PvuII upstream region. For a detailed description of 
the cloning strategy see section 3.3.1. See figure 8d, 19,
33 and 41.
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Figure 36.
Structure and Cloning Strategy of Recombinants 
pB51, pB56, pB62, pB72 and pB73 Containing the
445bp NRE-2 Region.
Restriction sites which are destroyed upon ligation are 
marked with a diagonal line across them. For a detailed 
description of the cloning strategy see section 3.3.1. See 
figure 8f, 42, 43 and 47.
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Figure 37 .
Structure and Cloning Strategy of Recombinants 
pB49, pB62, pB65 and pB67 Containing the 270bp
NRE-2 Sub-Region.
Restriction sites which are destroyed upon ligation are 
marked with a diagonal line across them. For a detailed 
description of the cloning strategy see section 3.3.1. See 
figure 8h, 36 and 44.
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Figure 38.
Structure and Cloning Strategy of c-myc-CAT Recombinant p B 4 .
For a detailed description of the cloning strategy see 
section 3.3.1. See figures 8g and 44.
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Table 3.
Activity of Hindlll-PvuII c-myc Upstream Sequences 
upon Homologous and Heterologous Promoters.
Recipient Cell Lines
Donor DNA LaTK “ HeLa NIH-3T3 K-562
a b
I . pB9 462 (1) 436 (20) 491 (57) 803
pB14 109186 (104) 2185 (100) 857 (100) 16526 (:
pB12 17909 (16) 569 (25) 514 (60) 1423
pB19 5052 (5) 881 (40) 483 (56) 1308
c
expts 3 3 4 2
II. pB9 462 (1) 436 (2) 491 (8) ND
pLW2 139818 (100) 19314 (100) 6567 (100) ND
pB16 72702 (52) 2188 (11) 2646 (40) ND
pB17 29955 (21) ND 850 (13) ND
expts 3 2 4
III.pB9 462 (16) ND ND ND
pB30 2981 (100) ND ND ND
pB37 1429 (48) ND ND ND
expts 3 - - -
a. Average of total counts (cpm) per flask (no more than 
15% variartion). ND= not done.
b. Average total counts (cpm) as a precentage of promoter 
alone (I:pB14, II:pLW2, III:pB30).
c. Number of separate experiments of duplicate flasks.
d. Donor DNA (eqimolar ratio of 5pq) was mixed with 
carrier salmon sperm DNA to a final concentration of 
20pg/ml in the calcium-phosphate precipitate and 
transfected as described in Materials and Methods.
e. CAT activity was assayed as described in Materials and 
Methods using total cell extract.
(see figure 45.).
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Figure 45.
Examples of CAT Assay Autoradiographs.
A. The effect of the 2.0Kb Hindlll-PvuII upstream sequence 
(pB16) on the activity of the HSV-IE gene promoter (pLW2) in 
LaTK- cells. (see table 3-II.)
B. The activity of the 5' deleted c-myc-CAT recombinants 
pB12 and pB29 compared to pB14 in LaTK~ cells. The 
promoterless CAT vector pB9 is also shown, (see figure 28.)
The equimolar amount transfected, and the plasmid 
name, is shown below each autoradiograph.
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Table 4.
Activity of the NRE-2 Sub-Regions upon the HSV-IE 
Gene Promoter in Transiently Transfected LaTK'Cells.
CAT Activity
a b c
Donor DNA Counts o. expt
pB9 5685 (11%) 2.1 3
pLW2 270952 (16%) 100 3
pB63 350850 (18%) 129 3
pB65 293293 (12%) 108 2
pB67 277120 (8%) 102 2
a. Average total counts (cpm) per flask with range 
of values expressed as a precentage in brackets.
b. Average total counts represented as a percentage 
of pLW2.
c . Number of separate experiments of duplicate 
flasks.
d. Donor DNA (equimolar ratio of 4pg) was mixed 
with carrier salmon sperm DNA to a final 
concentration of 20pg/ml in the calcium- 
phosphate precipitate and transfected as 
described in Material and Methods.
e. CAT activity was assayed as described in 
Materials and Methods using total cell extract.
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Table 5.
Transient Expression of Promoterless/Capless 
CAT Recombinants.
Recipient 
Cell Lines
Donor DNA LaTK" K-562
a
pB9 1.0 1.0
b
pB14 36.2 (±3.6) 20.6 (±2.0)
pBlO 1.2 (±0.1) 0.8 (±0.1)
pB13 1.0 (±0.1) 1.1 (±0.1)
pB72 12.7 (±3.3) ND
pB73 17.3 (±2.3) ND
pB4 1.0 (±0.1) 0.9 (±0.1)
a. Values represent the average total counts (cpm) 
from two separate experiments of duplicate 
flasks, normalised to the CAT activity of pB9. 
i.e. pB9=l. ND= not done.
b. Values in brackets indicate the range of 
activity between flasks observed.
c. Donor DNA (equimolar ratio of 10pg) was mixed 
with carrier salmon sperm DNA to a final 
concentration of 20pg/ml in the calcium- 
phosphate precipitate and transfected as 
described in Material and Methods.
d. CAT activity was assayed as described in 
Materials and Methods using total cell extract.
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3.4. Evidence for Repression Involving a Trans-Acting Factor
Since the studies on the location of the negative
regulatory element by 5' deletion, showed that with 
increasing amount of transfected DNA the level of repression 
decreased, the presence of a trans-acting factor which was
being titrated out was implied. To investigate this 
further, additional DNA-titration and competition
experiments were undertaken.
3.4.1. Recombinant Plasmid Constructions
Many of the recombinants used in this series of 
experiments have been described previously (see sections
3.2.1. and 3.3.1.).
(i). Recombinants for Competition Experiments
The 2.0Kb Hindlll fragment from pB7H containing DNase I 
HSS I, II-l and II-2, was inserted into Hindlll digested 
pUC12 to give pB18 (see figure 46). Subseguent AccI partial 
digest to linearlise pBl8, followed by Clal digestion 
allowed pB20 (comtaining DNase I HSS II-2; see figure 46) to 
be generated by self-ligation and the insertion of the 1.1Kb 
Accl-Clal fragment into AccI digested pUC12 gave pB21 
(containing DNase I HSS I and II-l; see figure 46).
(ii). Recombinants for in vitro Footprint Experiments
The following plasmid was made unintentionally but it 
proved to be a very fortuitous ligation! The 445bp NRE-2 
fragment from pB18, by KpnI-AccI digestion and subsequent 
low melting agarose gel isolation, was further digested with 
Rsal and Thai. The resulting fragment mixture (containing 
both the 169bp Rsal fragment and the 263bp Rsal-Thal 
fragment) was ligated into HincII digested pUC12. The 445bp 
NRE-2 fragment is contained in pB50 in a mixed orientation, 
i.e. 5' - 270bp - 170bp - 3' (see figure 47), by ligation of
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the flush Rsal and Thai ends of the internal fragments (see 
section 3.4.2.). The whole of the 445bp fragment is present, 
but the blunt ended fragments are in each others position, 
i.e. the originally 5' 170bp fragment is now located 3 ’ to 
the 270bp fragment. The orientation of both fragments 
remains the same.
3.4.2. Restriction Enzyme Analysis of Recombinant Plasmids
Extensive restriction enzyme analysis has been used to 
identify each of the recombinant plasmids described. 
Representative digests are shown in figure 42, 43, 48 and
relevant restriction maps in figures 8f, 8 g .
(i). Plasmids for Competition Experiments
The 1940bp c-myc fragment can be dissected from pB18 
by Hindlll-Clal digestion to reveal the 5' (1030bp) and 3'
(910bp) fragments. These fragments can be identified in pB21 
by Hindlll digestion and pB20 by BamHI-Hindlll digestion 
respectively (apparent disparity in sizes is due to linker 
modification or the presence of pUC derived polylinker 
seguences). Both pB56 and pB62 have been described 
previously (see 3.3.2.).
(ii). Plasmids for in vitro Footprint Experiments
To define pB50 the insert was identified by BamHI-PstI 
digestion (440bp), and its orientation (which is mixed) was 
confirmed by Hinfl digestion. The apparent disparity in size 
of the 1454bp fragment was probably due to the proximity of
this lane to the edge of the gel. The c-myc derived 62bp
fragment is diagnostic of the NRE-2 domain, while the 209bp 
and 1454bp fragments confirm the relative positions of the 
two internal fragments in this recombinant. Rsal-Thal
digestion of pB34 shows the parental Rsal and Rsal-Thal
fragments.
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In addition to restriction enzyme analysis, the 
configuration of the insert in pB50 was confirmed by the 'G' 
sequence tract used in the footprint analysis.
3.4.3. Expression Assay Results
By increasing the amount of DNA transfected we assume 
the amount of DNA taken up by the cells is increased, which 
would (and does) manifest itself as an increase in CAT 
activity (see figure 14; Weintraub, Cheng and Conrad, 1986). 
Thus any cellular factor which functions in trans on the DNA 
might be the limiting parameter and could in effect be 
titrated out, as the amount of DNA transfected increases. 
In addition, if a competitor plasmid (containing only the 
cis-acting element sequences and no coding sequences) is 
co-transfected in increasing amounts, with the indicator 
recombinant (containing the transcription regulatory element 
in cis to the reporter gene) again the trans-acting 
factor(s) might be titrated out by interaction with the 
competitor plasmid. Both these strategies have been used to 
positively identify a role for a trans-acting factor(s), 
interacting with the cis-acting NRE-2, to bring about the 
repression activity seen in these studies.
3.4.4. DNA Titration Studies
These experiments involved the transfection into LaTK 
cells of increasing equimolar amounts of plasmid DNA. The 
resultant CAT activites were then represented as a ratio to 
pB14 (i.e. at each DNA amount pB14 gives a value of 1), as 
shown in figure 49. The test plasmids used were pB12, pB28,
pB34, pB46, pB14 and pB9 (see section 3.2.4.). When pB46
and pB14 are compared by DNA titration (pB46 gave the same 
activity as pB14) the resulting CAT activity implied that 
they have an equal potential for transcription, as was shown 
for previous experiments (see section 3.2.4.). This infers 
that only the proximal 350bp upstream of the c-myc promoter 
PI are required for full promotion of the c-myc gene, and
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that the -607 to -350bp region has no obvious functional 
role in control of expression in this system.
The CAT control (pB9) also increases linearly with 
pBl4 but at only a fraction of its activity level. As 
already mentioned this is probably not due to an artifact of 
the CAT assay but an intrinsic property of pB9 (see section
3.2.6.). However, when pBl2 is compared with pBl4 (or pB46)
the repression ratio at low equimolar amounts (equimolar 
amounts are used to ensure that an equal plasmid copy number 
is available to the cell) is 10-fold greater than that at 
high equimolar amounts (20pg) of transfected DNA. This 
implies the presence of a trans-acting factor (repressor), 
which is being titrated out as the number of exogenously 
introduced plasmid copies getting into the cell increases 
(i.e. self titration).
The titration effect can be seen for pBl2, pBl9 and
pB28. However, pB34 is repressed when compared to pB14 but 
not to the same extent as pB12 (see 3.2.1. and 3.3.3.). This 
indicates that part of the NRE-2 domain may be 5 1 to the 
Kpnl site. This region (around the Kpnl site) may be 
involved in conferring a structural alteration upon the
NRE-2 domain induced by trans-acting factors binding to the 
NRE-2 domain directly. Why such sequences are 5 1 to the 
NRE-2 is not immediatly obvious, however these studies would 
not identify 3' sequences with a similar property. Since the 
competition studies (see 3.4.5.) show that the 445bp Kpnl- 
AccI fragment can greatly relieve repression, it is unlikely 
that sequences 5 ’ to the Kpnl site act as recognition 
elements for trans-acting factors. However it remains a 
possibility that the 445bp fragment could conceivably be 
titering out only an essential factor(s), but not all the
factors required for repression. It is also posssible that 
the deletion from the Kpnl restriction site could
truncate part of the negative regulatory element 
trans-acting factor recognition domain.
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However, the differences in repression ratio between 
pB12, pB28 and pB34 are relatively small when compared to 
the actual repression ratio observed. Therefore this may 
reflect the assay variation rather than functional domains 
(see section 3.6.). Interestingly, repression appears to be 
greater in the larger recombinants (pB12 > pB28 > pB34).
Therefore, it is possible that the difference in repression 
ratio may just reflect a more efficient repressor-NRE-2 
interaction in the larger recombinants, possibly due to some 
form of conformational restraints.
Titration experiments for pB12, pB14 and pB9, were also 
done with K-562 cells acting as the transfection recipient. 
No titration-effeet is seen in K-562 cells, which show the 
greatest repression activity. K-562 cells exhibit a very 
poor transfection efficiency (D.Spandidos and P. Montague, 
personal communication) and this result may reflect this. 
If the assumption is made that this poor efficiency is due 
to a poor DNA uptake, then even though lOpg of DNA are 
transfected the cell may only be taking up a small amount of 
the available co-precipitate. (N.B. The poor efficiency 
could also be due to poor DNA transport to the nucleus or 
inefficient DNA expression.) If this is so, then these 
results may only be at the start of a DNA-titration-curve 
and explain why no titration effect is observed. 
Experiments using larger amounts of DNA (20pg and 40pg) were 
attempted but this heavy precipitate resulted in a dramatic 
change from adherent cells to suspension cells (the K-562 
cell line was selected for its adherence properties: see
section 2.3.1.) and although results were obtained (not 
shown) they were not reproducible.
If this cell line is indeed only taking up a small 
proportion of the available DNA this could explain the 
results of section 3.2.3. The 5' deletion results infered 
that K-562 cells contained either a very active 
repressor(s ), or that the repressor factor(s) was present in 
this cell line at high concentrations. The titration results
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indicated that the lower the amount of DNA transfected into 
the cell, the greater the repression ratio is (i.e. less 
self titration of repressor). Taking these two results 
together suggests that the high level of repression seen in 
K-562 cells may be a consequence of the low amount of DNA 
taken up by these cells (i.e. low nuclear levels of 
exogenous plasmid).
To investigate whether a titration effect could be 
observed in other cells, pB16 (containing the 2.0Kb NRE-2 
regulating transcription from the HSV-IE promoter) was 
transfected in increasing amounts into LaTK”and HeLa cells. 
The resultant CAT activities are plotted in figure 51. The 
titration-effect was also observed for the 5' c-myc region 
driven repression of the HSV-IE gene promoter (pB16) in LaTK" 
and Hela cells. To confirm earlier results with this 
recombinant the repression appears to be greater in Hela 
than LaTK- cells. Whether this is due to an increased 
presence of c-myc-interacting trans-acting factor(s) in 
these cells or the respective ability of each cell to 
express the viral promoter is unknown. Because LaTK" cells 
function as very efficient transfection recipients it is 
possible that at equal DNA amounts (i.e. at Ipg) the number 
of plasmid copies taken up and expressed by the nucleus is 
far greater for the LaTK cells than for the HeLa cells. This 
would make it technically difficult to see the lower end of 
the titration curve (see section 3.1.6.). The limited 
titration done for pB30 and pB37 (containing the human 
e-globin gene promoter) also showed the titration-effeet 
(unpublished result).
Although these results imply the presence of a trans­
acting repressor which is being titrated out, the titration 
out of positive factors can not be dismissed. Indeed the 
expression curve seen for the c-myc-promoter (pB14) and the 
HSV-IE promoter (pLW2) do show a slight leveling off before 
the saturation plateau is reached. This may indicate a 
titration-effect on a positive factor. Therefore, to further
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indicate that it is the repressor which is being titrated 
out competition experiments were undertaken.
3.4.5. Competition Experiments
In these experiments the indicator recombinant 
containing the reporter gene (CAT) driven by the desired 
cis-acting regulatory elements was transfected (constant 
equimolar amount) in the presence of increasing equimolar 
amounts of the competitor recombinant (containing only the 
relevant cis-acting regulatory element). LaTK~ cells were 
used as the transfection recipients for these competition 
experiments. The carrier DNA used for these competition 
experiments was pUC plasmid DNA, thus ruling out the 
titrating out of trans-acting factors by the plasmid vector 
sequences.
The 2.0Kb Hindlll-PvuII NRE-2 fragment has been shown 
to represses heterologous promoters, therefore it was used 
as the first competitor (see figure 52). Increasing amounts 
of this fragment inserted in pUC12 (pB18) were used as the 
competitor to the indicator plasmid pB12. At a 5 molar 
excess of competitor to indicator, the titration-out of 
repression was observed. No CAT activity was observed for 
pBl8 alone (data not shown).
Since the repression activity had been localised to a 
fragment containing DNase I HSS II-2 located in the the 3' 
half of the c-myc sequences in pB18, this region was used as 
a competitor (pB20) against pB28 (c-myc 5' deletion from 
HincII retaining NRE-2). Again, release from repression was 
observed at 5 molar excess of competitor to indicator (see 
figure 52). When the 5 ’ half of pB18 is used as a competitor 
(pB21) against the indicator pB28 there is no obvious 
release from repression (there is a very slight rise in 
activity; see figure 52). This would apparently exclude any 
sequences 5' to the Clal site from acting as an additional 
"sink” (see 3.6.4.).
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Previous results indicated that the 445bp KpnI-AccI 
fragment although containing an essential component of the 
negative element may not include the whole domain. 
Therefore, competition experiments similar to those 
described above were done using the 445bp NRE-2 region 
(pB56) or the 270bp NRE-2 sub-region (pB62) to see if these 
fragments alone could compete out the repression activity 
(see figure 53). Both the 445bp fragment and the 270bp 
sub-fragment compete out repression at approximately the
same molar excess of competitor to indicator as pB20 (about 
5-10 fold). Unfortunately, during these experiments the 
growth state of the recipient cells was somehow impaired 
(slower growth), as reflected by the low absolute values 
obtained. However , the result was obtained from two
separate experiments thus indicating a competition effect. 
This implies that the 445bp and its 270bp sub-fragment 
contain, at least, an essential component of the cis-acting 
negative element (NRE-2), and that repression is mediated 
through the interaction of at least one trans-acting factor 
(the repressor).
3.4.6. Analysis of in vitro Footprint Studies
Since titration and competition results imply the
presence of a trans-acting repressor factor(s) the obvious 
question is whether and which specific DNA binding 
protein(s) interact with the NRE-2 domain. One method for 
the identification of such an interaction is by DNase I in 
vitro footprinting (Galas and Schmitz, 1978), which is now 
used quite extensively to answer this type of question (e.g. 
analysis of Spl : Kadonaga, Jones and Tjian, 1986).
In the basic technique a ^P-end-labelled j^ a  probe 
containing at least one putative protein binding site is 
incubated with a protein extract, lightly treated with DNase 
I and then electrophoresed on a denaturing polyacrylamide 
gel. Regions of DNA that are bound by a trans-acting 
DNA-binding protein will appear as protected areas (the
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"footprint"). DNA footprinting was carried out on the 
NRE-2 domain (the 445bp KpnI-AccI fragment: Whitelaw et al,
in press) using a partially purified nuclear DNA-binding 
protein preparation (HO.3), and two highly purified 
preparations prepared by specific DNA affinity 
chromatography from Hela cells, highly enriched for 
transcription factors Spl and CAATT Binding Transcription 
Factor (CTF) repectively (Kadonaga and Tjian, in press; see 
figure 7). As a partially purified protein extract (HO.3) is 
used it is possible that not all the protein factors present 
in the nucleus were included.
Figures 54 and 56 show the DNA footprints, and where 
they map, obtained from the 445bp NRE-2 (pB50). Four 
distinct footprints were obtained, one of which can be 
accounted for by Spl binding, one by a Spl-like factor and 
two by CTF binding. In addition, several in vitro DNase I 
hypersensitive sites were observed. The limits of the 
footprints and the location of the in vitro DNase I 
hypersensitive sites are shown relative to the DNA sequence 
in figure 56. These results indicate (from 5'-3') one Spl 
site (51-GCCCCTCCCA-3'), one Spl-like site
(5'-CAGGAGGGGC-31) and two CTF sites in opposite 
orientations respectively (51-TTTGG-31) and (5'-CCAAT-3') 
are located within this fragment, as defined by in vitro 
analysis.
Weak Spl binding sites have been observed for other 
gene promoter regions (Kadonaga, Jones and Tjian, 1986), and 
therefore what is termed a Spl-like factor binding site may 
just reflect a weak Spl site. The 5' CTF consensus is not as 
good an homology as would be expected. There is another
consensus (31-ATTGG-5') nearer the 3' end of this footprint,
but this would then make the symmetry of the two CTF 
footprints different. As yet it is not known whether 
symmetry is essential or not. Thus whether both footprints 
indicate a similar binding activity (or even an identical
protein) is still debatable. There is also a relatively
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strong hypersensitive site within the 5' CTF footprint.
These results imply the possible involvement of either, 
or both, Spl and CTF in the trans-mediation of repression 
observed in these studies, but in no way excludes the 
presence of additional protein interactions.
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Figure 46.
Structure and Cloning Strategy of c-myc-CAT 
Recombinants pB18, pB20 and pB21.
For a detailed description of the cloning strategy 
see section 3.4.1. See figure 8g and 48.
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Figure 47.
Structure and Cloning Strategy of c-myc-CAT
Recombinant pB50.
Restriction sites which are destroyed upon ligation are 
marked with a diagonal line across them. For a detailed 
description of the cloning strategy see section 3.4.1. See 
figure 8g, 42, 43 and 46.
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Figure 49.
DNA Titration Analysis of 5' Deleted c-myc-CAT
Recombinants in LaTK'cells.
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a.Ratio represents the fold difference between pB14 and the 
various c-myc-CAT recombinants. Values represent (as a 
ratio) the average total counts (cpm) of two to ten separate 
experiments of duplicate flasks.
b. Equimolar ratios of donor DNA were transfected into LaTK 
cells as described in Materials and Methods. CAT activity 
was assayed as described in Materials and Methods.
c. Key:   =pB12;   -pB46; ~pB28;
-------  =pB34.
(see figure 45).
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Figure 50.
Expression of 5' Deleted c-myc-CAT Recombinants 
in K-562 Cells.
101
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a. Ratio represents the fold difference between pB14 and
?B12. Values represent the average of total counts (cpm) rom three separate experiments of duplicate flasks. 
Vertical bars represent range of values obtained.
b. Equimolar ratios of donor DNA were transfected into K-562 
cells as described in Materials and Methods. CAT activity 
was assayed as described in Materials and Methods.
c. Key:   =pB12;   =pB14.
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Figure 51.
DNA Titration Analysis of c-myc-HSV-CAT 
Recombinants in LaTK'and HeLa Cells.
1CH
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a. Ratio represents the fold difference between pLW2 and 
pB16. Values represent the average of total counts (cpm) 
from two separate experiments of duplicate flasks. Vertical 
bars represent range of values obtained.
b. Equimolar ratios of donor DNA were transfected into LaTK 
and HeLa cells as described in Materials and Methods. CAT 
activity was assayed as described in Materials and Methods.
c. Key:    =pLW2;   =pB16 in LaTK cells;
---------  =pB16 in HeLa cells.
(see figure 45).
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Figure 52.
Competition Assays with the c-myc Upstream Sequences.
A. Competition experiment with pB12 (indicator) and 
pB18 (competitor).
B. Competition experiment with pB12 (indicator) and 
either pB20 or pB21 as the competitor.
a. Average total counts (cpm) from two experiments of 
duplicate flasks represented as a percentage of pB14. 
Vertical bars indicate the range of values obtained.
b. Donor indicator DNA (equimolar amount of 2pg) was mixed 
with increasing amounts (represented as a molar ratio) of 
competitor DNA (equimolar amounts of l-10pg) , and adjusted 
to 20pg/ml with pUC12 carrier DNA.
c. DNA was transfected into LaTK- cells as described in 
Materials and Methods. The resultant CAT activity was 
assayed as described in Materials and Methods.
d. The hatched lines represent the activity of the 
indicator DNA alone, while the continuous lines represent 
the activity of the indicator in the presence of competitor 
DNA.
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Figure 53.
Competition Assay With the NRE-2 Sub-fragments as 
Competitors.
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a. Average total counts (cpm) from two separate experiments 
of duplicate flasks as a percentage of pB14. Vertical bars 
represent the range of values obtained.
b. Donor indicator DNA (equimolar amounts of 2pg) was mixed 
with increasing equimolar ratios (0-10) of competitor DNA 
(pB56 or pB62) and adjusted to 20pg DNA/ml with pUC12 
carrier DNA.
c. The calcium-phosphate transfection of LaTK'cells was done 
as described in Materials and Methods. CAT activity was 
assayed as described in Materials and Methods.
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Figure 55.
Photoraph of the in vitro DNase I Hypersensitivity Pattern 
of the NRE-2 Domain showing Spl Interaction.
The H.03, CTf-enriched and Spl-enriched cell extracts 
were used as indicated (see Materials and Methods for 
detailed description of the experimental technique). The 
fragment are labelled at the 5' end. The Roman numerals 
refer to the footprint (DNase I protected domains) observed. 
From this gel sites III and IV are again shown to bind CTF, 
while sites I and II appear to bind Spl. In addition, a 
strong in vitro hypersensitive site was observed between the 
two CTF protected domains. These results have been confirmed 
by gaining the same results from two further experiemnts.
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Figure 56.
Sequence of the NRE-2 Region Indicating the in vitro 
DNase I Footprints (Protected Domains).
A. The footprints indicated were obtained using Spl and 
CTF enriched protein extracts (see figures 54 and 55). The 
relevant restriction sites are shown. The in vitro DNase I 
protected domains are boxed. The open arrows indicate in 
vitro DNase I hypersensitve sites (width of arrow 
correspomnding to the intensity of the site).The consensus 
sequences (see figure 74) for Spl and CTF are shown by 
dotted lines. The in vivo DNase I hypersensitive site 
(Siebenlist et al, 1984) is shown by the Roman numeral II-2.
^.Kon , S P  1
CGPGTftCCCCCTECQCC.TCC.QATftTTCTCCfcGTCTAGCACCTTTGaTTTCTCCCfiACCCGGCAGC
CCGAGACTGTTGCAAACCGCCACAGGGCGCAAAGGGGATTTGTCTCTTCTGAAACCTGGCTGAGA
ftsa I
ATTGGGAACTCCGTGTGGGAGGCGTGGGGGTGGGACGGTGGGGT ACAGACTGGCAGAGAGCAGGC
AACCTCCCTCTCGCCCT AGCCCAGCTCTGGAACAGGCAGACACATCTCAGGCT AAACAGACGCCT
-0- ! SP1 m, fl CTF
CCGCACGGGGCCCCACGGAAGCCTGAGCA^GCGGGGCAGg^agfiQCGGTAljCTGCTbCII.T.ggCA
_____ -0- -O-________ CTF iJl
AGAAT-TEGGGGACTckfeTCTGGGTGGAAGGTATCCAATCCAGtATAGCTGTGCATACATAATGCAT
Tha I Acc I
AAT ACATGACTCCCCCCAACAAATGCAATGGGAGTTTATTCAT AACGCGCTCTCCAAGTATACGT
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3.5. Identification of an Upstream Promoter Element
A repeated, fairly well conserved sequence occurs 
approximately H O b p  5' to PI in the c-myc gene (human: 
Siebenlist et al, 1984; feline: Stewart et al, 1986; murine: 
Bernard et al, .1983). As it is by nature a conserved 
non-coding sequence (this is the argument first used to 
identify transcription control elements) it is thought 
likely to have same role in the regulation of transcription. 
In addition, this region contains the in vivo DNase I HSS 
III-l (Siebenlist et al,. 1984). Transient functional 
analysis of this region identified it to pocess weak 
promoter activity, again with an apparent lack of 
tissue-specificity.
3.5.1. Recombinant Plasmid Constructions
Again some of the recombinants used in this series of 
experiments have been described previously (see 3.2.1.).
(i). Recombinants for Upstream Promoter Element Analysis
By inserting the Smal-Xbal fragment from pBl2 into 
Smal-Xbal digested pUCl2, the c-myc driven CAT recombinant 
pB36 was generated (see figure 57), which contained only 
97bp of upstream sequences.
PvuII Smal double digestion of pB3 and subsequent 
self-ligation gave pB66 (see figure 57), which contains the 
whole c-myc 5 ’ flanking region except DNase I HSS III-l 
region (a 250bp fragment). Subsequent insertions of the 
2.6Kb Hindlll fragment into Hindlll digested pB9 gave pB74, 
(see figure 57), the c-myc driven CAT recombinant which had 
all the 5' flanking region except DNase I HSS III-l.
(ii). Recombinant for in vitro Footprint Analysis
PvuII Smal double digest of pB2 releases a 250bp
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fragment, containing DNase I HSS III-l, which when inserted 
into HincII digested pUCl2 gave pB57 (see figure 58).
3.5.2. Restriction Enzyme Analysis of Recombinant Plasmids
Extensive restriction enzyme analysis has been used to 
identify each of the recombinant plasmids described. 
Representative digests are shown in figure 59 and relevant 
restriction maps in figures 8b, 8c and 8i.
(i). Recombinants Containing DNase I HSS III-l
The c-myc deleted recombinant pB36 upon Xbal digestion 
gives a linear fragment of 4.2Kb (compare with pB14 digested 
with EcoRI; see figure 26). Smal-Hindlll digestion of pB36 
reveals the c-myc fragment of 610bp and the CAT-terminator 
domain fragment of 895bp. The 250bp 5' adjacent domain of 
c-myc was deleted from pB12 to give pB74. HincII digestion 
of pB12 and pB74 gives respectively fragments of 3865, 1670, 
830bp and 3865, 1420, 830bp, with the deleted fragment
easily identified. To confirm this, pB74 was digested with 
Hindlll to give fragments of 3575bp and 2540bp (pB12 has
2375bp and 2790bp fragments), and linearalised with Kpnl to 
give a 6115bp fragment (250bp shorter than linear pB12 of 
6365bp).
(ii). Recombinant used for in vitro Footprinting Studies
The c-myc derived 250bp fragment is shown in pB57 by 
BamHI Hindlll digestion (260bp).
3.5.3. Identification and Localisation of the Upstream 
Promoter Element
A DNA titration experiment with pB36, pB14 and pB9
using LaTK and HeLa cells as the recipients was done in an
attempt to functionally study the -350 to-lOObp region 5 f
to PI (see figure 60). As described before (see section
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3.2.6.), 5' deletion to the PvuII site 353bp 5' to Pi (pB14) 
retains all the sequences required for promoter activity. 
Further 5' deletion to the Smal site, leaving only 97bp 5' 
to Pi (pB36), results in a halving of activity. This result 
was reproducible and observed in LaTK'and Hela cells (also 
MRC-5 cells, data not shown). Such a decrease in activity 
implies the presence of an element weakly involved in the 
promoter domain of c-myc, although this deletion may be just 
disecting an element. In addition, in both LaTK'and Hela 
cells a weak titration-effect was observed, possibly 
indicating the involvement of a trans-acting factor. It must 
be stressed that the activity seen for this region is very 
weak (2 fold), but since it is both reproducible and present 
in two different cell lines, it probably reflects some in 
vivo involvement in promoter activity. Again a lack of 
specificity (tissue and species) between the cell lines 
analysed was observed.
3.5.4. Analysis of in vitro Footprint Studies
The same protein preparations as previously described 
(see sections 3.4.6.) were used to in vitro footprint the 
UPE domain (pB57; see Whitelaw et al, in press.)
The footprints observed for pB57 comprised a long,
partially overlapping region of protection (see figures 61 
and 62). This footprint cluster coincides with several (well 
conserved in mouse and feline c-myc genes: see figure 70)
Spl consensus sequences, implying the presence of several 
putative Spl in vitro binding sites located between -160 and 
-100. No footprints were observed between -350 and -160bp 5 1 
to PI. These results imply an upstream region (UPE) of 
partially overlapping weak Spl (or Spl-like sites).
DNase 1 in vitro footprint analysis of the region 
spanning from -100 to +500 (which includes PI and P 2 :
N.Wilkie and J.Lang, personal communication) has identified
several other GC-rich elements, which bind protein factors
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(the HO.3 extract was used), so whether they bind Spl is not 
known). No DNase 1 footprints were observed adjacent to P2, 
although hypersensitive sites were seen after protein 
binding. On the basis of HO.3 titration experiments, the 
upstream sites appear to be weaker targets for Spl than the 
proximal site, or targets for a different DNA binding 
protein(s) .
These results might imply an involvement of Spl factors 
in the trans-mediation of the promoter domain. Obviously, 
other factors are likely to be involved.
3.5.5. Additional Studies on the Upstream Promoter Element
The evidence described in this thesis makes it probable 
(see section 5.1.), that during a competition co­
transfection experiment cis-recombination may occur. 
However, the additionally transfected competitor sequences 
will function as trans-acting factor sinks and thus the 
experiment is still a valid indicator for the presence of 
such a factor.
Competition experiments were done as described in 
section 3.4.5., to preliminarily analyse the UPE domain. The 
resultant CAT activity is represented as a percentage of 
pB14, as shown in figure 53. When the 250bp UPE domain in a 
pUC vector (pB57) were used as a competitor against the 
indicator plasmid pB12 (the myc recombinant containing all 
the 5' sequences) the observed CAT activity was slightly 
greater than that expected for pBl2 alone (see figure 63). 
This elevation of expression was considerably less than that 
observed when the NRE-2 competitor (see figure 52) was used. 
It is possible that the UPE region (see section 3.5.4.) may 
be acting as a "sink" for the Spl factor required for the 
NRE-2 (in vitro footprint requirement), thus marginally 
reduing the functional efficiency of the NRE-2 domain.
However, when pB57 (containing the 250bp UPE domain) is
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used as a competitor against the indicator plasmid pBl4 (the 
c-myc 5' deletion recombinant containing 350bp of 5' 
flanking sequences) a large increase in CAT activity, 
compared to pB14 alone, was observed with a titration-effect 
occuring at the higher molar ratios. Perhaps the initial 
increase in activity is due to cis-activation due to 
recombination between the plasmids after transfection (which 
could also explain the pB57/pBl2 results above; see section
5.1.) while at the higher molar ratios the competitor 
sequences are acting as a Spl "sinks". However, if this 
result were taken in isolation, the competing out of a 
repression function would be the obvious conclusion. Thus, 
the UPE domain may posses different functions in different 
situations.
However, when the 250bp PvuII Smal fragment containing 
the UPE is deleted from pB12 (pB74) the resulting CAT 
activity upon transfection into LaTK~cells was greater than 
that of pB12, but less than that of pB36 (and thus pB14, 
i.e. the c-myc promoter driven CAT recombinant). This 
result (see figure 64), in agreement with the pB57/pB14 
competition result, indicates that this region could 
function as a negative regulator of expression. This 
presents an anomaly in this series of experiments which as 
yet can not be explained fully. Perhaps the internal 
deletion affects the chromatin structure of the entire c-myc 
sequences present, thus affecting the functional efficiency 
of the NRE-2 domain. Alternatively the UPE domain may 
function to mediate the repression instigated by the NRE-2 
domain, i.e. the UPE may function as a positive regulator of 
transcription until there is some form of interaction 
between it and the NRE-2. The internal UPE deletion result 
implies that this interaction would be essential for maximal 
repression to occur. However previous results imply that the 
NRE-2 can function independently from the UPE (repression of 
heterologous promoters, see 3.3.3.), thus the postulated 
NRE-2/UPE interaction is not an absolute requirement for the 
NRE-2 repression function.
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Figure 57.
Structure and Cloning Strategy of c-myc-CAT
Recombinant pB36,pB66 and pB74.
Restriction sites which are destroyed upon ligation are 
marked with a diagonal line across them. For a detailed 
description of the cloning strategy see section 3.5.1. See 
figure 8i, 19 and 62.
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Figure 5 8 .
Structure and Cloning Strategy of
Recombinant pB57.
For a detailed description of the cloning 
see section 3.5.1. See figure 8i, 18 and 67.
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Figure 60.
CAT Activity of c-myc-CAT Recombinants with the 
Upstream Promoter Element 5' Deleted.
100
CAT 80  
Activity 
(%)
60
40
20
  . .       -
1 2 3 4 5 6 7 8 9  10 20
DNA Amount
a. Average total counts (cpm) from three to six separate 
experiments of duplicate flasks as a percentage of pB14. 
Vertical bars represent the range of values obtained when 
the LaTK cella were used as the transfection recipient.
b. Equimolar amounts (l-20pg) of donor DNA were transfected 
into LaTK“(continuous line) and HeLa cells (hatched line) as 
described m  Materials and Methods. CAT activity was assayed 
as described in Materials and Methods.
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Figure 61 .
Photoraph of the in vitro DNase I Hypersensitivity Pattern 
of the UPE Domain.
The H.03 cell extract was used (see Materials and 
Methods for detailed description of the experimental 
technique). The Spl-enriched cell extract has shown these 
sites to be at least Spl-like (J.lang and N.Wilkie, personel 
communication). The samples shown are labelled at the 5' end 
(the experiment was repeated twice). The Roman numeral refer 
to the footprint (DNase I protected domain) observed. It is 
possible that this one relatively large protected domain 
comprises of three smaller domains (unfortunatly no gel 
could unambiguously clarify this).
YFootprint- myc UPE
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Figure 6 2•
Sequence of the UPE Region Indicating the in vitro 
DNase I Footprints (Protected Domains).
The footprints indicated were obtained using the 
Spl-enriched protein extract (see figures 64). The relevant 
restriction sites are shown. The in vitro DNase I protected 
domain is boxed. The arrows indicate Tn vitro DNase I 
hypersensitve sites.The consensus sequences (see figure 74) 
for Spl is shown by dotted lines. The in vivo DNase I 
hypersensitive site (Siebenlist et al, 1984”) is shown by the 
Roman numeral III-2.
CAGCTGTTCCGCCTCGGATGAT TT AT ACTCACAGGACCAGGAT GC GGTTTGTCAAACAGTACTG 
CT ACGG AG GAG CA GCAGAGAAAGGGAGAGGGTTTGAGAGGGAGCAAAAGAAAATGGT AGGCGCG 
c g t a g t t a a t t c a t g c g g c t c t c t t a t t c g t g t t a c a t t c c t a g a g c t a g a g t g c t c g g c t g c c
A.
F'vu I I
CGGGTGAG(rCT_CrjCGCCACCTTCCCC_ACCCTCCCCACCCTCCCCATAAGCgCCC:CTC^C.qGG
I 1 t
HSS HSS HSS
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Figure 63.
Competition Assay using the Upstream Promoter Element 
(UPE) in LaTK Cells.
Indicator DNA3 0 0
2 5 0
200
CAT
Activity 1 5 Q
100 pBI 4
- A
5 0 pB36
1 2 3 4 5 6 7 8 9
b
Molar Ratio
a. Average total counts (cpm) from one experiment of 
duplicate flasks represented as a percentage of pB14.
b. Donor indicator DNA (equimolar amounts of 2pg) was mixed 
with increasing equimolar ratios (0-10) of competitor DNA 
(pB57), and adjusted to 20pg/ml with pUC12 carrier DNA.
c. The calcium-phosphate transfection of LaTK” cells was 
done as described in Materials and Methods. The resultant 
CAT activity was assayed as described in Materials and 
Methods.
Indicator : Competitor
d. Key : continuous line = pB14 : pB57
hatched line = pB36 : pB57
hatched/dotted line = pB12 : pB57
dotted lines = indicator plasmids alone
(pB14, pb36, pB12, pB9)
e. Schematic representation of relevant plasmids.
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Figure 64.
Deletion Analysis of the UPE in LaTK Cells.
100
80
a
CAT
AcHTitY 60
40
2 0
0)co T- (DCO
b
Donor DNA
a. Average total counts (cpm) from two separate experiments 
of duplicate flasks as a precentage of pB14. The bars 
indicate the percentage variation in values observed.
b. Equimolar amounts (of 8pg) of each donor DNA was 
transfected into Latk"cells as described in Materials and 
Methods. The resultant CAT activity was assayed as described 
in Materials and Methods.
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3.6. Preliminary Analysis of Far Upstream Region
Although the 5' deletion studies did not indicate any 
obvious functional significance in the far upstream region 
(-2290 to -1248bp) there are two in vivo DNase I 
hypersensitive sites (I and II-l) located within this 
region. One of these sites (II—1) is located near an 
Nuclear Factor-1 (NF-1) consensus sequence, and does indeed 
compete for NF-1 binding in an in vitro assay (Siebenlist et 
al, 1984). In addition, sequence analysis shows the 
presence of several interesting putative consensus elements.
Due to the restricted range of recombinants analysed, 
these results are only preliminary, however, they do 
indicate the presence of two putative domains (one positive, 
the other negative) within the far upstream region (-2290 to 
-1248) which deserve further analysis.
3.6.1. Recombinants Plasmid Constructions
All constructions used pB9, pB12, pLW2, pB30 and pBl8 
as the parental plasmids (see sections 3.2.1.and 3.3.1.).
(i). Recombinants Containing the Far Upstream Region
Clal digestion and Klenow flush-ending of pB18 followed 
by Hindlll linker modification and self-ligation gave pB47 
(see figure 65). Hindlll digestion of pB47 releases a 1.1Kb 
Hindlll fragment (containing DNase I HSS I and II-l) which 
was inserted in both orientations (pB70 and pB71; see figure 
65) into Hindlll digested pB30 (containing the 0-globin 
promoter), and in a 5' to 3' orientation (pB69; see figure 
65) into Hindlll digested pLW2 (containing the HSV-IE 
promoter).
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(ii). Recombinants Containing Sub-Regions of the Far
Upstream Region
By digesting pB69 with AccI and Smal, plus Klenow 
flush-ending and subsequent self-ligation, pB76 was 
generated (see figure 66). This recombinant contains only 
the c-myc sequences encompasing DNase I HSS I (-2290 to 
-1530) upstream of the HSV-IE gene promoter (pLW2). HincII 
digestion and subsequent self-ligation of the resulting 
linears of pB12, pB69 and pB70, recombinants with only the 
very far 5' region (307bp) of c-myc upstream sequences 
(-2290 to -I983bp) located 5' to the promoterless CAT gene 
(pB27), the HSV-IE gene promoter (pB78) and the human 
e-globin gene promoter (pB77) were constructed (see figure 
67). This 307bp fragment is designated E in these 
experiments.
3.6.2. Restriction Enzyme Analysis of Recombinant Plasmids
Extensive restriction enzyme analysis has been used to 
identify each of the recombinant plasmids described. 
Representative digests are shown in figures 68, 69 and
relevant restriction maps in figures 8j .
(i). Plasmids Containing the Whole Far Upstream Region
The Clal site of Pbl8 aws converted by linker 
modification to Hindlll in pB47, and upon Hindlll digestion 
of pB47 the two c-myc fragments (1035bp and 915bp) 
identified. The 5 ’ region (1035bp fragment) was inserted 
into pLW2 (pB69) and pB30 (pB70 and pB71). HincII digestion 
of pB69 (4080bp and 845bp), pB70 (4070bp and 845bp) and of 
pB71 (4605bp and 310bp) confirmed the oreintation (the size 
of the smaller fragment was diagnostic) of the c-myc derived 
sequences.
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(ii). Plasmids Containing Sub-Regions of the Far Upstream
Region
PstI digestion of pB76, pB77 and pB78 gave respectively 
diagnostic fragments of 1510bp, 1115bp and 1135bp,
confirming the size of the c-myc derived fragment. HincII 
digestion of pB27 gave a 3.8Kb linear fragment, again 
identifying the size of the c-myc derived fragment.
3.6.3. Activity Within the Far Upstream Region
Several transient transfection experiments with thse 
far upstream recombinants were done using LaTK cells as 
recipients. Depending on the test promoter different 
equimolar DNA amounts were transfected: equimolar ratios of
2pg for the HSV-IE promoter and promoterless CAT 
recombinants and an equimolar ratio of lOpg for the e-globin 
promoter recombinants. The greater DNA amounts were required 
for the e-globin promoter recombinants due to the very weak 
activity observed when using this promoter.
In this set of experiments pB69, pB70 and pB71, with 
the controls pB9, pB30 and pLW2 were transfected into LaTK 
cells (see table 6). 5' deletion through this region had no
affect on CAT activity (see section 3.2.4.), however, when 
inserted 5' of the HSV-IE promoter (pB69) a slight reduction 
in CAT activity was observed. A greater reduction (4- to 5- 
fold) was observed when this region was inserted, in either 
orientation, 5' to the e-globin gene promoter (pB70 and 
pB71). Thus, when placed 5' to a promoter this region 
represses expression (although to a lesser degree than 
NRE-2), and these results therefore imply the presence of a 
putative weak second negative regulatory element (NRE-1) 
within this region.
The two obvious candidate locations for such a region 
are the two in vivo DNase I hypersensitive sites (I and 
II-l), although other regions can not be excluded. In a
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preliminary attempt to localise the NRE-1, recombinants 
containing either the DNase I HSS I or II-l were constructed 
and analysed by transient transfection into LaTK- cells as 
descibed below.
3.6.4. Activity upon Deletion of Site II-l from the Far 
Upstream Region
Deletion of site II-l results in only the far 5' 760bp
of c-myc upstream flanking seguences remaining. This region 
not only contains the in yivo DNase HSS I which has been 
shown to be conserved in the mouse c-myc (Fahrlander, 
Piechaczyk and Marcu, 1985), but 3 closely-associated 
enhancer core sequences (for review see Khoury and Gruss,
1983). Obviously sequence i ns peciTo/\ does not imply 
function but it does allow preliminary experimentation to be 
directed.
When this region was inserted, 5'-3' (pB76), upstream
of the HSV-IE gene promoter (pLW2) no alteration in CAT 
activity was observed (see table 6). This result implies 
that the region deleted from pB69 to give pB76 (-1530 to 
-1248) would contain the repression activity seen for the 
whole far upstream region (see section 3.3.4.). This 282bp 
region contains the DNase I HSS II-l which has an associated 
NF-1 concensus sequence, but does not bind NF-1 in an in 
vitro assay (Siebenlist et al, 1984). A putative weak second 
negative regulatory element, NRE-1, is tentatively located 
within this region approximately 1300bp upstream from Pi.
This region contains homologous sequence strings to the 
NRE-2 domain (e.g. the NF-2 element), and to investigate if 
there were any functional similarities between the two, a 
competition experiment was done (see section 3.4.5). The 
competitor pB51 (containing the 445bp NRE-2 fragment) was 
transfected at a 5 molar excess with the indicator pB69 (see 
table 6). The 445bp KpnI-AccI NRE-2 competitor fragment 
relieved the slight repression, observed for pB69 when
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compared to pLW2 . Previously pB21 was shown not to (or only 
very slightly: see section 3.4.5.) compete out repression,
i.e. NRE-1 does not compete out NRE-2 but the NRE-2 can 
relieve the slight NRE-1 mediated repression. This implies 
that at least one of the trans-acting factors (probably an 
accessory factor) involved in the repression mediated 
through NRE-2 may be required for NRE-1 activity.
3.6.5. Preliminary Analyis of Enhancer Core Sequences
Upon sequence / as p ecti'o a  of this far-upstream 
region, 3 enhancer core sequences were found near to the 
DNase I HSS I. Two of these consensus sequences were exactly 
40bp apart, and are exact copies of each other. Several 
possible Spl consensus sequences are also present in this 
region. It must be stressed that these enhancer core 
sequences have been identified by sequence homology alone. 
They are located in the distal 320bp region of the c-myc 5' 
flanking sequences of pMC41, just upstream of the in vivo 
DNase I HSS I (Siebenlist et al, 1984). The 320bp Hindlll 
HincII fragment (designated E) used in this series of 
experiments contains the 3 enhancer core sequences, but does 
not contain the centre of the in vivo DNase I HSS I .
LaTK cells were used as the recipients in these 
experiments (see section 3.6.4. and table 6). Earlier 
results from analysing pB76 expression levels implied that 
these sequences do not function as an enhancer, and pB78 CAT 
activity (being the equal to that of pLW2) agrees with this 
conclusion. Both these constructs use the HSV-IE gene 
promoter to drive CAT expression. However, when this E 
region is placed 5' to a promoterless CAT gene (pB27) a 
dramatic induction in CAT activity is observed. This level 
of activity although substantial (12 times that of pB9) it 
is only l/6th that of pLW2. This level of activity is 
comparable to results obtained on enhancer activation of a 
promoterless gene (Lang, 1984). In addition, when this 
region is placed 5' to the human e-globin gene promoter
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(pB77) the resulting CAT activity is double that of pB30.
These results tentatively imply the presence of a 
positive regulatory element (PRE) located in this distal 
320bp fragment.
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Figure 6 5 .
Structure and Cloning Strategy of Far Upstream
Region c-myc-CAT Recombinants pB47, pB69, pB70 and
pB71.
For a detailed description of the cloning strategy
see section 3.6.1. See figure 8j , 71 and 72.
PB18
Hd
He
Ac
C He
B47
HdHd
He
Ac
He- ' Hd
Hd
Hd
B30
Hd
LW2
214
Figure 66-
Structure and Cloning Strategy of c-myc-CAT
Recombinant pB76.
Restriction sites which are destroyed upon ligation are 
marked with a diagonal line across them. For a detailed 
description of the cloning strategy see section 3.6.1. See 
figure 8j and 71.
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Figure 67.
Structure and Cloning Strategy of "E" Domain
c-myc-CAT Recombinants pB27, pB77 and pB78.
For a detailed description of the cloning strategy 
see section 3.6.1. See figure 8j and 71.
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Table 6.
Transient Expression of Far Upsteam Region
Recombinants in LaTK'Cells.
a
DNA Amount
b
Donor DNA 2 10 expt
pB9
c d 
1.4 ±0.4 18.9 ±2.1 4
pB27 16.4 ±0.9 ND 4
pLW2 100.0 ND 4
pB69 74.2 ±8.9 ND 3
pB69 
Comp.pB5l
116.0 ±11.0 ND 3
pB76 102.9 ±6.3 ND 2
pB78 95.3 ±8.9 ND 3
pB30 ND 100.0 3
pB70 ND 27.2 ±1.1 3
pB71 ND 19.9 ±3.2 3
pB77 ND 209.0 ±15.2 2
pB77 
Comp.pB48
ND 53.8 ±1.1 2
a. Equimolar amounts of 2 or 10pg Donor DNA were 
transfected.
b. Number of separate experiments of duplicate flasks.
c. Average total counts (cpm) per flask as a percentage 
of pLW2 and pB30 respectively. ND= not done.
d. Range of variation of values.
e. Competitor plasmids ( prefix = Comp.) were co­
transfected at a 5 molar excess over the
indicator plasmid.
f. Donor DNA was mixed with carrier salmon sperm DNA to
a final concentration of 20pg/ml in the
calcium-phosphate precipitate and transfected as 
described in Material and Methods.
g. CAT activity was assayed as described in Materials 
and Methods using only 50pl of cell extract.
219
CHAPTER FOUR
DISCUSSION
2 20
Before discussing the significance of the results of 
this work, and their relevance to observed biological 
characteristics, the usefulness of tissue culture 
experimentation, and any drawbacks with the respective assay 
systems utilised, need to be mentioned.
4.1. Gene Expression Assay Systems
Expression can be defined in several ways: the level of 
transcription, mRNA abundance or the amount of translation 
product. Quantification of expression can be by assay of 
the structural gene product, either for the RNA or protein, 
or by measuring its effect in a biological system. 
Obviously the level of expression can be thought of as a 
direct consequence of the activity of the gene's regulatory 
domains (transcriptional or post-transcriptional). Thus any 
expression assay concommitantly measures that gene's 
transcriptional regulatory regions (within the constraints 
of the assay system used). Recombinant DNA techniques can 
be used to "remodel" the cellular chromatin in vivo in 
defined ways, and thus precise characterisation of the 
regulatory domains can be carried out. A large number of 
assay systems have been developed which allow measurement of 
gene expression within cell-free lysates in vitro and within 
live animal cells in vivo.
In vitro assay systems (Weil et al, 1979, Manley et al, 
1980) have allowed the characterisation of a number of 
eukaryotic gene promoter sequences. Unfortunately such 
assays do not always reflect the true in vivo situation for 
two reasons. Firstly they rely on fully functional 
transcriptional machinery within the cell-free lysates and 
secondly, the template is added naked DNA and as such the 
presumably important role of secondary structure is not 
taken into account.
The in vivo assay systems allow the quantification of 
the level of expression of exogenous genes introduced into
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cultured mammalian cells, thus bypassing some of the 
drawbacks of the in vitro systems. Such a system must 
incorporate within its methodology a gene transfer mechanism 
for the introduction of genes into the cell nucleus. There 
are now many such techniques, e.g. calcium phosphate 
precipitation,DEAE-dextran, microinjection, electroporation, 
liposome-mediated transfer, protoplast fusion, chromosome- 
mediated transfer. Each of these methods have their own 
specific preferred application, e.g. DEAE-dextran transfer 
for assaying the infectivity of viral DNA, microinjection 
when cell numbers are limiting (Spandidos and Wilkie, 1984).
However, the most widely used technique due to its 
ease, and versatility is that involving cellular uptake of 
the exogenous DNA via a calcium phosphate precipitation 
(Graham and van der Eb, 1973). Although this method is 
extremely useful for introducing exogenous DNA into cells, 
there are some cell lines in which the take up of DNA is 
very inefficient, e.g. HL-60 and Friend cells (G.Birnie and 
J.Frampton, personal communication). Perhaps electroporation 
will allow a more efficient DNA transfer into these cells. 
Recenty, vectors based on viruses, e.g. vaccina virus, 
adenovirus and retrovirus, have been developed and early 
results imply that they may prove very useful in the future. 
Each vector system has its own points of merit, e.g. 
retroviruses allow single copy transformants to be 
generated. However, these systems also have drawbacks (see 
section 4.1.2.). Recently techniques have been developed 
which allow the entry of DNA (naked cloned DNA or retrovirus 
vectors) into fertilised oocytes thus producing transgenic 
animals (Adams et al, 1986; Palmiter and Brinster, 1986). 
Perhaps this will allow unambiguous analysis of gene
regulation in vivo.
After introduction of the exogenous DNA into the cell,
expression can be measured either after a few days
(transient assay; Benoist and Chambon, 1981; Gorman et al,
1982) or after a few weeks (a long-term expression assay;
222
(Spandidos and Wilkie, 1984). Generally transient 
expression assays are convenient monitors of promoter 
activity in that they are both rapid and measure gene 
expression before integration into the host cell genome.
Two basic methods have been employed for transient 
assays. Firstly, by the direct ligation of a promoter 
sequence to the coding sequence of a reporter gene (e-g- 
CAT, _yc), the promoter's activity can be measured (Gorman, 
Moffat and Howard, 1982a; Lang, Spandidos and Wilkie, 1984). 
This technique relies on the reporter product being either 
easily detected above the endogenous gene product, or there 
being no endogenous gene product, e.g. the promoter product 
is of prokaryotic origin. Secondly, the gene of interest 
(control and coding sequences) can be transfected into the 
relevant recipient cell and the resulting mRNA levels can be 
quantified (e.g. by Northern blot, SI analysis, in vitro 
run-on assay). This technique is not as easy, quick or 
versatile as that of the reporter system, e.g. where a 
eukaryotic gene is being analysed in a mammalian cell line 
the expression of an exogenously introduced gene has to be 
easily identified above that of the endogenous gene's mRNA.
Long-term transformation assays have the advantages 
that stable cell lines can be developed and that induced 
phenotypic changes can be monitored (Spandidos and Wilkie,
1984). To enable the generation and identification of stable 
transformants a selectable marker is commonly used, e.g. tk, 
APH, DHFR. However, some of these markers require the use of 
mutant cell lines as recipients, e.g. tk, and thereby limit 
their versatility. Although this method allows the stable 
host cell regulation of the introduced gene, the actual site 
of integration into the host cell's genome could have a 
drastic effect on the specificity of expression. In 
addition, there is the possibility that the introduced DNA 
may become rearrangedduring either its intergration into the 
cell or sometime after (Sussman and Milman, 1984).
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There is a good correlation between the expression 
levels obtained during the transient phase of expression and 
the subsequent biochemical transformation frequences, but 
biochemical transformation can be the more sensitive 
technique (Sussman and Milman, 1984; Spandidos and Wilkie, 
1984; Lang, 1985). In the studies described in this thesis, 
transient assays were undertaken in preference to long-term 
transformation to allow a greater range of recombinant 
plasmids to be analysed, therefby hopefully answering more 
questions. To investigate the same range of recombinants by 
the establishment, and the .subsequent characterisation, of 
stable transformants would take considerably longer than if 
the same experiments were done in a transient expression 
system. The actual assay system, using the chloramphenicol 
acetyltransferase (CAT) gene as the reporter gene, is 
described below (see section 4.1.1.).
4.1.1. A Critique of The CAT Assay
Although RNA levels represent a good gauge of promoter 
activity, quantification of RNA is tedious and it is often 
difficult to obtain accurate measurements unless the 
promoter being analysed is particularly strong or amplified. 
It is often preferable to determine the function of a 
promoter by joining it to a second gene segment (which lacks 
its own promoter) coding for a readily assayable protein, 
the reporter gene. In the CAT assay (Gorman, Moffat and 
Howard, 1982) the bacterial chloramphenicol acetyltransferase 
(CAT) gene is used, with the enzymatic function of CAT being 
both quickly and precisely assayable.
The transient assay system based on the control of the 
bacterial chloramphenicol acetyltransferase (CAT) gene, the 
reporter gene, is a convenient technique for the 
characterisation of eukaryotic transcriptional control 
sequences in a cell culture situation. Importantly, it is 
sensitive enough to detect the variations in expression 
levels obtained with different promoters. Primer extension 
and Si nuclease studies have been used to show that the
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steady state mRNA levels correlate with the level of CAT 
activity (Gorman et al, 1982), and that RNA initiation 
occurs at the correct point (Gorman et al, 1982; Alwine, 
1985; Remmers, Yang and Marcu, 1986). A major advantage of 
the CAT assay over some other transient assay systems (e.g. 
tk), is that any cell line could probably be used as the 
transfection recipient. Thus the CAT assay presents itself 
as a convenient system in which to monitor the expression of 
specific promoter DNA seguences, which correlates very well 
with the actual mRNA levels. Nevertheless, this does not 
imply that all promoter seguences can be identified by this 
system (e.g. control elements may be located within 
transcribed sequences).
This assay shows a high level of specificity due to the 
CAT gene being absent from all mammalian cells looked at, 
(metabolism of chloramphenicol being via glucosyl 
transferase). Thus there is no endogenous background CAT 
activity. In addition, there is no interference from other 
endogenous enzymatic activities which could compete for the 
substrate or cofactors (Gorman, Moffat and Howard, 1982). 
The assay is rapid, sensitive and reproducible, as well as 
only requiring the low grade radioisotope as its
labelled marker. Finally, quantification of the result can 
be easily and accurately carried out in a scintillation 
counter. These advantages make the CAT gene marker, at the 
moment, the most convient developed assay for transient 
expression studies. There are other transient assay systems 
available, e g . (3-galactosidase, but they are either more 
cumbersome or less sensitive than the CAT assay.
4.1.2. A Critique of Cell-Culture Experimentation
Firstly, the cells used as recipients, although 
considered to represent the cell-type they were originally 
derived from, require their phenotype to be questioned. 
After long-term tissue culture propagation their actual 
relatedness to their parental phenotype is not always clear.
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They are abnormal, immortal and some being polyploid 
(Freshney, 1983). Therefore the molecular events which 
occur within them need not necessarily mimic what occurs in 
the parental cell type in its normal environment. In the 
studies presented within this thesis HeLa cells were used at 
two stages: once for transfection recipients, and again as
the source of the nuclear protein extracts. In the first 
instance, they are an adherent cell-line, while the nuclear 
extracts were obtained from a suspension cell line. Both 
cell-lines go under the name HeLa, but they have been 
sub-cultured for their respective properties. It is hard to 
imagine they are identical. Another example concerns mammary 
epithelial cells. No mammary cell line available responds 
correctly to the normal cocktail of lactation hormones to 
which the mammary gland is responsive in vivo, e.g. 
expression of the milk genes.
Secondly, any exogenously introduced DNA may not form 
the same overall conformation with respect to the protein: 
DNA association as found in vivo. In addition, for 
transient expression assays, the actual plasmid copy number 
per cell may be as many as 1,000 (Perucho et al, 1980). 
Again this is very different from the in vivo environment. 
Obviously stable transformation overcomes part of this 
problem, but as a consequence other problems (e.g. the 
chromatin state at the site of integration can confer 
position effects) are raised. However, as long as these 
caveats are put upon any interpretation of transfection
results (or any cell-culture analysis) then meaningful
studies will be obtained by such experimentation.
Obviously, such in vivo analysis will be superior to the in 
vitro techniques we have available, although the in vitro 
assays could be used to complement the in vivo results. 
Perhaps, the recently developed transgenic techniques will 
allow the accurate in vivo analysis of these types of 
questions. Having just criticised both the present day in 
vitro and in vivo techniques, their already proven
usefulness in quickly giving aAinsight (but it is only that)
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into the answers, has to be stated
4.1.3. Cell-Specific Expression and Transfection Efficiency
Expression of the c-myc recombinants was observed in 
each cell line analysed, i.e. fibroblastoid, epithelial, 
erythroid - both of human and murine origin. In addition, 
the repression function was observed in all the cell lines 
transfected in these studies. This would imply both a lack 
of tissue- and species- specificity for the c-myc 
transcriptional control domains identified in these studies.
The repression ratio observed for the c-myc 
recombinants varied between the different cell lines (see 
section 3.2.3.). The repression ratio represents the fold 
difference in activity (cpm) between the repressed (NRE-2 
containing) and the non-repressed (NRE-2 deleted) c-myc-CAT 
recombinants. There are two obvious candidate explanations 
for this. Firstly, the variations in repression ratio could 
reflect the tissue and species from which these cell lines 
were derived. However, there is no obvious correlation 
between the variations in repression ratios and the various 
cell lines with respect to their origins. In addition, the 
variations in repression ratios are small, while the 
variation in absolute expression levels are relatively 
large. Thus the second explanation, that the variation in 
expression is due to the different transfection efficiencies 
(DNA uptake and subsequent expression) of the different cell 
lines, is more plausible, i.e. different numbers of plasmid 
are being expressed in the different cell lines. LaTK" and 
HeLa cells are routinely used for transient expression 
studies in this and other laboratories, while NIH-3T3 cells 
have been the recipient cells used in the now historical 
identification of the ras gene family. Therefore, these 
cells have an assumed high transfection (DNA uptake and 
expression) efficiency, and in correlation, it is in these 
cell lines in which c-myc recombinants are fairly active. 
In addition GM468 and MRC-5 have been found in our
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laboratory to be poor recipients (D.Spandidos and J.Lang, 
personal communication), and again correlating with this, it 
is in these cell lines in which a low level of activity was 
observed. However, K-562 cells in this laboratory are 
considered poor recipients (D.Spandidos and P.Montague, 
personal communication) but give relatively high c-myc 
expression levels. This may in part be due to the uptake and 
expression efficency of K-562 cells. DNA titration 
experiments with K-562 cells (see section 3.4.4.), even at 
10-20pg of transfected DNA did not show a titration effect. 
Indeed, the effect was comparable to that seen at l-2pg for 
LaTK cells. This may indicate that only a small proportion 
of the DNA present in the transfected precipitate is 
actually expressed within K-562 cells.
In an attempt to identify any variation in transfection 
efficiency present between the respective cell lines, a 
positive control was used. The positive control in these 
studies was the CAT gene driven by an HSV-IE gene promoter 
(see section 3.2.3.). The proportional levels of activity 
for the two c-myc recombinants (pBl2 and pBl4) varied quite 
drastically from the two controls (pB9 and pLW2) in the 
various cell lines. This may reflect differential basal 
levels for c-myc expression in these cell types, however, 
there is no correlation between the cell types used and the 
activity of the c-myc recombinants in these studies. 
Another possibility, is that the basal level of expression 
of the c-myc recombinants may be constant, and it is the 
positive control (pLW2) which is showing a variation in its 
specificity of expression. No studies have been done to 
elucidate this (with reference to pLW2) as far as I know. 
The tissue specificity of the immediate early enhancer 
domain of HSV-1 has been analysed (Spandidos, Lang and 
Wilkie, 1984), but the domain used in these studies is not 
directly comparable to the promoter domain of pLW2.
In conclusion, without a positve control, which has its 
tissue and species specificity absolutely defined
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(impossible with to-day's methodology), any variation in 
expression levels observed in this type of assay could be 
due to either specificity of the promoter in question, or 
differences in transfection efficiency between the recipient 
cell lines. However, the c-myc-CAT recombinants were 
expressed, and the repression function was observed (when 
the NRE-2 domain was included in the recombinant), in each 
cell line analysed. This implies a certain promiscuity with 
respect to tissue- and species- specificity for the 
regulation of c-myc expression.
The erythroid cell line K-562 (a human erythroleukaemia 
derived cell line) was included in these studies, as its 
endogenous c-myc expression levels are greater than that 
found in other erythroid cells (Wong-Staal et a l , 1983). It 
was therefore hoped that this cell line would be permissive 
for expression of the exogenously introduced c-myc 
recombinants. If this was indeed the case, it could 
represent a lack of repressor (or functional repressor), as 
no gross rearrangement of the endogenous c-myc locus has 
been found. However, the results presented show clearly 
that a functional repressor is present and active in the 
K-562 cell line, as it represses exogenously introduced 
c-myc-CAT recombinants. As a correlation to this, the 
elevated endogenous c-myc mRNA levels may not be due to a 
lack of repressor, but may indicate that either a
rearrangement of the NRE-2 domain or an alteration in
stability of the c-myc message has occurred. Another 
possibility is that of some functional alteration in the 
positive regulation of the endogenous c-myc in this cell 
line. Sequencing of the endogenous K-562 c-myc 5' flanking 
sequences would help in our understanding of the mechanism 
by which the c-myc gene is deregulated in these cells.
4.1.4. A Critique of in vitro DNase 1 Footprinting
Once having identified a requirement for a trans-acting 
factor, identification of this factor is obviously an
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important consideration. To start these studies in vitro 
DNase 1 footprint analysis was carried out. This is now a 
widely used technique, but there are obvious drawbacks 
associated with it.
This is an in vitro technique and therefore cannot be 
unambiguously taken to indicate what happens in vivo. At 
best, it will tell us the likely involvement and location of 
DNA-binding proteins, allowing if nothing else, a strategy 
for further analysis to be proposed. To give an example of 
the possible problems: the sequence 5'-AGCCCTCCCG-3'
(located in the middle of exon 1) which fits the Spl 
consensus except for the 5' G (should be C or T), gave in 
only one experiment (result not shown) a very faint 
footprint when using the Spl enriched extract. Possibly 
this footprint was an in vitro assay antifact, caused by the 
presence (in an inappropriate position) of a Spl-like 
consensus sequence. However an in vivo role for a protein 
interaction at this site can not be ruled out. There are 
several other Spl-like consensus sequences which do not bind 
a protein, by in vitro footprint analysis (personal 
communication R.Tjian: this thesis). Therefore the presence
of a consensus sequence does not always result in a protein 
interaction. Presumably the actual recognition sequence 
requirements for such a protein have yet to be stringently 
defined.
When in vitro footprinting is combined with in vitro 
transcription analysis, as has been done for Spl (Kadagowa, 
Jones and Tjian, 1986), a direct in vitro correlation 
between protein binding and transcriptional activation can 
be demonstrated. This, although not by in vivo methods, 
still forms a good argument for a functional role for the 
trans-acting factor in transcription regulation. Since some 
of these factors have been purified, the near future 
hopefully holds some exciting developments regarding the 
trans-acting factors which regulate gene transcription.
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The protein extracts used in the work described in this 
thesis were kindly given by B.Tjian. They represent various 
degrees of purification. THe Spl and CTF preparations are 
essentially pure, while the H O .3 extract is basically a 
crude salt preparation which is thought to contain the 
majority of cellular trans-acting factors (B.Tjian, personal 
communication). These preparations are all from HeLa cells. 
Since the HO.3 extract has had some enrichment it may not 
contain all trans-acting factors (especially since we can 
only identify a few).
A technical point of relevance, regarding the actual 
footprint observed, comes from a report on the 3-dimensional 
structure of the DNase 1 molecule (Suck and Oefner, 1986). 
Due to the size of the enzyme, steric hindrance between it
and the trans-acting factor already bound to the DNA
fragment in question will cause the footprint (DNase 1 
sensitive region) to be larger than the actual DNA region 
bound by protein (by 6 bp at the 5* end and 4 bp at the 3' 
end). This should help in identifying the actual recognition 
sequence used by the factor, by reducing the observed size 
of the protected domain.
One avenue of investigation not attempted during this 
study, which could utilise the DNase 1 footprinting assay, 
is to attempt to analyse the presumably different
trans-acting factors present in proliferating versus 
quiescent, or immature versus mature cells. Since several 
transcriptional control domains have been identified during 
these studies, there are now localised candidate sites for 
the interaction of these factors, and experiments could be 
devised to investigate these questions.
4.2. Identification and Analysis of the Transcriptional 
Control Elements of the c-myc Gene
The CAT assay allows quantification of expression 
level, and as such, can not directly distinguish between
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transcriptional and post-transcriptional (e.g. stability, 
transport, translation) regulation. However, presumably 
cis-acting elements, e.g. the NRE-2 and UPE domains 
discussed in this thesis, function to regulate the level of 
transcription, as it is hard to imagine how sequences 
located outwith the trancribed unit can affect the 
expression level of that gene by regulating 
post-transcriptional activities. In the following
discussion the accepted nomenclature for nucleotide 
numbering is used, i.e. increasing negative values to all 
nucleotides 5' to be mRNA cap site (taken to be PI). The 
results described in this thesis have identified two 
transcriptional control regions 5' to the human c-myc and 
hinted at two additional regulatory elements (see figure 
73). Evidence is also presented which indicates a role for 
at least one trans-acting factor in the transcriptional 
regulation of the human c-myc gene.
In the work presented in this thesis, the CAT assay has 
allowed the identification of both positive and negative 
regulatory elements, located within the human c-myc 5' 
control region. Due to the versatility of the CAT assay 
regarding cell line usage, the relative specificity of these 
elements has been tested. During the course of these studies 
one important aspect of DNA transfection (probably 
applicable irrespective of marker system) has emerged, which 
when utilised has allowed more information on the respective 
elements to be analysed. Upon increasing the amount of 
transfected DNA a titration effect was observed irrespective 
of the test recombinant plasmid. This is considered to 
represent a titration out of the trans-acting factors 
required in the regulation of the individual transcriptional 
control elements due to increasing input of test plasmid 
molecules. This titration effect, when used in combination 
with competition experiments, has allowed the identification 
of a requirement for a trans-acting factor in the repression 
function seen in the c-myc transcriptional control domain.
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A point raised by this titration effect, but not 
investigated, is what effect do large numbers of 
exogenously introduced plasmid molecules have on the 
expression of the endogenous c-myc gene. It is conceivable 
that the presence of numerous plasmids containing the 
negative element would allow release from any repression the 
endogenous gene may be under. Perhaps a more exciting 
question is, do vast amounts of exogenously introduced DNA 
fragments containing a positive regulatory element (e.g. 
Spl) have an effect on the endogenous gene expression of the 
recipient cell? To my knowledge, although many 
transcriptional control domains have been identified by 
transient expression assays the effect on the respective 
endogenous genes has not been analysed. This is an 
interesting question in itself.
Evidence has been presented (see section 5.1.) to 
indicate that plasmids co-transfected recombine in cis at 
some stage during the transfection procedure. The presence 
of very large concatemers post-transfection has been 
previously reported (Wigler et al, 1979; Weber and Shaffner,
1985). However, not all studies show concatemerisation 
(Weinberg, Cheng and Conrad, 1986). As discussed, this 
cis-involvement of co-transfected plasmids must be borne in 
mind when interpretating competition experiment results. 
How and when cis-recombination occurs, indeed whether it 
involves many sites or a specific site, is unknown. 
Southern analysis of transiently transfected cells may give 
an answer, but could equally just give a mass of 
indecipherable bands. Initially, as a negative control, to 
confirm that insertion of a DNA fragment upstream of the CAT 
transcription unit did not induce expression if no obvious 
promoter was present, pB4 was made. This construct although 
containing the c-myc dual promoter region also contained the 
intron 1 splice donor site and the first 620 bp of intron 1. 
As expected no CAT activity was observed. Since the level 
of activity was slightly less than that of pB9 
(promoterless CAT recombinant), in all likelihood the CAT
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coding sequences have been spliced out. A dramatic decrease 
in mRNA stability (or any other post-transcriptional 
mechanism) brought on by the inclusion of the 3' 40bp of 
exon 1 can not be excluded. The untranslated first exon of 
c-rnyc may confer instability upon the message (see section
1.5.3.). For the low level of CAT activity found for pB4 to 
be due to a post-transcriptional mechanism, a very dramatic 
change in the mRNA processing requires to be postulated. 
Without analysis of the resultant RNA this question can not 
be conclusively answered. Analysis of the stability of the 
c-myc message was considered to be outwith the scope of this 
thesis, but it would merit future investigation.
4.2.1. The Promoter Domain
The promoter domain of the human c-myc gene appears to 
be a complex region spanning from -350 to +164 (i.e.P2): the 
first transcribed base of the PI transcript is taken as +1. 
Both mRNA start sites have associated, and highly conserved, 
TATA consensus sequences (murine, feline and human; see 
figure 72) which are positioned approximatly 30 bp 5' to PI 
and P 2 . These regions have been footprinted and neither have 
been shown to be protected, although several hypersensitive 
sites were identified implying some protein:DNA interaction 
(J.Lang and N.Wilkie, personal communication). TATA-binding 
proteins have been identified (Wu, 1984). Therefore the lack 
of a TATA footprint may reflect the absence of the relevant 
binding protein(s) from the specific protein extract (HO.3) 
used in these experiments, or that the these protein(s) are 
present but fail to function unless in a highly enriched 
form. However the possibility that this sequence is not 
involved in c-myc transcription (although very unlikely) can 
not be ruled out.
By sequential 5' deletion of the c-myc upstream 
sequences, only the proximal 350bp (pB14) have been shown to 
be required for maximal promoter activity. Upon further 5 1 
deletion, leaving only the proximal lOObp (pB36), a halving
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of promoter activity was observed. These effects were shown 
for both LaTK and HeLa cells, possibly reflecting a certain 
promiscuity with respect to tissue- and species-
specificity. In addition, titration results tentatively 
imply a possible interaction of a trans-acting factor with 
the -350 to -100 domain (termed the Upstream Promoter 
Element, UPE).
The whole promoter region is GC rich (63%) with several 
(conserved) consensus seguences for the GC-rich/Spl binding 
element being present (see figures 70 and 71). By DNase 1 in 
vitro footprinting a diffuse footprint was identified (-152 
to -100) with the HO.3 extract. This footprint is located on 
a very GC-rich region (73%) containing 4 putative 
Spl-binding elements. The in vivo hypersensitive site III-l 
(Siebenlist et al, 1984; Dynan and Tjian, 1985) is localised 
around -126, i.e. in the middle of this footprint. Since in 
the in vivo studies, this hypersensitive site is located in 
a region of relatively poor resolution on the gel, rather 
than defining a hypersensitive site, it only localises a 
hypersensitive domain or a close cluster of sites. Therefore 
the domain around -126 (probably about 50 bp) is 
hypersensitive to DNase I in vivo. Thus the observed in 
vitro footprints fall within the in vivo hypersensitive 
domain.
Subsequent experimentation has further identified 
footprints (with H O .3 extract) near to PI, located on Spl 
consensus sequences. No footprints were found in the region 
between PI and P2 although several in vitro DNase 1 
hypersensisitve sites were identified. These sites 
correlate well with the in vivo site III-2 (Siebenlist et 
al, 1984), and were in the same relative positions to the 
sites surrounding Spl footprints 5' to PI (J.Lang and 
N.Wilkie, personal communication). Thus, there may be a 
cluster of Spl elements just 5' to the c-myc transcription 
start sites (see figure 70). Such regions within promoter 
domains have been found before, e.g. for the SV-40 immediate
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early, HSV immediate early, mouse DHFR and Ha-ras genes 
(Kadonaga, Jones and Tjian, 1986; Ishii et el, 1986).
The c-myc promoter recombinant (pB14) contains all of 
this GC-rich region and additional sequences to -353, 
(although no additional footprints have been found between 
-353 and -152). Upon 5' deletion to -100 (pB36) the
promoting activity of this region is halved. It is 
therefore likely that this region functions as an upstream 
promoter element, possibly by the trans-action of Spl (or 
Spl-like) factors. Perhaps, as shown for other genes (e.g. 
Ha-ras: Ishii et al, 1986), for c-myc it is the proximal
(putative) Spl elememts which have the major bearing on 
transcription, while the more distal have only a minor role 
in the regulation of transcription. This is in agreement 
with the observed results. Why there are (in several genes) 
clusters of Spl sites, when only the proximal few are 
required for optimal transcription is unknown. It is 
conceivable that under certain circumstances this region
could have a greater function (e.g. respond to specific
inducers) which has not been detected by these studies.
Preliminary DNase 1 in vitro footprint analysis on the 
chicken c-myc gene (which does not contain an obvious TATA
consensus) has been done (M. Plumb, in press). Although no
purified protein extracts were used, several 20-30bp 
footprints were found just 5' to the mRNA initiation sites 
(which cluster to a 7bp domain: Nottenburg and Varmus,1986). 
Some of these sites overlay Spl consensus sequences, of 
which again there are many in this region (see figure 70).
From these results, it is possible that Spl or similar 
factors may play a crucial role in the promoter domain 
function of c-myc. When a species comparison is done for 
this region a strong conservation of these Spl sites is 
found (see figure 70). Both orientations are found, but 
whether Spl functions in an orientation independent manner 
is now considered unlikely (Kadonaga, Jones and Tjian,
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1986). The presence of weak transcripts originating from 
this region but from the anti-sense strand (Bentley and 
Groudine, 1986), may be due to the presence of these
putative Spl elements, since Spl has been shown to induce 
bipolar transcription (for review see Dynan, 1986). Although 
current data implicates Spl as a positive regulator of 
transcription (Kadonaga, Jones and Tjian, 1986) results
presented in this thesis may imply that it has a broader
function (see section 4.2.2.).
There is slowly emerging a group of genes which, by 
lacking a TATA consensus, do not fit in with our now 
classical description of promoter/initiation sites. These 
new promoters have a very high GC content, and are nearly 
all limited to housekeeping genes (for review see Dynan, 
1986). Perhaps the c-myc gene could be the classified among 
them, although it does possess a TATA consensus. 
Conceivably, genes containing both GC-rich elements and a 
TATA consensus may form a third distinct class.
However, the UPE domain appears to have a dual 
personality in respect to its transcription regulatory 
function. When the 250bp UPE domain (-350 to -100) is
internally deleted, or is used as the competitor in
competition experiments, the results imply a role for the
UPE in regulating the repression of the c-myc gene. This 
involvement of the UPE in the repression function is not an 
absolute one, since a DNA fragment containing the NRE-2 
domain can repress heterologous promoters (see section
3.3.3.). The interaction of the NRE-2 and the UPE is 
discussed in section 4.3.
This region of the human c-myc gene (-400 to -100,
which contains the UPE defined in this thesis) has been
shown to contain a negative regulatory element but no 
positive activity, by R. Dalla-Favera (Marcu et al, 1986). 
The 5 'deletion results presented in this thesis indicate the 
UPE to have a role in the positive regulation of c-myc
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transcription, although an involvement in the repression 
function is also seen. As far as I can tell, without seeing 
the actual data, basically the same constructs and cell 
lines were used in the work described in this thesis and the 
work presented by R.Dalla-Favera. At the moment this anomaly 
remains. In the murine system no negative function has been 
assigned to the colinear region
4.2.2. The Negative Regulatory Element
(i). Identification and Localisation of the NRE-2.
By 5' and internal deletion (this thesis) an essential 
component of a Negative Regulatory Element (NRE) has been 
identified and located to -1052 to -607 (a 445bp region), 
with respect to the human c-myc gene. The DNase 1 
hypersensitive site II-2 (Siebenlist et al, 1984), is 
located within this region at -750. Recent work on the 
murine c-myc gene has localised a similar element (the 
dehancer), to a region between -1188 and -428bp 5' of the 
first murine c-myc promoter (Remmers, Yang and Marcu, 1986), 
which encompases the location of the corresponding negative 
regulatory element in the human c-myc gene. The location of 
this element correlates well with the proposal of Yang et al 
(1985), which was based on analysis of murine plasmacytoma 
translocation breakpoint clusters.
However, there are some surprising differences between 
the murine dehancer (Remmers, Yang and Marcu, 1986) and the 
human NRE-2 described in this thesis. They both function in 
an orientation-independent manner, but the dehancer has a 
greater repressing activity on an heterologous promoter than 
on the normal homologous c-myc promoter. The converse is 
found for the human NRE-2. Although competition experiments 
were attempted, no evidence for the involvement of a 
trans-acting factor was found for the murine dehancer, 
although such an involvement has been convincingly shown for 
the human NRE-2. Additionally, although a similarly
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constructed recombinant to pB36 (5' deleted c-myc-CAT 
recombinant retaining omly lOObp of 5' flanking sequences) 
was analysed, no evidence for UPE activity (see section
4.2.1.) was found. Why there are such differences remains a 
matter for speculation.
Perhaps the same gene is regulated by subtly different 
mechanisms in the different species. However, this seems
unlikely. In the studies presented in this thesis, the human 
NRE-2 domain responded to trans-acting factors from murine 
cells, implying conservation of the regulatory mechanism. 
In the experiments of Remmers, Yang and Marcu, (1986) on the 
murine c-myc dehancer, the competition was done at only a 2 
molar excess of competitior over indicator recombinant.
Therefore it is highly likely that the competition effect, 
rather than not being present, was not observed through 
inadequate experimentation (i.e. from the competition
experiments described in this thesis, at least a 5 molar 
excess was required to see an effect). Different cell lines 
(although some are in common) and promoters (SV40 in the 
murine studies, HSV and E-globin in the human studies) were 
used, and this may account for some of the differences. The 
answer to this question awaits further experimentation.
In addition, the basic constructs used in these two 
lines of work differ. The murine c-myc-CAT recombinants
include about lObp of intronic sequences (i.e. contains the
splice donor site). As already described (see section 
3.3.8.), when a similar recombinant was tested for the human 
c-myc (pB4), no activity was detected. Perhaps the small 
amount of murine intronic sequence is not enough to form the 
correct environment for the splicing event. However, these 
results do imply that the full first exon does not confer 
extreme instability upon the c-myc message directly (or at 
least not in the murine system).
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(ii). NRE-2 Directed Repression is Mediated by at Least One 
trans-Actinq Factor.
Both DNA titration and competition experiiments 
indicated that the human NRE-2 functioned by the interaction 
of at least one trans-acting factor. In vitro DNase 1 
footprint analysis showed four protected areas to reside 
within the 445bp region. All the protected regions obtained 
with partially purified DNA binding proteins (HO.3) could be 
associated with footprints obtained with the purified 
extracts, and identified one strong 5' Spl site, one weak 
Spl site, and two strong CTF sites (see section 3.4.6.; 
figure 71). Transfection competition experiments indicates 
that at least an essential function of the NRE resided in 
the 270bp sub-fragment (-882 to -607). The two CTF, and the 
weak Spl footprints are located within this sub-fragment, as 
is the in vivo DNase 1 hypersensitive site II-2 (Siebenlist 
et al, 1984). As discusssed (see section 4.2.1.), the 
location of this in vivo hypersensitive site probably 
defines a domain of 50-80bp (or close cluster of sites) 
which is hypersensitive in vivo. Thus the two CTF sites and 
the weak Spl-like site are all located within a region which 
is hypersensitive to DNase I digestion in vivo.
However, the two CTF footprints differ slightly, 
possibly implying a different binding activity, or even the 
presence of additional proteins. Indeed, there may be two 
distinct factors (CCAAT binding protein, CBP and CCAAT 
Transcription factor, CTF) capable of binding to the CCAAT 
consensus (McKnight and Tjian, 1986). Within the 3' CTF 
footprint is a weak homology to the NF-1 consensus sequence, 
which has previously been shown not to bind NF-1 in vitro 
(Siebenlist et al, 1984).
Recently however, NF-1 has been shown to be similar to 
CTF (if not actually the same; R.Tjian, personal 
communication). The data presented by Seibenlist et al 
(1984) constitutes only weak evidence for a NF-l-like factor
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interacting with the in vivo DNase I hypersensitive site 
II-l, and no interaction occurring at site II-2. In this 
experiment a crude nuclear extract was used to identify the 
retention of cloned DNA fragments on nitrocellulose filters. 
The data presented for the identification of the binding 
domains by restriction digestion of the cloned c-myc DNA 
fragments does not clearly distinguish the hypersensitive 
domains II-l and II-2. Indeed, when different temperatures 
were used for their protein-DNA binding reaction, a protein 
was selectively retained by both II-l and II-2. In addition, 
they found no protein interaction with the UPE domain 
described in this thesis. Since the UPE domain was shown 
(see section 3.5.4.) to bind several Spl-like factors, and 
Spl is thought to be a relatively common (and abundant) 
protein, the actual composition of their protein extracts is 
unclear. NF-1 has been shown to have a role in the 
transcriptional regulation of at least one viral gene 
(Shaul, Ben-Levy and De-Medina, 1986). Obviously, these 
points need to be clarified in the future. Possibly
site-directed mutagenesis of each individual site, and in 
vitro transcription experiments using purified protein
extracts would give a clearer picture. At the moment a
synthetic oligonucleotide of this region, containing the two 
CTF sites and the weak Spl site is being analysed in the 
laboratory (N.Wilkie and J.Lang, personal communication).
This suggests that either or both CTF sites and the 
associated Spl site may have a role in modulating the 
negative regulatory effect. If this is true, it is of
considerable interest, since previously both Spl and CTF 
have only been associated with up-regulation of promoter 
and/or enhancer-like domains (Dynan and Tjian, 1985). Both 
these elements may have only a supplementary or ancillary 
(albeit essential) role in regulating transcription. Thus 
their presence in a negative element would not be too 
surprising. They may function to hold specific DNA domains 
in a correct conformation for the interaction of other 
proteins or in some way increase the binding efficiency of
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other proteins. The in vitro results presented do not 
exclude the involvement of other and/or additional 
trans-acting factors (see section 4.4.3.). Perhaps the 
interaction of multiple closely located sequence-specific 
transcription factors will emerge as a common property of 
transcriptional control sequences in general.
Recent data presented by Bentley and Groundine (1986) 
reported the existence of an upstream transcript (PO) which 
orginated from the -650 to -550 region. They also 
identified, at a low level, transcripts originating at this 
point but from the anti-sense strand. It is conceivable that 
the Spl and/or the CTF sites localised to the NRE-2 may in 
vivo induce this upstream transcript. Perhaps spurious 
transcription initiation is a consequence of the NRE-2 
domain with its associated multiple protein interactions. 
Upstream start sites, which have been subsequently localised 
to transcriptional control elements have been found for 
other genes (Zhu, Allan and Paul, 1984). The open reading 
frames identified for this transcript from human cells 
(Bentley and Groudine, 1986) are noticeably not conserved in 
the colinear murine c-myc sequence. What role, if any, this 
PO transcript has on the expression of the c-myc gene is 
unknown.
(iii). Characterisation of the NRE-2 Domain.
The results presented in section 3.3.6. and 3.3.7., 
show that the 445bp (and the 270bp sub-fragment) which 
contain at least an essential component of the NRE-2, do not 
confer repression upon an heterologous promoter (HSV-IE 
promoter). When the same fragments are inserted, in either 
orientation, upstream of a promoterless/capless CAT gene, 
transcription of the CAT gene is induced. It is possible 
that these complementary fragments contain the promoter 
responsible for the PO transcript. Since Spl functions 
independently of orientation to promoter transcription (for 
review see Dynan, 1986), it is possible that it is the Spl
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site within the 270bp domain of the NRE-2 which activates 
the CAT gene, and in vivo may regulate the PO transcription 
start site. This result (the 445bp domain does not repress 
an heterologous promoter) implies that the repression 
function may require at least one other trans-acting factor 
and additional cis-acting sequences not present within the 
445bp domain, i.e. the 445bp fragment may have truncated the 
NRE-2 domain..
Two other potentially important structures of the NRE-2 
were gleaned from sequence i n.s on . Just downstream 
of the 3' CTF in vitro site lies a small stretch of 
alternating purines and pyrimidines. Such sequences have 
the potential to form Z-DNA. Whether this region is 
required for functional repression is not known, but what 
makes this small stretch noticeable is the near complete 
lack of such sequences elsewhere 5' to PI. Secondly the 
whole 445bp region is GC-rich (51%) with localised 
sub-regions being 75% GC-rich, one of which contains the 
above-mentioned weak Spl site.
When a sequence comparison is made with the murine 
c-myc there are several large regions of homology 5' to exon 
1 (Corcoran, Cory and Adams, 1985). However, the sequences 
about DNase 1 hypersensitive site II-2 do not fall into one 
of these highly conserved regions. Upon closer inspection 
small conserved stretches can be identified. The 5' Spl 
region has two possible homologous domains in the murine 
c-myc, while the weaker Spl footprint has no obvious 
homology except for a stretch of 15 G s . Again the region 
just 5 1 to the CTF sites is very GC-rich as it is in the 
human c-myc. However, there is no appreciable alternating 
purine-pyrimidine stretch to the 3' end of the region as 
there is in the human sequence. Both CTF footprint regions 
are fairly well conserved (5' site at 67% and 3' site at 
58%) but within this are small stretches of conserved 
sequences, including the putative CTF recognition sites. 
Perhaps more important than overall sequence homology is the
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general spacing of these elements (see section 4.3.).
Footprint analysis of the murine region would help to 
clarify these guestions. The in vivo DNase 1 hypersensitive 
site for both the human and murine sequences is colinear 
(Fahrlander, Piechaczyk and Marcu, 1985) thereby implying 
some interaction event occuring at this site. Although 
individual seguences may form the recognition sites for 
trans-acting factors perhaps the overall geometry of the 
domain is reguired for effective binding.
Several other negative regulatory elements have 
recently been identified in association with eukaryotic 
genes. There are no striking homologies between these 
elements (Remmers, Yang and Marcu, 1986), especially since 
most of these elements have only been given approximate 
locations. The HI domain of the mouse (3-major globin gene 
has been shown to repress expression in an orientation 
independent manner (Gilmour et al, 1984), as does the human 
c-myc NRE-2. However, unlike the HI domain, the c-myc NRE-2 
does not have a large potential Z-DNA domain. Other negative 
regulatory elements can repress independently of their 
orientation. Perhaps, in a similar fashion to enhancers 
(Sassone-Corsi and Borrelli, 1986), certain negative 
regulatory domains may share common factors.
Recent investigation into enhancer function has shown 
that in certain situations these elements can be repressed 
by some cellular or viral trans-acting factor (Borrelli and 
Chambon, 1984; Gorman, Rigby and Lane, 1985). The human 
c-myc NRE-2 domain may have the ability to act both 
positively and negatively with respect to transcription 
regulation. It is slowly being realised that the repression 
of genes may be a common phenomenon.
4.2.3. The Far Upstream Region
The far upstream region (-2280 to -1240) contains two
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sequence and two clustered enhancer core consensus sequences 
(Siebenlist et al, 1984). Associated with the 3' CTF 
footprint of the NRE-2 is the sequence 5'-TGGAAGGTATCCAAT-31 
which is hiqhly homologous to the reported target sequence 
for the cellular protein nuclear factor -1 (NF-1), but which 
may not actually bind NF-1 as shown by preliminary in vitro 
competition experiment (Siebenlist et al, 1984; see section
4.2.2.). As well as the presence of this sequence in the 
NRE-2 domain a similar sequence 5'-TGGAAGGCAGCCAA-3' is 
located adjacent to the in vivo DNase 1 hypersensitive site 
II-l. Previous studies have suggested that this sequence is 
a target for NF-1 binding (Siebenlist et al, 1984). 
Comparing this sequence with that of the murine c-myc 
colinear (to site II-l) sequence, shows this region to be 
fairly well conserved with two completely homologous 
stretches of 11 bp and 16 bp. However, the NF-1 consensus is 
not conserved (Corcoran, Cory and Adams, 1985). In addition 
there are no CTF recognition sites in either sequence, and 
neither sequences show any obvious Spl consensus signals.
Of interest, a recent report using computer-assisted 
analysis of several genes (viral and eukaryotic) identified 
a consensus sequence, 5'- TTGnnnTTTTTT -3', which was 
postulated to be involved in negative control of 
transcription (Renan, 1985). No functional studies have been 
done to substantiate these observations. Homologues of the 
consensus sequence, as stated, can be found at many sites 
throughout the c-myc gene, but whether they bind a factor or 
have any functional significance awaits investigation.
Results described in this thesis implicate the -1525 to 
-1240 region in possessing another negative regulatory 
element, and it is therefore tentatively termed NRE-1. This 
negative function can be conferred upon an heterologous 
promoter (HSV-1E), and shows a certain promiscuity with 
respect to its tissue- and species- specificity. The 
repression conferred by this domain can be competed out by a 
cotransfected plasmid containing the NRE-2 domain. Thus
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there is at least one factor common to both domains. Further 
investigation is required to characterise this domain. 
Whether this element has a role in controlling c-myc 
expression is not known.
Near to the conserved DNase 1 in vivo hypersensitive 
site I are two core enhancer consensus sequences 
(51-GCTGGAAAC-3': Sassone-Corsi and Borrelli, 1986) which
are 40 bp apart (see figure 72), the 3' consensus being 
conserved in the murine sequence (Fahrlander, Piechaczyk and 
Marcu, 1985). Evidence summarised by Fahrlander, Piechaczyk 
and Marcu (1985), correlated this region with 
transcriptionally active genes, however, previous arguments 
pointed to this region being the recognition site for a 
repressor (Siebenlist et al, 1984). This region is located 
approximately 1900bp 5' to PI. This region has the ability 
when covalently linked to either the CAT gene alone 
(promoterless) or to a heterologous promoter-CAT hybrid 
(e-globin) to activate transcription. Therefore this region 
is tentatively termed a Positive Regulatory Element, PRE. In 
competition studies this activator/promoter activity could 
be competed out, hence the interaction of a trans-acting 
factor is implied. Again a certain promiscuity with respect 
to its tissue- and species- specificity was observed.
Sequence scrutinisation of the 5' flanking region of 
another oncogene, c-mos, which is thought to be 
down-regulated by a repressor (exhibits very strict tissue 
specific expression), shows various consensus sequence 
coincident to c-myc. There are several CTF and enhancer 
consensus elements, in approximatly the same positions 
(relative to the transcription start site) as c-myc, within 
its 5' flanking regiom (Wood et al, 1984). It is conceivable 
that both the c-myc and the c-mos genes may be regulated, at 
least in part, by similar mechanisms. However, recent data 
(from SI nuclease and nuclear run-on experimentation) 
indicates that sequences within the c-mos 5' region may 
function as a transcription termination signal. This region 
can also, when inserted between the HSV-1 thymidine kinase
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gene and its promoter, cause a 99% drop in tk transforming 
activity (McGeady et al, 1986). The 5' flanking sequences of 
the c-myc gene (as far as is known) do not contain a 
transcription terminator activity, thus presumably making 
the regulatory machinary for these two oncogenes different.
This difference in control does not exclude a role for 
CTF in the regulation of the c-mos gene. Seibenlist et al 
(1984) presented tentative evidence for a similar protein 
interaction with both the DNase I hypersensitive sites II-l 
and II-2, and the transcription termination domain of the 
c-myc gene. If CTF does bind to the 5' flanking region of 
c-mos gene (and this awaits investigation) and this region 
does indeed possess a transription terminator, could CTF 
have a role in transcription termination?
4.3. How Might These Elements Function ?
Although the trans-acting factors involved in the 
repression of c-myc expression have not been conclusively 
identified, how the repression function may occur can be
speculated on. From the work presented in this thesis,
there is a cis-acting element and at least one trans-acting 
factor involved in this repression. In addition the
deletion studies on the UPE imply that this region has some 
involvement as well as the NRE-2. However, because 
repression of heterologous (eukaryotic and viral) promoters 
occurs when only sequences containing the NRE-2 and not the 
UPE domain are inserted adjacent to them, the involvement of 
the UPE is probably not a prerequisite for repression 
(unless both the HSV-IE and human e-globin promoter domains 
contain an analogous element). Although only speculation, 
several models of how the interaction of the repressor with 
the NRE-2 domain may occur, can be thought of.
4.3.1. Direct Steric Hinderance
According to this model, the repressor upon binding to
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the NRE-2 physically blocks the interaction of the RNA
polymerase II or a positive transcription factor to the DNA. 
This is the mechanism used by many bacterial repressors 
(Pabo and Sauer, 1984). This model evokes the requirement 
of a positive activator of transcription which would also 
use the NRE-2 as a recognition signal, or in some situations 
a lack of repressor. It is hard to envisage a role for the 
UPE in repression in this model, although it does fit with 
the enhancer-like properties of the NRE-2.
4.3.2. Indirect Steric Hindrance
According to this model, the repressor once bound to 
the NRE-2 domain interacts with auxiliary proteins (e.g. a 
histone complex) such that the auxiliary proteins block the
accessibility of the essential promoter sequences to the
polymerase or a transcription factor. This would involve a 
specific higher order interaction of proteins. The 
association of transcriptional control domains with scaffold 
binding regions has been reported recently (Grasser and
Laemmli, 1986). A function for the UPE domain as a positive 
regulator of transcription fits into this model, as does the 
enhancer-like properties described for the NRE-2. However, 
again it is hard to conceive how the UPE may augment 
repression.
4.3.3. Alteration of DNA Topology
According to this model, the interaction of the 
repressor with the NRE-2 domain induces a structural change 
in the local topology of the DNA thereby preventing the
interaction of the RNA polymerase or a transcription factor 
with this region. There is a substantial amount of evidence 
to implicate this method as a form of repressional control 
(Peck and Wang, 1985; Brahms et al, 1985; Weintraub, Cheng 
and Conrad, 1986). The easiest explanation for this would 
involve an alteration (e.g. supercoiling) of the DNA.
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This can explain UPE involvement, if this change of DNA 
structure upon reaching the UPE domain causes a change in 
that region as well. Such a change could allow a different 
factor to interact with this region, thus causing repression 
rather than activation. This factor may then work by steric 
hindrance (see previous models). This model evokes two 
proteins, one a repressor, the other an activator, both of 
which are capable of specifically recognising and binding to 
the UPE domain. However, it must be noted that repression 
can occur without the involvement of the UPE domain, 
although in these cases other promoter elements (i.e. the 
HSV-IE and e-globin promoters) may function analogously and 
somehow innteract with the NRE-2. However, the promoter 
domain of the HSV-IE gene contains GC-rich elements 
(possibly Spl), while the e-globin gene promoter is A-T rich 
and contains a CCAAT consensus. Thus domains of these two 
promoters are not obviously similar. The greatest repression 
is seen when the NRE-2 is regulating its homologous 
promoter. Recent evidence indicates, that positive factors 
also function optimally on their homologous promoter (Garcia 
et al, 1986). Perhaps the repression function of the UPE can 
be interchanged with other promoter domains irrespective of 
their individual elements, with only a quantitative change 
in the repression function.
4.3.4. Diffusion Blockage
According to this model, the binding of the repressor 
to the NRE-2 prevents movement of the polymerase or a 
transcription factor to the transcription start site. The 
whole upstream region, of the c-myc 5' sequences (Hindlll to 
PvuII), can repress even when in a flipped orientation, this 
would insist (if this model was true) that the polymerase or 
co-factor first interacted with the DNA more than 2.3Kb 
distant from the transcription start site. Whether RNA 
polymerases can diffuse over such distances is not known. 
The looping out of the intervening sequences is a possible 
mechanism by which the potential problem of long distances
249
could be negotiated. Again it is hard to conceive how the 
UPE domain may play a role in this model.
4.3.5. Repressor Diffusion
According to this model, the repressor upon interaction 
with the NRE-2 diffuses to another location where it 
prevents the polymerase or a transcription factor from 
reaching the transcription start site. This model is evoked 
to explain the involvement of the UPE domain. The repressor 
after using the NRE-2 as an entry site diffuses to the UPE 
domain thereby shutting down transcription by preventing the 
normal protein-DNA interaction at this site. In the absence 
of the repressor the UPE domain would function as a positive 
regulator of transcription. The repressor need not displace 
the normal protein-UPE interaction, if upon becoming close 
to each other, an interaction between the two proteins can 
take place. Such co-operative binding has been reported for 
the A  repressor (Hochschild and Ptashne, 1986; Ptashne, 
1986).
Whether one of these models, a combination of them or 
another model altogether accounts for the repression of 
c-myc can only be speculated on as yet. Hopefully future
investigation will answer the question.
4.3.6. How the Far Upstream Elements May Function
Very little is known about these elements. If the PRE 
located about -1900 bp 5' to PI has a role (unkown as yet) 
in the regulation of c-myc transcription, perhaps it is to 
allow the entry of the RNA polymerase II molecules onto the 
DNA, or in some way keeps the whole gene domain in an open 
chromatin configuration by some interaction with the nuclear 
superstructure. Recently, the association of enhancer 
domains with scaffold binding regions has been reported
(Grasser and Laemmli, 1986). There are two enhancer
consensus elements within this domain, one of which is
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conserved in the murine c-myc sequence. It is tempting to 
speculate that the PRE may be involved in the association of 
the active c-myc gene with the nuclear matrix (see section
4.4.3.).
What role, if any, the NRE-1 domain has on the 
regulation of c-myc transcription again is unknown. The 
competition results imply the interaction of a factor common 
to both NRE-1 and NRE-2. It is conceivable that the NRE-1 
domain could regulate repression in other cell types, or 
stages of cell growth and differentiation, in which the 
NRE-2 domain functions.
4.4 Involvement of These Elements in Cellular Biological
Events
The exact level of involvement of the different 
transcriptional control domains located 5 1 to the human 
c-myc in the various biological situations where c-myc 
expression is known to be up or down regulated is not as yet 
known. However, speculation as to their roles can be made.
4.4.1. Cell Division
Although the function of c-myc is unknown, there is
great expectation that it may be involved in regulating the 
normal division of a cell. If this is indeed the case then 
obviously a cell would want to keep such a gene under tight 
expressional control. The tight down-regulation
(repression) of such a gene is a good candidate for this 
control. Thus the c-myc gene would be expressionally silent 
(repressed) until required, being turned on either by
removal of the controlling repressor or the involvement of
an activator. Both of these factors require a cis-acting
recognition sequence, with both sequences conceviably lying 
adjacent to or even overlapping each other. The NRE-2 domain 
and/or the UPE domain are good candidates for this element.
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Upon serum stimulation of quiescent cells c-myc 
expression is induced along with the growth response of the 
cell. Both transcriptional and messenger stability changes 
have been suggested as the cause of this increase in 
expression (see section 1.5.). Since in the results 
described in this thesis transcriptional control domains 
were identified, the following discussion will concentrate 
on the possible involvement of these transcription 
regulatory elements in the control of c-myc gene expression, 
without directly discussing the possible involvement of 
post-transcriptional control mechanisms. The c-fos gene is 
also serum responsive, and a cis-element has been identified 
which confers this upon the gene (Treisman, 1986). This 
serum-responsive element, like the NRE-2, exhibits 
enhancer-like properties. Could the NRE-2, the site from 
where repression is instigated, also act as the 
serum-responsible element? Serum stimulation could induce 
an activator or inactivate (or convert to an activator) the 
repressor. In either case a structural alteration requires 
to be envisaged, as protein inhibitors superinduce c-myc 
expression in this system (Kelly et al, 1983). However, 
there is no obvious sequence homology between the c-fos 
serum responsive element and the c-myc NRE-2. Of note is 
that when the NRE-2 domain is isolated from its normal 
position it can function to promote transcription of a 
heterologous promoter (see section 4.2.2.).
The search for the serum responsive domain of the c-myc 
gene would form a good line for future research. In 
addition, ingenious experiments could be devised utilising 
antisense mRNA (Weintraub, Izant and Harland, 1985) to 
investigate the role of c-myc in the growth response, as has 
been done for c-fos (Holt et al, 1986).
It is becoming apparent that the same upstream element 
can act both positively and negatively with respect to 
regulation of transcription (Borrelli, Hen and Chambon, 
1984; Gorman, Rigby and Lane, 1985; for review see Jones,
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1986). This change of personality must be due to the 
specific trans-acting factors involved in each situation. It 
is conceivable that the NRE-2 domain could have either a 
negative or positive function, depending on the specific 
trans-acting factor (or cocktail of factors) interacting 
with it.
4.4.2. Differentiation
In the mature cell c-myc transcription is repressed. 
Transcriptional and post-transcriptional mechanisms have 
been suggested, but the complete repression of transcription 
would appear most sensible for a cell. Although not always 
clear, the data amassed to-date implicates the in vivo DNase 
1 hypersensitive site I region to be associated with this 
phenomenon (Siebenlist et al, 1984; Dyson et al, 1985; 
Fahrlander, Piechaczyk and Marcu, 1985). From the results 
presented in this thesis, this region may have 
characteristics of a positive regulator of expression, 
however, no direct role in c-myc expression has been shown. 
Perhaps this domain could function to keep the whole c-myc 
gene domain in an open chromatin-state, possibly by 
interacting with the nuclear matrix. This site becomes
strongly hypersennsitive after induction of HL-60 cell 
differentiation by DMSO (Dyson et al, 1985), and is the only 
hypersensitive site seen for the silent c-myc allele in some 
Burkitt Lymphoma cell lines (Siebenlist et al, 1984;
Fahrlander, Piechaczyk and Marcu, 1985). Could this site be 
the recognition signal for a differentiation-specific
protein which somehow represses c-myc gene expression in the 
mature cell, possibly by preventing association with the 
nuclear matrix?
This site could conceivably form the key to allowing 
expression of the c-myc gene. Depending on the trans-acting 
factor(s) interacting with the PRE, the gene could be in a 
competent or repressed state (for reveiw see Weintraub,
1985). Once in a competent state, additional factors would
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be required to induce (or repress) expression, perhaps with 
the NRE-2 domain.
4.4.3. Neoplasia
Although there are several instances where the c-myc 
gene is amplified (Graham, Tindle and Birnie, 1985, for 
review see Alitalo, 1985), no sequence data is available for 
these cases. However, in Burkitt's lymphoma or murine 
plasmacytoma cells the c-myc locus has been (in most cases) 
rearranged by reciprocal translocation with an immunoglobin 
locus. In some cases the Ig heavy chain enhancer is 
positioned adjacent to the c-myc coding exons, but this is 
rare (Marshall, 1985). However, in all cases the c-myc gene 
appears to be expressionally deregulated, as it is 
constitutively expressed.
By analysing the chromosome breakpoints of these cells 
it is clear that in the majority of cases the NRE-2 domain 
has been removed. Indeed some of the breakpoints found in 
murine plasmacytoma cells cluster between -500 and -350 bp 
5' of the first c-myc exon (Yang et al, 1985). Translocation 
breakpoints within this region are also found in Burkitt's 
lymphoma cells (Dyson and Rabbits, 1985). Thus these 
translocatons would remove the NRE-2 domain from its normal 
location. Perhaps the observed deregulated c-myc expression 
is due to this translocation event which rearranges the 
positioning of the NRE-2 with respect to the promoter 
domain. Leder et al (1983) proposed a similar model, except 
that the promoter domain was implicated as the recognition 
site for the repressor.
The cases where the breakpoints leave the NRE-2 domain 
adjacent to the c-myc gene can not be explained as easily. 
In such cases the constitutive c-myc expression may be due 
to some interaction with the immunoglobulin locus as a 
consequence of the translocation which overrides the 
activity of the NRE-2, or there could be small 
rearrangements (e-g- point mutations) within the NRE-2
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domain, thereby destroying its function. For the majority of 
known cases no sequence data is available. However, in a 
B-cell lymphocytic leukaemia, even though the translocation 
breakpoint is 1077 bp 5 1 to PI (i.e. 5' to the NRE-2
domain), several mutations have been identified within the 
transcribed sequences (Care et al, 1986). Perhaps point 
mutations/deletions could have disrupted the NRE-2 domain 
rendering it inactive (sequencing of the 5' flanking region 
would give the answer). There are other possibilities to 
explain these translocations and the associated deregulated 
c-myc, (e.g. mutation of c-myc repressor gene; possibly the
pvt-1 locus: Cory et al, 1985).
This raises the question of the identity of the 
repressor (see sections 1.6.3., 1.6.4.). One candidate is 
the c-myc gene product itself. No direct experimentation on 
this question was undertaken during these studies, but the 
K-562 cell results are of relevance to this point. These
cells have elevated c-myc transcript levels (thus
presumably elevated protein levels). They also showed the 
greatest repression ratio in these studies. The DNase I 
footprinting results described in this thesis implicate a 
role for CTF in the repression of the c-myc gene.
Coincidentally the purified CTF extract of Cohen, Sheffery 
and Kim, (1986) contained as its major component a 64 Kd 
protein, which is the same size as the c-myc gene product. 
In addition, studies on the hsp70 gene showed that its 
expression could be enhanced by co-transfection of the c-myc
gene (Kingston, Baldwin and Sharp, 1985). By in vitro DNase
I footprint analysis, the only protected domains within the 
region required for optimal expression of the hsp70 gene 
were a HSE (heat shock element) and a CTF site (Bienz, 
1986). Highly speculatively (and with a good imagination), 
it is conceivable that the c-myc gene family could encode a 
CTF-like family of transcriptional regulators.
At nearly every stage of the investigation into the
c-myc oncogene, cross-reference to the adenovirus Ela gene
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is possible (see section 1.6.4.). The Ela gene product 
regulates its own transcription (Borrelli, Hen and Chambon, 
1984): could the c-myc gene product do likewise? Perhaps
these two genes will, when fully understood, be categorised 
together. Recent evidence suggests that the Ela gene product 
may function by binding to sequence-specific DNA-binding 
proteins. Perhaps the c-myc gene transcriptional repressor 
(possibly the c-myc gene product itself) might function in 
an analogous manner: binding to either the CTF or Spl (or
both) factors which have been shown in vivo to bind to the 
NRE-2 domain (this thesis).
The experiments of Borrelli, Hen and Chambon, (1984), 
which identified the adenovirus Ela gene product as having 
the ability to repress certain enhancer elements, and 
similar studies which implied that the c-fos gene product 
could trans-activate certain promoter domains (Setoyma et 
al, 1986), could be mimicked for the c-myc.
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4.4. Conclusion
The work described in this thesis identifies, and 
partially characterises, several transcriptional control 
domains within the 5' flanking region of the human c-myc 
proto-oncogene (see figure 73). Both negative and positive 
regulatory domains have been localised to regions previously 
found to be hypersensitve to DNase I in vivo (Siebenlist et 
al, 1984). By comparing the sequence of the colinear domains 
from the murine (Bernard et al, 1983: Fahrlander, Piechaczyk 
and Marcu, 1985) and feline c-myc genes (Stewart et al,
1986), regions of homology are present. Therefore it is 
probable that these domains represent conserved 
transcriptional control elements.
The activity of these domains was identified when 
either human- or mouse- derived cells were used as the 
recipients in transient transfection studies. In addition, 
activity was observed in cells of erythroid, fibroblastic or 
epithelial origin. Presumably this indicates a certain 
promiscuity with respect to tissue- and species- specificity 
for the transcriptional control domains identified. However 
the whole story of how these elements function is far from 
known. For example, the NRE-2 domain can function to promote 
transcription, while the repression function although 
instigated by the NRE-2 domain, can somehow involve the UPE 
domain as well. Future investigation into these domains will 
hopefully clarify the picture.
Both in vivo transfection competition and in vitro 
DNase I footprinting studies implicate roles for trans­
acting factors in repression and activation (promotion) of 
the human c-myc gene. The in vitro DNase I footprint data 
implicated that either, or both CTF and Spl factors were 
involved with the repression function, while Spl-like 
factors were involved in the functioning of the promoter 
domain. This is the first time either CTF or Spl have been 
associated with the negative regulation of a gene. The data
25 7
described in this thesis suggest that the transcriptional 
regulation of the c-myc gene requires the interaction of 
several factors. Perhaps the interaction of multiple 
closely located sequence-specific transcription factors will 
emerge as a common property of transcriptional control 
sequences in general.
It is conceivable that one or more of these domains may 
be involved in either, or both, the serum-induced activation 
or the differentiation-associated repression of the c-myc 
gene. Since several transcriptional control domains for the 
c-myc have been identified (this thesis, Remmers et al,
1986), experiments to test this involvement can now be 
devised.
The c-myc gene is intimately associated with the 
genesis of the neoplastic state. In transgenic mice which 
contain an exogenously introduced c-myc gene under the 
transcriptional control of an inducible promoter, the 
resultant constitutive transcriptional deregulation of the 
gene (in cells which are permissive for the promoter) 
appears to act as a heritable, predisposing factor favouring 
the development of tissue-specific neoplasms (Stewart, 
Pattengale and Leder, 1984). This predisposition may in part 
be due to a maturation arrest of the sensitive cells 
(Langdon et al, 1986). Thus the deregulation of the c-myc 
gene appears to be a central step in the progression from a 
normal cell to the full neoplastic state.
With this in mind, deregulation of the c-myc gene is
associated with Burkitt's lymphoma and murine plasmacytoma 
cells, where reciprocal chromosome translocation joins the 
c-myc gene with one of the immunoglobulin loci (see section
1.5.3.c). Comparison of the location of, some of, the
translocation breakpoints shows a clustering around -500 to
-350 from the transcription start site (Yang et al, 1985; 
Dyson and Rabbits, 1985). These translocations would 
rearrange the NRE-2 domain described in this thesis, with
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respect to the c-myc promoter-gene unit. It is therefore not 
unreasonable to suggest that, in at least some cases, 
removal or rearrangement of the NRE-2 domain would result in 
deregulation of expression of the c-myc gene, and that this 
deregulation is an important step in the genesis of the 
observed cancer.
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Figure 70.
Comparison of Species Conservation of GC-Rich 
Elements.
This diagram shows the relative positions (by sequence 
analysis) of the GC-rich elements (open circles) and their 
orientation (arrow), in the various c-myc genes sequenced; 
M= murine, H= human, F= feline, C= chicken. PI and P2 are 
the two major transcription initiation sites (heterogenous 
starts are found for chicken c-myc). (Bernard et al, 1983; 
Stewart et al, 1986; Nottenburg and Varmus, 1986).
See figures 65, 74 and 76.
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Figure 71.
Comparison of DNase I Protected (Footprint) Sequences.
A. h-c-myc Spl-like sites (detected using Spl enriched 
protein extract). They are arranged 5' to 3' (i.e.
the first is the most distant from PI the 5' major 
transcription initiation site). The consensus 
sequence is shown, with small letters referring to 
the less frequently observed bases (Kadonaga, Jones 
and Tjian, 1986; R.Tjian, personel communication)
consensus
T G G G A G G G G C
C A G G A G G G G C
G G G G A G G A G A
G G G G A G G G T G
C G G G A G G G G C
A G G G C G T G G G
T G G G C G G A G A
G G G G C G G G G C
T a t A A T
a g
g
Four of the sequences footprinted in these studies 
show complete homology with the consensus sequence, while 
three show a single base miss-match (underlined).
B. h-c-myc CTF sites (detected by using a CTF enriched 
protein extract).They are arranged 5' to 3', with both the 
possible recognition sites for the 5' footprint shown. The 
consensus sequence is shown (Benoist et al, 1980; R.Tjian 
personel communication).
consensus
c c C C A A T t c
t G C C A A a g c
a t C C A A T C c
G G C C A A T C A
T T
The base miss-matches are shown as small letters. The 
core consensus is found in two of the possible recognition 
sites, with a one base miss-match (T to A) being present in 
the other sequence.
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Figure 72.
A.Conservation of the Far Upstream Regulatory Domain.
Hindlll 250bp
****** ****** human
TGGCTGGAAACTTGGTTTT-AAGGAACCGCCTGTCCTTCCCCCGCTGGAAACCTTGCACC 
ACCGGAAGCTTGTCTTAGGCAAGGAAGCATCTTGCCCAGAAC--CTGGAAACCCTGCAGC
****** murine
45bp HincII
HincII 95bp
human I human
AGAGGGGCGGAGGGAAA ATAGCGATTGGTTGCTCC
TGAGGGGCGGGGAAA—  CTAGGGftTTGHTGGCTCT
murine murine
<27bp>
310bp Aval
The best alinement of the human and murine c-myc 
sequences for the colinear Far Upstream Doamin are shown 
above (Fahrlander, Piechacyzk and Marcu, 1985).The location 
of the in vivo Dnase I hypersensitive site is indicated by 
the Roman numeral I. Distances are given in base pairs (bp) 
from the indicated restriction sites to the relevant 
sequence, and between the putative Spl (continuous line) and 
CTF (dashed line) consensus elements (designated by sequence 
only). The putative enhancer core elements are indicated by 
asterisks.
B. Species Conservation of the TATA-Consensus Domain.
human T T T A T A A T G C
murine T T T A T A T T C C
feline T T T A T A T G C G
chicken G C T T T A A A G A
human A G T A T A A A A G
murine A G T A T A A A A G
feline T G T A T A A A A G
This diagram shows the high degree of conservation that 
exists between the sequenced c-myc genes within the 
TATA-consensus domain. PI and P2 refer to the two major 
c-myc transcription initiation sites. The greatest species 
homology is found within the P2 domain. In addition, the 
chicken sequence, which contains only one putative 
TATA-conensus, shows better homology to tne P2 domain than 
to the PI domain. The above sequence data was taken from 
Bernard et al, 1983; Siebenlist et al, 1984; Nottenburg and 
Varmus, 1986; Stewart et al, 1986.
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Figure 73.
Model for cis-Actinq Transcriptional Control Domains.
The 5' flanking region and first exon of the human 
c-myc gene is shown. PI and P2 refer to the two major 
transcription initiation sites. Roman numerals refer to the 
in vivo DNase I hypersensitive sties of Siebenlist et al,
(1984). Horizontal arrows indicate Spl consensus elements 
and their orientation. Circles indicate Spl-like protected 
domains (filled = strongly protected, open = weakly 
protected). The black bars represent CTF proteced domains, 
while the vertical arrow represents the location of a strong 
in vitro DNase I hypersensitive site. Distances are from PI.
Key: PRE = Positive Regulatory Element
E = putative Enhancer domain
NRE = Negative Regulatory Element
UPE = Upstream Promoter Element
NF1 = Nuclear Factor-1 consensus sequence 
CTF = CCAAT-binding Transcription Factor 
Spl = GC-rich sequence binding transcription 
factor
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5. Appendix
5.1. Evidence for Possible Cis-Recombination Between 
Co-Transfected Supercoiled Plasmids
Initial results (see table 7) showed that pB25 (MoLTR 
enhancer sequences in a pUC vector, not described) could 
compete out repression to a greater extent that either pBl8 
or pB20 (c-myc 5' flanking sequences) from the indicator 
plasmid pB12 (c-myc-CAT recombinant: see section 3.4.5.).
This was initially taken to indicate that the trans-acting 
factor(s) involved in repression also recognised the 
enhancer element. However, as controls in latter 
experiments, pB25 was shown to elevate the expression level 
obtained from pB14 (c-myc-CAT recombinant which does not 
contain the negative element) by co-transfection, while pBl8 
had no affect on pB14. This may imply that the MoLTR 
enhancer element was functioning in cis to activiate the 
c-myc promoter. Thus, in the co-transfection experiment 
although the enhancer may be acting as a sink for the 
repressor factor(s), it could also be cis-activating 
(possibly by over-coming the NRE-2) the c-myc recombinant.
Further evidence for cis-activation came from
experiments with the UPE domain. When pB57 (containg the
250bp UPE domain) was co-transfected with pB36 (c-myc-CAT 
recombinant containing only 97bp of 5' flanking sequences), 
an elevation of expression was observed at the lower molar 
ratios, with a gradual titration-effeet being seen as the 
molar excess of competitor over indicator was increased. 
This may imply that the UPE domain (from pB57) was acting in 
cis to activate expression. However, an alternative 
explanation could be that the UPE domain was competing out a 
repressor factor which interacted with sequences within 
pB36.
Although these results tentatively imply that
cis-recombination between co-transfected supercoiled 
plasmids may occur at a relatively high rate. However, the
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sequences present in excess could concurrently titrate out 
any trans-acting factor which bound to that sequence (as 
seen in the competition experiments, see section 3.4.5.).
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Table 7.
Competition Experiments with Enhancer Elements 
in LaTK~Cells.
a d
Donor DNA CAT Activity
pB9
b
385
c
±29 1.2
pB14 31810 ±1111 100
pB14 
Comp.pB25
155687 ±8011 489
pB14 
Comp.pB18
• 32189 ±2568 101
pB12 3533 ±479 11
pB12 
Comp.pB18
13281 ±922 42
pB12 
Comp.pB20
10823 ±562 34
pB12 30869 ±434 87
Comp.pB25
a. Equimolar ratios of lpg of indicator plasmid was 
transfected, and where relevant (prefix = Comp.), a 
5 molar excess of competitor plasmid was 
cotransfected with the indicator.
b. Activity was expressed as the average of total 
counts (cpm) per flask for two separate experiments 
of duplicate flasks.
c. Range of variation of values.
d. Average counts (cpm) represented as a percentage 
of pB14.
e. Donor DNA was mixed with carrier salmon sperm DNA to 
a final concentration of 20pg/ml in the 
calcium-phosphate precipitate and transfected as 
described in Material and Methods.
f. CAT activity was assayed as described in Materials 
and Methods using total cell extract.
2 6 7
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